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Abstract
There is substantial evidence that the use of aspirin and related nonsteroidal
anti-inflammatory drugs (NSAIDs) is associated with colorectal cancer prevention.
Although some data indicates a role for inhibition of cyclooxygenase (COX)
enzymes, the underlying mechanisms of the anti-tumorigenic effects of NSAIDs are
complex and poorly understood. It has previously been shown by the host laboratory
that aspirin activates the nuclear factor-kappa B (NF-kB) pathway via
phosphorylation and degradation of the NF-kB inhibitor protein, IkBcl (Stark et al.,
2001). More recent work has established that nucleolar translocation of the RelA
component of NF-kB in response to aspirin is causally involved with repression of
basal NF-kB transcriptional activity and apoptosis (Stark and Dunlop, 2005).
The first research strand in this thesis was to determine whether non-aspirin
NSAIDs also induce apoptosis of colorectal cancer cells via modulation of the NF-
kB pathway and to elucidate the upstream mechanisms involved. Experimental
evidence presented here shows that sulindac, sulindac sulfone and indomethacin
cause NF-kB pathway activation. It was found that non-aspirin NSAIDs induce
nucleolar translocation of the NF-kB component, RelA, repression of NF-kB driven
transcriptional activity and apoptosis. Furthermore, in a similar manner to aspirin,
nucleolar translocation of RelA was demonstrated to be absolutely required for the
apoptotic effects of sulindac, sulindac sulfone and indomethacin. Flowever, in
contrast to aspirin, activation of the NF-kB pathway by the non-aspirin NSAIDs was
independent of IkBcx degradation. By means of phospho-specific antibodies,
chemical inhibition and genetic intervention, the tyrosine kinase c-Src was found to
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be activated in response to NSAIDs and this activation was causally involved in the
apoptotic mechanism of sulindac, sulindac sulfone and indomethacin.
The host laboratory was the first to demonstrate nucleolar sequestration of
RelA and so the second research strand in this thesis was to further understand the
mechanisms involved. Beta catenin (P-catenin) has previously been shown to interact
with RelA and modulate nuclear NF-kB activity (Deng et al., 2002). Therefore, the
role of the P-catenin pathway in NSAID-effects on the NF-kB pathway and apoptosis
was investigated. Aspirin, sulindac, sulindac sulfone and indomethacin all induced
activation of the (3-catenin pathway and nucleolar sequestration of p-catenin.
Blocking aspirin-induced nucleolar translocation of RelA blocked nucleolar
localisation of p-catenin, suggesting a possible interaction between the NF-kB and P-
catenin pathways.
It is increasingly apparent that post-translational modifications of RelA,
particularly acetylation and ubiquitination, are implicated in nuclear regulation of
NF-kB. The final strand of research in this thesis was therefore to determine whether
these modifications were involved in aspirin effects on NF-kB activity and apoptosis.
By means of immunoprecipitation and Western blot analysis, aspirin was found to
cause an increase in ubiquitinated RelA. Furthermore, the proteasome inhibitor,
MG132, mimicked the effects of aspirin in terms of nucleolar translocation of RelA
and P-catenin, repression of NF-kB activity and increased ubiquitinated RelA.
Moreover, both aspirin and MG132 mediated a reduction in proteasome levels and
caused proteasomes to localise to the nucleolus, providing support for the notion that
RelA and/or P-catenin are subject to ubiquitin-mediated proteolysis in the nucleolus.
Additionally, the finding that there is a decrease in acetylated RelA after aspirin
2
treatment provides further evidence that acetylation is important in the response to
aspirin.
Collectively, the data in this thesis establishes a novel mechanism whereby
NSAIDs induce apoptosis of colorectal cancer cells. Activation of the NF-kB
pathway is critical in this process, although the upstream mechanism of activation
differs between NSAIDs. Cross-talk between the NF-kB and P-catenin pathways
could represent an important regulatory mechanism in response to NSAIDs and the
nucleolus might be a key site for such cross-regulation. Moreover, post-translational
modifications, including ubiquitination and acetylation, seem to play a significant
role in sequestration to the nucleolus of key NF-kB and P-catenin pathway
components. Elucidating the mechanisms whereby NSAIDs induce apoptosis of
colorectal cancer cells is of vital importance for the rational design of new
therapeutic agents.
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Chapter 1 - Introduction
Colorectal cancer is a substantial public health problem worldwide,
particularly among developed populations. The disease has a complex epidemiology,
with both genetic and environmental contribution. There is considerable morbidity
associated with colorectal cancer and its treatment, which has led to the development
of prevention strategies to combat the disease. Nonsteroidal anti-inflammatory drugs
(NSAIDs) are known to reduce incidence and mortality from colorectal cancer and
so show promise as chemopreventative agents. However, there is a considerable
amount of work still needed to determine the optimal means of preventing the
disease. While the focus of this thesis is on the effects ofNSAIDs on nuclear factor-
kappa B (NF-kB) signaling as a key mechanism of the anti-tumour effects of
NSAIDs against colorectal cancer, it is important to consider this in the context of
colorectal cancer as a whole. Hence, this introduction will discuss the incidence and
mortality of colorectal cancer (1.1); treatment and survival rates (1.2); modifiable
genetic and environmental risk factors for prevention (1.3); chemoprevention (1.4);
mechanism ofNSAID action (1.5); and the need for novel therapeutic agents (1.6).
1.1 Incidence and Mortality of Colorectal Cancer
Colorectal cancer is the third most common malignant neoplasm worldwide
(http://www.cancer.gov) and Figure l.l demonstrates the global distribution of the
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Colon and rectum. Males
Age-Standardized incidence rate per 100,000
■ < 4.0 ■ < 7.2 < 12.3 ■ < 27.6 ■ < 58.5
GLOBOCAN 2002, 1ARC
Colon and rectum. Females
Age-Standardized Incidence rate per 100,000
■ < 3.5 ■ < 5.8 < 11.6 ■ < 19.6 ■ < 42.2
GLOBOCAN 2002, IARC
Figure 1.1 - Global Incidence of Colorectal Cancer in Males and Females
[Figures obtained from: http://www-dep.iarc.fr/]
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disease in males and females. It is noteworthy that the areas with the highest
incidence are similar in males and females, namely United States, Western Europe
and Australia. Indeed, colorectal cancer is the second most common fatal malignancy
in both sexes combined after lung cancer in the Western population, accounting for
over 10% of all cancer related deaths. The annual incidence in the United States is
approximately 184,300 (affecting 72,600 males and 75,700 females) with 56,600
deaths (Lynch and de la Chapelle, 2003). In Europe in 2004, colorectal cancer was
estimated to account for 13.2% incident cases of cancer diagnosed and
approximately 203,700 deaths (Boyle and Ferlay, 2005). In the UK in particular,
there were approximately 34,500 new cases of colorectal cancer in 2001 (affecting a
higher proportion of males, 18,500, than females, 16,039) with 16,107 deaths from
colorectal cancer in 2003 (http://www.cancerresearchUK.org). Figure 1.2 illustrates
the mortality rates of bowel cancer in selected countries by sex. It is of significance
that not only does colorectal cancer seem to affect a higher proportion of males than
females, as mentioned for Europe and the UK, but there are higher mortality rates in
general among males than females for bowel cancer. It is also noteworthy that the
mortality rate for colorectal cancer is correlated with age - the rate increases
exponentially from approximately age 40-45 in both males and females, exemplified
by recent Scottish data for 2004 which is documented on the ISD Scottish Health
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Figure 1.2 - Age Standardised (World) Mortality Rates of Bowel Cancer in Selected
Countries, by Sex, 2002 Estimates.
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Figure 1.3 - Number of Deaths and Age-standardised Mortality Rates for Colorectal
Cancer in Males and Females in Scotland, 2004.
[Data obtained from: http://www.isdscotland.org]
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1.2 Treatment and Survival Rates of Colorectal Cancer
There has been significant improvement in the survival rate of colon cancer
patients over the past few decades as a result of earlier detection and better treatment
of patients, with a current five year survival rate of approximately 51% here in
Scotland, based on recent data presented on the ISD Scottish Health Statistics
website (http://www.isdscotland.org). In particular, Figure 1,4A highlights the
improvement in one year and five year survival rates from colorectal cancer in
Scotland for both males and females during the period 1971-2001. Predictably,
survival from colorectal cancer is dependent on age at diagnosis, with poorer survival
rates observed among patients diagnosed later in life and Figure 1.4B illustrates this
in the case of Scotland. Survival can be as high as 70% after curative surgery
(Dunlop, 1997). Flowever, this depends on early diagnosis and treatment prior to the
development of metastasis.
Approximately 19% of colorectal cancer patients have metastatic disease at
initial presentation (Goldberg, 2005). 5-fluorouracil (5-FU) has been basis of
conventional chemotherapy treatment for patients with metastatic colorectal cancer
over the past 40 years (Kohne et al., 2004) and works by inhibiting thymidylate
synthase, which is important in pyrimidine synthesis (Napier and Ledermann, 2000).
However, this drug has a significant degree of toxicity, with side effects including
nausea/vomiting, diarrhoea and hand-foot syndrome (Xiong and Ajani, 2004).
Moreover, resistance to the drug can occur (Banerjee et al., 2002). More recent
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Figure 1.4 - Colorectal Cancer Survival Statistics for Scotland. (A) One and five year relative
survival rates (%) for colorectal cancer in males and females in Scotland diagnosed during the period from 1971-
2001. (B) Relative survival (%) rates of colorectal cancer in males and females in Scotland by age at diagnosis,
2004.
[Data obtained from http://www.isdscotland.org]
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include: capacitabine (thymidylate synthase inhibitor) and oxaliplatin
(diaminocyclohexane platinum, a DNA cross-linker) (Napier and Ledermann, 2000),
both of which are now in routine clinical practice. Other second line drugs, for
example CPT11 (irinotecan, a DNA topoisomerase I inhibitor), are available but like
5-FU, these agents also have a significant degree of toxicity. Adjuvant chemotherapy
and radiotherapy can help reduce the chance of recurrence of disease and
significantly improve overall survival in patients with early stages of colorectal
cancer undergoing surgery (Chau and Cunningham, 2002). However, for patients
with advanced disease, median survival is around six to 12 months, with an overall
5-year survival rate of only 10%. Conventional chemotherapy can perhaps improve
this by about three to six months (Goldberg, 2005; Simmonds, 2000).
1.3 Modifiable Risk Factors for Prevention of Colorectal
Cancer
The lifetime risk of colorectal cancer in the general population is
approximately 5% in females and 6.1% in males, based on recent Scottish data
documented on the ISD website (http://www.isdscotland.org). Given that
conventional chemotherapy offers only marginal survival benefits and that early
detection and prompt surgery in the early stages of colon cancer offer the only hope
of long-term cure, there has been a great deal of focus on developing primary,
secondary and tertiary prevention strategies to combat the disease. Primary
prevention is concerned with etiological factors, such as lifestyle and dietary
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modification, to eliminate potential mutagens (Krishnan et al., 1997). Secondary
prevention attempts to reduce incidence by identifying and treating pre-malignant
conditions in subjects at risk (Rigas and Williams, 2002). In tertiary prevention or
chemoprevention, naturally occurring or pharmacological agents are used to prevent
the initiation of carcinogenesis in healthy individuals and to prevent recurrence,
invasion and metastasis in people diagnosed with symptomatic disease (Vainio and
Miller, 2003).
1.3.1 Genetic Susceptibility
Prevention in the general population is a worthy long-term goal but patients
identified to be at high risk would gain particular benefits. Studies carried out on
cohorts of twins from Sweden, Denmark and Finland suggest that approximately
35% of colorectal cancer incidence can be attributed to a genetic component
(Lichtenstein et al., 2000). Moreover, approximately 20% colorectal cancers occur in
individuals with a positive family history (Rowley, 2004). It follows that first-degree
relatives of a person who has had colorectal cancer are predictably at increased risk
of developing the disease themselves, especially if the relative had the cancer at a
young age (ffopper, 2005). If there is a clear family history of the disease - those
who have two or more first- or second-degree relatives (or both) with colorectal
cancer - then the risk is even higher (Lynch and de la Chapelle, 2003). Therefore,
there is undoubtedly a genetic contribution to this disease.
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Familial colorectal cancers can broadly be divided into two groups: those
characterised by the presence of multiple benign colorectal polyps (polyposis) and
those characterised by the absence of polyposis (Kinzler and Vogelstein, 1998a). The
two major, highly penetrant, autosomal dominant gene disorders that predispose
individuals to colon cancer, namely familial adenomatous polyposis and hereditary
non-polyposis colorectal cancer, fit into these two categories respectively (Rowley,
2005). Taken together, these syndromes probably account for less than 5% of all
cases of colorectal cancer (de la Chapelle, 2004).
1.3.1.1 Familial Adenomatous Polyposis
Familial adenomatous polyposis (FAP) is an autosomal dominant inherited
disease that is characterised by the presence of hundreds to thousands of benign
adenomatous polyps throughout the colorectum that usually appear at an average age
of 16 years (de la Chapelle, 2004; Rowley, 2005). Colorectal cancer subsequently
presents at approximately 39 years of age in these patients (Rowley, 2005). FAP
occurs in 1:7000 to 1:14,000 live births (Rowley, 2004; de la Chapelle, 2004) and is
responsible for less than 1% of all colorectal cancers (Fearnhead et al., 2002).
Flowever, the risk of cancer is so high that identification of gene carriers is of vital
importance (Dunlop, 1997). The adenomatous polyps observed in FAP patients
resemble sporadic polyps that develop in the general population, but the large
number of polyps present in FAP patients essentially guarantees that some will
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progress to malignancy, although an individual polyp is no more likely to become
cancerous than a sporadic polyp (Kinzler and Vogelstein, 1998a).
The genetic basis of FAP lies in a germ line mutation of the adenomatous
polyposis coli (APC) gene (Fearnhead et al., 2002). Linkage analysis of families with
FAP led to the mapping of the APC gene to chromosome 5q21 (Bodmer et al., 1987).
The APC gene was then cloned, identified and characterised in 1991 (Groden et al.,
1991; Nishisho et al., 1991). APC encodes a multi-functional protein that is involved
in several key cellular processes, such as cell adhesion and migration (via interaction
with E-cadherin), signal transduction (via interaction with beta-catenin ((3-catenin)),
microtubule assembly and chromosome segregation [reviewed in (Senda et al., 2005;
Bienz and Hamada, 2004; Fodde et al., 2001b; Fearnhead et al., 2001; Sieber et al.,
2000; Polakis, 1997)].
As can be seen in Figure 1.5, the APC gene consists of 8535 bases that
encode a 2843 amino acid multi-domain protein. The functional domains of APC
include heptad repeats, which occur within the oligomerisation domain (amino acids
6-57) at the amino-terminus (N-terminus) of the APC protein and mediate APC
homodimer formation. Amino acids 453-767, termed the armadillo region, are
known to control cell adhesion and motility via modulation of the actin cytoskeleton.
Two motifs in APC mediate binding and downregulation of p-catenin respectively: a
15 amino acid repeat (occurring three times between residues 1020-1169) and a 20
amino acid repeat (occurring seven times between residues 1262-2033). Moreover,
the 20 amino acid repeats contain a consensus site for glycogen synthase kinase-3-
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Figure 1.5 — Domain Structure Of the APC Gene. Protein domains of APC include: the heptad
repeats that mediate APC oligomerisation; the armadillo repeat, which binds to Asef; the 15 and 20 amino acid
repeats that are involved in binding and regulating p-catenin and which are interspersed with SAMP amino acid
motifs that mediate axin binding; several nuclear localisation and export sequences; a microtubule-binding domain;
and sites for binding EB1/RP1. APC also contains several consensus sites for phosphorylation by p34cdc2, five
nuclear export signals (E) and two nuclear import signals (I). Most somatic mutations of APC occur in the mutation
cluster region and these usually lead to truncated proteins being produced.
[Figure adapted from (Fodde et al., 2001b)]
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repeats, which are located between the third and fourth, fourth and fifth and after the
seventh 20-amino acid repeats, allow interaction of APC with axin/conductin. The
'basic' domain of APC lies within the carboxyl-terminus (C-terminus) between
amino acids 2200 and 2400 and has been demonstrated to act as a binding site for
microtubules (Munemitsu et al., 1994) and other proteins, including: EB1 (Su et al.,
1995), a protein that associates with mitotic spindles, microtubules and centrosomes;
HDLG (Matsumine et al., 1996), the human homologue of the Drosophila discs large
tumour suppressor protein; and the protein tyrosine phosphatase, PTP-BL (Erdmann
et al., 2000). Finally, APC contains five nuclear export signals (NES) and two
nuclear import signals (NIS).
The involvement of APC in FAP comes as no surprise given that it is such a
multi-functional protein and that each of the roles of APC outlined above could
potentially be linked with cancer. It was proposed that the single gene, APC,
essentially acts as the 'gatekeeper' of colonic epithelial cell proliferation and that
inactivation of this gatekeeper is required for net cellular proliferation (Kinzler and
Vogelstein, 1996). Gatekeepers essentially function to maintain a constant cell
number in renewing populations, ensuring that cells respond appropriately to
situations requiring cell growth. FAP was therefore postulated to result from an
increased rate of tumour initiation due to abrogation of the gatekeeper function of
APC.
The vast majority (95%) of APC germ line mutations are nonsense or
frameshift mutations that result in a truncated protein product with abnormal function
(Fearnhead et al., 2002). Colorectal tumours from FAP patients carry additional
somatic APC mutations or loss of heterozygosity at this locus in addition to the
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original germ line mutation (Powell et al., 1992; Miyoshi et al., 1992). These
observations are in accordance with Knudson's two-hit hypothesis which states that
both copies of APC must be inactivated during tumorigenesis. APC has therefore
been defined as a tumour suppressor gene. It is noteworthy that most sporadic
colorectal cancers also carry two inactivating APC mutations (Fearnhead et al.,
2001).
Another gene found to give rise to the multiple adenoma phenotype is the
base excision repair gene, MutYH (Al-Tassan et al., 2002). Base excision repair
essentially acts to prevent mutagenesis induced by 8-oxo-7,8-dihydroxy-2'-
deoxyguanosine (8-oxo-dG) (Sieber et al., 2003). Specifically, MutYH removes
adenines mispaired with 8-oxo-dG or guanine and a defect in this repair mechanism
was suspected from the observation that tumours from these patients had an excess of
somatic mutations comprising G:C-»A:T transversions in the APC gene, which is
typical of changes caused by oxidative damage to DNA (Lipton and Tomlinson,
2004). It is noteworthy that the genetic defect responsible for the polyposis
phenotype acts as a recessive trait in these families (Strate and Syngal, 2005) and is
very rare.
1.3.1.2 Hereditary Non-polyposis Colorectal Cancer
Hereditary non-polyposis colorectal cancer (HNPCC), also called Lynch
syndrome, is the most common form of hereditary colorectal cancer, accounting for
approximately 3 to 5% of all colorectal cancer cases (Rowley, 2004). HNPCC is
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characterised by the onset of colorectal cancer at an average age of 44 years and
frequent occurrence of other cancers such as endometrial, stomach, ovarian, small
bowel, hepatobiliary epithelium, uroepithelial epithelium and brain (de la Chapelle,
2004; Rowley, 2005). Patients with HNPCC have a 70-80% risk of developing
colorectal cancer (Rowley, 2005) and so the identification of carriers is clearly of
importance.
HNPCC is caused by mutations in one of the DNA mismatch repair (MMR)
genes, most commonly hMLHl, hMSH2, hMSH6, PMS1 or PMS2, and the condition
is inherited as an autosomal dominant (Rowley, 2004). Identification of HNPCC
kindreds has been facilitated by Amsterdam Criteria refined in 1999 (Lynch and de la
Chapelle, 2003). Individuals at risk in HNPCC kindreds are heterozygous for MMR
genes and so loss of MMR function requires both the germ line mutation and a
somatic mutation (Fearnhead et al., 2002). The MMR genes normally maintain
fidelity of DNA replication by correcting nucleotide mispairs and small insertions or
deletions generated by misincorporation or slippage of DNA polymerase during
transcription (Rowley, 2004). Dysfunction of these genes essentially causes
widespread genome instability, which can manifest as different numbers of simple
repeated sequences, such as microsatellites (Fodde et al., 2001a; Hopper, 2005). This
phenomenon is known as microsatellite instability (MSI) and disruption of
microsatellites is observed in the vast majority (>90%) of HNPCC patients and is
also seen in approximately 15% sporadic colorectal cancers (Fearnhead et al., 2002).
Unlike FAP, HNPCC patients lack a marked increase in the number of precursor
adenomas but tumours that do arise in these patients are genetically unstable and
rapidly progress to cancer (Kinzler and Vogelstein, 1998a). Thus, in contrast to FAP,
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which mainly affects tumour initiation, HNPCC primarily affects tumour
progression.
1.3.1.3 The Benefits of Screening for High Risk Individuals
The identification of a causative germ line mutation for colorectal cancer in a
patient's family by genetic testing would aid prevention because the option of
chemotherapy or as a last resort, prophylactic surgery, would be available before
presentation of metastatic disease (Kinzler and Vogelstein, 1996). Other current
screening methods for colorectal cancer include faecal occult blood test, rigid and
flexible sigmoidoscopy, colonoscopy and double contrast barium enema (Ahmed,
2003; Vainio and Miller, 2003; Hawk and Levin, 2005). Ultimately, early
identification of individuals and/or families at high risk should lead to a reduction in
the morbidity and mortality from colorectal cancer because a program of cancer
surveillance and treatment can be tailored to personal risk.
Knowledge of the molecular genetic basis of colorectal cancer is vital not
only to increase our understanding of the disease but to help identify targets that may
be important in treatment and/or prevention. Therefore, in addition to screening for
known mutations in genes implicated in hereditary colorectal cancer, the
identification of low-penetrance susceptibility alleles and modifier genes responsible
for sporadic forms of the disease is also imperative (de la Chapelle, 2004).
Prevention may be difficult on a population basis, but these studies would help to
identify individuals at risk for targeted prevention.
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1.3.2 Non-genetic and Environmental Susceptibility
Numerous genetic, experimental and epidemiological studies carried out to
date suggest that colorectal cancer is largely an environmental disease. The majority
of colorectal cancers are therefore described as being 'sporadic' as they have no
apparent underlying genetic predisposition. Sporadic colorectal cancer is associated
with a variety of risk factors, including: age, diet and lifestyle, and these are outlined
below.
1.3.2.1 Age
Age is the single most important risk factor for colorectal cancer - the risk of
developing colorectal cancer rises exponentially with age, commencing at 40 years,
rising to 50 years, and doubling with each decade, where it peaks at 70 years
(Heavey et al., 2004). Indeed, approximately 50% of the Western population
develops a colorectal tumour by the age of 70 and in about l in 10 of these
individuals, progression to malignancy ensues (Kinzler and Vogelstein, 1998b;
Kinzler and Vogelstein, 1998a).
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1.3.2.2 Diet
Epidemiological studies strongly suggest that the prevalence of colon cancer
can be influenced by diet. However, due to the complexity of human diets, it has
been difficult to determine which dietary components are responsible for this
modulation. Most research has therefore concentrated on the main groups of food
that are consumed, namely: fats, sugars and complex carbohydrates, proteins, and
fruit and vegetables.
1.3.2.2.1 Dietary Fat
There is substantial evidence that diets high in fat, especially saturated animal
fats, are associated with an increased risk of colorectal cancer [reviewed in
(Martinez, 2005; Correa Lima and Gomes-da-Silva, 2005)]. Colon cancer rates are
high in populations with high total fat intake but are lower in populations consuming
less fat. In high-incidence Western countries, fat comprises about 40-50% of total
caloric intake whereas in low-risk countries, fat only accounts for about 10% of
dietary calories (http://www.cancer.gov). Furthermore, there is an increased risk of
colorectal cancer among populations migrating from low to high risk areas (Key et
cil., 2002). Laboratory animal studies have shown that increasing the fat composition
of the diet is associated with an increase in incidence of colon tumours (Correa Lima
and Gomes-da-Silva, 2005). The reason for the increased incidence of colon cancer
as a result of high fat intake, particularly saturated fats, could be due to increased bile
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acid and cholesterol in the colonic lumen (Giovannucci and Willett, 1994; Mason,
2002). Colonic bacteria can convert these compounds to tumour-promoting
secondary bile acids and other cytotoxic metabolites that could potentially induce
cell proliferation and hence act as promoters of cancer of the colon (Gill and
Rowland, 2002). The discovery of the MOM1 gene in the multiple intestinal
neoplasia {Min) (APCMin/+) mouse model of colorectal cancer further supports the
idea that lipids are among the critical dietary components contributing to colorectal
cancer risk. The MOM1 gene encodes secreted phospholipase A2, an enzyme
involved in fat metabolism. This gene is a major modifier locus affecting intestinal
neoplasia in the Min mouse (Kinzler and Vogelstein, 1996). However, underscoring
the complexity of genetic susceptibility to colon cancer in humans, PLA2 has not
been associated with colon cancer risk (Tomlinson el al., 1996; Papanikolaou et al.,
2000; Fijneman, 2005). It is noteworthy that in contrast to saturated animal fats, there
is some evidence to suggest that consumption of polyunsaturated fats, in particular
marine fish oil and olive oil, has a protective role in colon carcinogenesis (Correa
Lima and Gomes-da-Silva, 2005). However, despite there being substantial evidence
that dietary fat intake may be correlated with incidence of colorectal cancer, the




There is reasonably consistent evidence from epidemiological data indicating
that that eating red meat (lamb or beef) and processed meat (sausages, salami, ham,
bacon) is positively related to risk of colorectal cancer (Martinez, 2005; Ahmed,
2004; Heavey et al., 2004; Lewin el al., 2006). Furthermore, this association tends to
be independent of the fat content of meat (Giovannucci, 2003). There are several
mechanisms to explain the association between meat consumption and colorectal
cancer [reviewed in (Cross and Sinha, 2004)]. Processing of meat may increase the
presence of nitrates and nitrites in the diet (Key et al., 2002). Although these
chemicals do not cause cancers directly, they can be converted to nitrosamines in the
body, which may help cause digestive system cancers. There has also been some
suggestion that the excess iron intake, which is more readily absorbed in the haem
form found in red meat, may also be associated with increased risk of colorectal
cancer (Kushi and Giovannucci, 2002). Flaem iron could influence the risk of cancer
via the generation of hydroxyl radicals in the colonic lumen (Correa Lima and
Gomes-da-Silva, 2005). It has been suggested that cooking methods of meat and fish
may also play a role, with the hypothesis that consumption of 'well done' meat
increases the risk of colorectal cancer compared with rare or medium rare intake
(Lewin et al., 2006; Giovannucci, 2002). This is most likely due to higher levels of
mutagenic heterocyclic aromatic amines in well done meat (Lewin et al., 2006; Cross
and Sinha, 2004). It is noteworthy that while red meat consumption is positively
associated with risk for colorectal cancer, non-red meat sources of animal protein,
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including fish and poultry, have typically been found to have little or even a slight
preventative effect against colorectal cancer (Giovannucci, 2002).
1.3.2.2.3 Dietary Fibre
Another important dietary factor that has been suggested to influence the
incidence of colorectal cancer is dietary fibre, although the evidence is conflicting. A
very recent pooled analysis of 13 prospective cohort studies revealed that dietary
fibre intake was inversely associated with risk of colorectal cancer in age-adjusted
analyses, but after accounting for other dietary risk factors, high dietary fibre intake
was not found to be associated with a reduced risk of colorectal cancer (Park et al.,
2005). These data are in contrast to the majority of animal and epidemiological
studies which show a protective effect of dietary fibre on colon carcinogenesis
[reviewed in (Ahmed, 2004; Martinez, 2005)]. Fibre is a very complex form of
carbohydrate that is either insoluble, typified by wheat bran and cellulose, or soluble,
for example legumes (Ahmed, 2004). Inclusion of fibre in the diet could influence
carcinogenesis in the large bowel by a number of mechanisms. Fibre generally
increases the bulk of stools, thereby decreasing the concentration of lumenal
carcinogens and tumour promoters, and reduces colonic transit time, thus limiting the
time of exposure of the colonic epithelium to carcinogens (Lao and Brenner, 2004).
Fibre can also bind bile acids and hence can lower stool pH, which in turn can
prevent the conversion of primary to harmful secondary bile acids (Gatof and Ahnen,
2002). Fibre may also act as a substrate for bacteria in the gut for fermentation,
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resulting in an increase in concentration of short chain fatty acids such as butyrate
(Campos et al., 2005). Butyrate has been shown to be anti-carcinogenic and can
induce apoptosis in colon adenoma and colon cell lines (Key et al., 2002).
Furthermore, butyrate is an important fuel for regeneration of the colonic epithelium
and may also have protective effects by lowering the pH in the colonic lumen
(Heavey et al., 2004). It is not clear whether the possible protective effects of fibre
described above against bowel cancer are due to fibre itself or to other protective
effects of fruit, vegetables and cereals that contain fibre.
1.3.2.2.4 Fruits and Vegetables
Colorectal cancer is less prevalent in Mediterranean countries where diet is
characterised by high consumption of foods of plant origin and low intake of red
meat, compared to countries that have a diet rich in meat, high in saturated fat and
poor in fibre (Correa Lima and Gomes-da-Silva, 2005). It is noteworthy, however,
that vegetarians in developed countries have not shown low death rates from
colorectal cancer, suggesting that vegetable and meat consumption may not be key
factors contributing to high rates of colorectal cancer in these countries (Key et al.,
2002). Many epidemiologic studies have examined the role of fruit and vegetable
intake in the incidence of colorectal cancer although these studies have provided
mixed results. Three large, prospective cohort studies did not observe a protective
effect of fruit and vegetables against colorectal cancer [reviewed in (Mason, 2002;
Lao and Brenner, 2004)]. In contrast, recent preliminary findings from the European
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Prospective Investigation into Cancer (EPIC) study suggest a moderate protective
effect for vegetables against colorectal cancer and the results of an Adelaide case-
control study have shown that a high intake of certain vegetables, such as onions,
legumes, cabbage, green leafy vegetables and raw fruit, is associated with a
decreased risk of colorectal cancer (Steinmetz and Potter, 1993). The protective
effects of fruits and vegetables have been attributed to various components of these
foods. In addition to being rich in fibre, fruits and vegetables contain
anticarcinogenic and antioxidant micronutrients such as beta carotene, folic acid,
ascorbic acid, phenols and flavonoids (Gatof and Ahnen, 2002). Dark leafy green
cruciferous vegetables, such as broccoli, have also been found to contain
glucosinolates, which can induce glutathione ^-transferase (GST) activity and have
been shown to exhibit chemopreventive activity by upregulating certain hepatic and
gut mucosal detoxification enzymes (Heavey et al., 2004; Martinez, 2005).
Furthermore, in one case-control study (Lin et al., 1998), the authors established that
subjects with the highest intake of broccoli (an average of 3.7 servings per week) had
an odds ratio of 0.47 for colorectal adenomas, when compared with people who
reportedly never ate broccoli.
1.3.2.2.5 Vitamins and Minerals
An abundant array of micronutrients, including: vitamins A, C, D, E, folic
acid and B6; minerals, for example calcium and selenium; and phytochemicals, such
as carotenoids and flavonoids, have been shown to have a protective effect against
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colorectal cancer. Table 1.1 summarises the common dietary sources and possible
mechanisms for the beneficial effects of some of these compounds.
1.3.2.3 Lifestyle and Colorectal Cancer
In addition to dietary factors, certain lifestyle factors, including: physical
activity, energy balance/obesity, alcohol consumption and smoking, are known to
influence the risk of colorectal cancer.
1.3.2.3.1 Physical Activity
A substantial body of epidemiological evidence supports an association of a
sedentary lifestyle with an increased risk of colorectal cancer (Martinez, 2005). In
fact, there is a strong inverse relationship between the levels of physical activity and
colon cancer incidence (Giovannucci, 2003; Lao and Brenner, 2004). At the
molecular level, dysregulation of the 5'-AMP-activated protein kinase (AMPK),
which is a key kinase involved in regulating cellular lipid metabolism and protein
metabolism in response to exercise, has been associated with a predisposition to
certain cancers, including colon cancer (Luo et al., 2005b). This kinase has therefore
been identified as a potential target for anti-cancer agents. In particular, inhibitors of
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Table 1.1 - Summary of Protective Effects of Micronutrients for Colorectal Cancer.
[Table adapted from (Correa Lima and Gomes-da-Silva, 2005)]
28
have been characterised and are in clinical development as anti-cancer agents
(Thomas, 2006). In general, an approximately 30% to 50% reduction in colorectal
cancer incidence has been documented among individuals with the highest levels of
physical activity compared to those with low levels of activity (Giovannucci, 2003;
Ahmed, 2004). The biological mechanisms which have been proposed for the
observation that increased physical activity protects against colorectal cancer
include: maintenance of a healthy body weight and facilitation of the transit time of
colonic contents, thus decreasing the time of exposure of the colonic epithelium to
potentially harmful agents (Gatof and Ahnen, 2002). At the molecular level, exercise
could positively influence metabolic pathways, such as the AMPK pathway, and
hence could protect against cancer, perhaps by countering or correcting insulin
resistance associated with obesity or by reducing triglyceride levels (Luo et al.,
2005b). Moreover, physical activity could have favourable effects on the immune
system, such as a reduction in concentration of prostaglandins in the rectal mucosa
(Martinez, 2005).
1.3.2.3.2 Obesity
A high calorie intake combined with a sedentary lifestyle results in a positive
energy balance and inevitably leads to weight gain, by virtue of increased adipose
tissue, and clinical obesity. Many retrospective and prospective studies have
demonstrated that a high body mass index (BMI), the result of being obese, is
associated with an increased risk of colorectal cancer [reviewed in (Gunter and
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Leitzmann, 2006; Ahmed, 2004; Martinez, 2005)]. A BMI of above 30 is associated
with about a twofold increased risk of colorectal cancer (Gatof and Ahnen, 2002).
Furthermore, there is evidence that a tendency for visceral or central adiposity,
expressed as the waist-to-hip ratio, is associated with a higher risk of developing
colorectal cancer, independent of the BMI (Giovannucci, 2003). Several mechanisms
have been proposed for the association of obesity with an increased risk of
developing colorectal cancer. Specifically, insulin resistance and resulting
hyperinsulinemia have been proposed as the major mechanisms (Giovannucci, 2002).
A high concentration of circulating insulin may have a mitogenic action on
colonocytes, affecting cellular proliferation and apoptosis via activation of signal
transduction pathways such as protein kinase C (PKC) and mitogen activated protein
kinase (MARK) pathways (Campos el a/., 2005; Gunter and Leitzmann, 2006).
Higher circulating levels of insulin may additionally increase the levels and
availability of insulin-like growth factor-1 (IGF-1), which can also promote cellular
proliferation (Giovannucci, 2003; Campos el al., 2005). The insulin hypothesis is
further supported by the observations that type 2 diabetes mellitus is associated with
a higher risk of colorectal cancer (Giovannucci, 2003; Martinez, 2005).
1.3.2.3.3 Alcohol
There is evidence from case-control and prospective studies of an association
between high alcohol intake and elevated risk of colorectal cancer, although there are
conflicting reports in the literature (Fleavey et al., 2004; Ahmed, 2004; Martinez,
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2005). The mechanism whereby alcohol increases the risk for colorectal cancer is
unknown but folate metabolism has been implicated (Giovannucci, 2002).
Acetaldehyde, a breakdown metabolite from alcohol, may inactivate N3-
methyltetrahydrofolate, the form of folate required for methionine synthesis, or may
inhibit the methionine synthetase complex or folate-related enzyme, MTHFR
(methylene-tetrahydrofolate reductase) (Giovannucci and Willett, 1994;
Giovannucci, 2003; Martinez, 2005). As mentioned previously, folate is implicated
in key cellular processes such as DNA synthesis and repair. It follows, therefore, that
reduced folate levels as a result of excessive alcohol intake could enhance the
process of carcinogenesis by interrupting these critical cellular processes. Indeed,
there is a 2-5 fold elevation in colorectal cancer risk among individuals with high
intakes of alcohol and low intakes of folate (Giovannucci, 2003). In addition to its
effects on folate metabolism, alcohol has been shown to stimulate cell proliferation
in the rectum (Correa Lima and Gomes-da-Silva, 2005) and can contribute to the
MSI phenotype (Heavey et al., 2004).
1.3.2.3.4 Smoking
A higher risk of adenomatous polyps has been consistently observed among
smokers in numerous studies (Giovannucci, 2002), although the evidence for a
positive association between smoking and colorectal cancer has been conflicting
(Ahmed, 2004; Martinez, 2005). An induction period of 30-40 years between
smoking and risk of colorectal cancer has been proposed to account for the
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discrepancy for the results of adenomas compared to colorectal cancer in relation to
smoking (Gatof and Ahnen, 2002). More recently published studies have found an
elevated colorectal cancer risk, approximately 2-4 times the average risk, for tobacco
smokers (Giovannucci, 2002; Ahmed, 2004). Cigarette smoking likely increases the
risk of colorectal cancer due to carcinogenic action of polycyclic aromatic
hydrocarbons, nitrosamines and aromatic amines that are found in burned tobacco
(Ahmed, 2004). Polycyclic aromatic hydrocarbons form harmful DNA adducts in the
colonic mucosa (Giovannucci, 2002) and furthermore, the carcinogenic compounds
found in tobacco smoke can cause MSI (Heavey et al., 2004).
1.3.2.3.5 Hormone Replacement Therapy
The correlation between hormone replacement therapy (HRT) and colorectal
cancer has been widely researched and the majority of case-control and cohort
studies to date have demonstrated that women who use HRT postmenopausally have
an approximately 20-40% decreased risk of colorectal cancer, independent of other
risk factors (La Vecchia et al., 2005; Hawk et al., 2004; Raju and Cruz-Correa,
2006). For example, a prospective cohort study of 59,002 postmenopausal
participants from the Nurses' Health Study found that current users of
postmenopausal hormones had a protective effect against the development of
colorectal cancer (relative risk 0.65), an association that was attenuated in past users
but disappeared by 5 years after cessation of therapy (Grodstein et al., 1998). It is
thought that the protective effects of HRT could reflect a direct benefit of estrogens.
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Estrogens have been postulated to prevent colorectal cancer by decreasing the
production of secondary bile acids and IGF-1, by exerting a direct effect on the
colorectal epithelium, or by a combination of both of these mechanisms (Janne and
Mayer, 2000; Ahmed, 2004). However, a recent study (Anderson et al., 2004)
documented no protective effect of estrogen-only HRT compared with placebo,
suggesting that progestin may be more important or that estrogen-independent
mechanisms exist for the protective effects of HRT.
1.3.2.4 Other Risk Factors
In addition to the dietary and lifestyle risks described above, the presence of
benign growths, called polyps or adenomas, can significantly increase the risk of
developing colorectal cancer (Winawer et al., 1996). Polyps or adenomas are not
uncommon in the general population. Indeed, approximately 5% of people have
polyps by age 50 and this increases to 50% for people over 70 years old (Kinzler and
Vogelstein, 1996). It is important to note, however, that only a small fraction of
polyps do develop into cancer and this process takes years.
People with other bowel diseases, such as ulcerative colitis, Crohn's disease
and inflammatory bowel disease are at greater risk of developing colorectal cancer
(Lichtenstein, 2002). These diseases cause continuous inflammation of the bowel
such that the lining of the bowel becomes damaged. This damage is constantly
repaired but the resultant increase in cell turnover augments the risk that a cancerous
cell might develop. In terms of prevention, it would therefore be important to closely
monitor patients with such bowel diseases for the development of colorectal cancer.
1.3.2.5 Dietary and Lifestyle Goals for Prevention of Colorectal
Cancer
General preventative strategies to help combat colorectal cancer have been
devised and proposed, based on the knowledge that dietary and lifestyle factors
contribute significantly to the development and progression of colorectal cancer, and
these are summarised in Table 1.2. Briefly, the consumption of saturated animal fat
should be kept to a minimum and only one portion of red meat should be consumed
per week. Five servings of fruit and vegetables should be eaten daily and the amount
of fibre in the diet should be around 30-35 g per day. Some authors suggest that
supplements of vitamins and minerals, in particular vitamins A, C, E and B6, calcium
and selenium, would be advisable although sufficient quantities of these
micronutrients can be obtained through the diet from eating fruits and vegetables. In
general, energy in the form of calories taken in from the diet should not exceed
energy expenditure so as to maintain a healthy body weight and prevent obesity. The
partaking of regular exercise is also important to help maintain a healthy body
weight, in addition to reducing colonic transit time. Finally, less than two drinks of
alcohol should be consumed a day and no cigarettes or tobacco smoked to help
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Table 1.2 - Summary of Dietary and Lifestyle Factors for Colorectal Cancer
Prevention.
[Table adapted from (Mason, 2002)]
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1.4 Chemoprevention of Colon Cancer
Although dietary and lifestyle intervention can have a considerable impact on
reducing the risk of developing colorectal cancer, it is very difficult to devise and
implement such prevention strategies on a large scale due to lack of compliance.
Chemoprevention therefore represents an attractive, alternative approach to reducing
the mortality from colorectal cancer and essentially involves the long-term use of
chemical agents that can delay, prevent or reverse the development of adenomas and
interfere with the multi-step progression from adenoma to carcinoma (Benamouzig,
2005; Arber and Levin, 2005). The challenge for chemoprevention is to develop safe
and effective drugs for colorectal cancer which are easy to administer and of low cost
(Thun et al. 2002). One class of compounds that have shown considerable promise in
the chemoprevention of colorectal cancer are NSAlDs.
1.4.1 NSAIDs Prevent Colorectal Cancer
In recent years, there is substantial evidence from animal models,
epidemiological reports, clinical observations, and in vitro studies that the use of
aspirin and related NSAIDs is associated with colon cancer prevention [reviewed in
(Arber and Levin, 2005; Thun et al., 2002; Haanen, 2001; Shiff and Rigas, 1997;
Smalley and DuBois, 1997)].
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1.4.1.1 Evidence of Protective Effects of NSAIDs from
Epidemiological Studies and Clinical Trials
Epidemiological studies with different design, location and population groups
have consistently shown that persons who regularly take aspirin or related non-
aspirin NSAIDs, have a 40-50% lower risk of developing colorectal neoplasias
[reviewed in (Benamouzig et al., 2005; Brown and DuBois, 2005; Imperiale, 2003;
Burke et al., 2003; Giovannucci, 1999; Shiff and Rigas, 1997)]. An inverse
association between aspirin use and the risk for colorectal cancer has been suggested
from studies of patients with rheumatoid arthritis. In both a Swedish cohort study
(Gridley et al., 1993) and Finish cohort study (Kauppi et al., 1996), which were
conducted on 11,863 and 9,469 patients hospitalised with rheumatoid arthritis
respectively using record linkage analysis, a reduction of approximately 40% in risk
for colon carcinoma was reported. Similarly, the results of the population-based
Melbourne colorectal cancer study (Kune et al., 1988), which included 715
colorectal cancer cases and 727 age/sex-matched controls, found an inverse
association between aspirin use and risk for colorectal cancer. A prospective study,
including 662,424 men and women from the Cancer Prevention Study II of the
American Cancer Society, subsequently reported that regular aspirin use at low doses
(>16 times per month) reduces the risk of fatal colon cancer by approximately 40%
in both men and women (Thun et al., 1991). Data from the Nurses' Health Study,
comprising a cohort of 121,701 U.S. female registered nurses aged 30-55 years,
suggested that regular aspirin use substantially reduces the risk of colorectal cancer,
although the protective effects may not be apparent until after a decade of aspirin
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consumption (Giovannucci et al., 1995). A more recent population-based cohort
study with secondary case-control analysis of 943,903 persons aged 40-79 years,
traced from the General Practice Research Database in the UK, reported a 40%
reduction in the risk of developing colon cancer among long-term users of aspirin at
doses of 300 mg daily (Garcia-Rodriguez and Huerta-Alvarez, 2001).
In addition to aspirin, there is also compelling evidence from epidemiological
studies that non-aspirin NSAIDs prevent colorectal cancer. An initial report that
sulindac therapy could induce polyp regression in FAP patients (Waddell and
Loughry, 1983) was followed by numerous other non-randomised studies
documenting similar findings. One study (Rigau et al., 1991) found a marked
reduction in the number and size of polyps in 7 patients with different forms of
adenomatous polyposis after treatment with sulindac for 6 months, an effect that was
reversed after withdrawal of the drug. Similarly, another study (Makela and Laitinen,
1994) demonstrated that sulindac therapy mediated the regression and/or
disappearance of rectal polyps in two FAP patients and that discontinuation of
treatment resulted in regression. The results of a prospective, controlled, non-
randomised study of 38 FAP patients demonstrated that there was a significant
reduction of adenomas in response to sulindac treatment after three years of therapy
(Winde et al., 1997). In an open prospective study of 17 patients with FAP, it was
found that daily treatment with 300 mg sulindac for four months, followed by a
washout phase of 6 months, led to a significant reduction in the number and size of
adenomas (Guldenschuh et al., 2001). The metabolite of sulindac, sulindac sulfone
(exisulind), has also been shown to have a protective effect against colorectal cancer.
One study (Stoner et al., 1999) demonstrated a 25% reduction in rectal adenomas in
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73 FAP patients treated with exisulind. A subsequent non-randomised Phase I trial of
exisulind in 18 FAP patients established that there was a trend towards increased
apoptosis in polyps at the maximum tolerated dose (600 mg/day) (van Stolk et al.,
2000). The only epidemiological data concerning the protective benefits of
indomethacin and risk of colorectal cancer comes from a population-based cohort
study with secondary case-control analysis using the UK General Practice Research
Database (Garcia Rodriguez and Iduerta-Alvarez, 2000). In that study, the relative
risk of either colorectal adenoma or colorectal cancer among regular users of
indomethacin was documented as being 0.4 (95% confidence intervals 0.2 to 1.0)
when compared to NSAID non-users.
It is important to note that all epidemiological studies, by their nature, are
observational and therefore provide little information as to the most effective dose
and duration of drug use. The most definitive evidence for the anti-tumour effects of
NSAIDs comes from randomised controlled trials. Until recently, only one
randomised trial of aspirin with respect to reduced risk of colorectal cancer had been
conducted, the Physicians' Health Study (Stunner et al., 1998). The authors reported
no significant protective effect either during the 5 year study period or up to 12 years
after the study began. However, the results of three new randomised trials suggest
that aspirin reduces the risk of recurrent adenomas among persons with a history of
colorectal cancer or adenomas. In one study (Sandler et al., 2003), the authors found
that daily use of aspirin (325 mg/day) is associated with a significant reduction in the
incidence of colorectal adenomas in patients with previous colorectal cancer. In a
separate study (Baron et al., 2003), it was demonstrated that low-dose aspirin (81
mg/day), but not a higher dose (325 mg/day), has a moderate chemopreventative
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effect on adenomas in the large bowel in patients with a recent history of adenomas.
Similarly, another study (Benamouzig et al., 2003) reported preliminary findings
from a 4 year trial that daily soluble aspirin intake (160 or 300 mg/day) is associated
with a reduction in the risk for recurrent adenomas, as identified by colonoscopy 1
year after starting treatment.
Although the results of a recent randomised control trial of sulindac in 41
FAP patients found that sulindac was ineffective for the primary treatment of FAP
and that the long-term use of sulindac resulted in resistance to the medication
(Giardiello et al., 2002), three previous randomised control trials have demonstrated
a protective benefit of sulindac therapy in FAP patients. A randomised, placebo-
controlled, double-blind cross over study was first conducted in 10 FAP patients with
rectal polyps, who had previously been treated by colectomy and ileorectal
anastomosis, and observed complete (6 patients) or almost complete (3 patients)
regression of polyps in patients treated with sulindac (300 mg/day) for two 4-month
periods separated by a one month wash-out phase (Labayle et al., 1991). These
observations were confirmed by a subsequent randomised control trial in 24 FAP
patients who had previously undergone prophylactic colectomy and had advanced
duodenal polyposis (Nugent et al., 1993). In that study, six months of sulindac
therapy was found to be associated with a trend towards duodenal polyp regression
(P=0.12). Similarly, the results of another randomised, double-blind, placebo
controlled study of 22 FAP patients, of which 18 had not undergone colectomy,
found that patients who received sulindac (150 mg twice a day) for nine months had
a statistically significant decrease in the mean number of polyps and mean diameter
of polyps, as compared with those given placebo (Giardiello et al., 1993). A very
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recent randomised, double-blind, placebo controlled, dose-response study of
exisulind in 281 patients with sporadic adenomatous polyps established that
treatment with exisulind (400 mg daily) for 12 months caused significant reduction
in median polyp size and inhibited disease progression as compared to placebo
treatment (Arber et al., 2006). However, in that study, treatment with exisulind was
associated with a degree of toxicity. There have been no clinical trials for
indomethacin specifically with regards prevention for colorectal cancer, but a
randomised, placebo-controlled trial of indomethacin (50 mg twice daily) or
prednisolone (10 mg twice daily) in patients with disseminated solid malignancy
(colorectal cancer 22% cases, liver/pancreatic cancer 33% cases) demonstrated that
indomethacin prolonged mean survival from 250±28 days to 510±28 days (P<0.05)
compared with placebo treatment (Lundholm et al., 1994).
Collectively, these data from epidemiological observations and clinical trials
clearly demonstrate that NSAlDs, in particular aspirin, sulindac, sulindac sulfone and
indomethacin, prevent colorectal cancer.
1.4.1.2 Evidence of Protective Effects of NSAIDs from Animal
Studies
In addition to epidemiological studies and clinical trials in humans, the anti¬
neoplastic properties of NSAIDs are clearly apparent in animal (mainly rodent)
models of colon cancer. One of the first studies discovered that rats co-administered
DMH (1,2-dimethylhydrazine), a colon carcinogen, and indomethacin developed
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fewer colon tumours compared with rats just given the carcinogen alone (Pollard and
Luckert, 1981). Similar studies in rats treated with azoxymethane (AOM), a
carcinogen that causes development of colorectal cancer, have demonstrated that
NSAIDs, including aspirin (Reddy et al., 1993), sulindac sulfone (Haanen, 2001) and
nimesulide (Fukutake et al., 1998), can suppress AOM-induced colon
carcinogenesis. Investigators in these and related studies concluded that NSAIDs
inhibit the initiation and development of carcinogen-induced tumours (Shiff and
Rigas, 1997). However, it is important to note that in these animal studies, the
anticancer effect of NSAIDs was shown to be reversible as tumour occurrence
increased when the agent was discontinued (Baron and Sandler, 2000).
More recently, studies have been conducted using mouse models of
hereditary colorectal cancer, the most common being the Min mouse model. The Min
(.APCMin/+) mouse is a neoplasia model in which an autosomal, dominant
heterozygous mutation of the mouse APC gene leads to spontaneous intestinal
neoplasia, resembling FAP in humans (Giovannucci, 1999). However, unlike
humans, who show colonic adenomas, the predominant location of tumours in the
mouse is in the small intestine. In this mouse model, the administration of the
NSAIDs, sulindac (Chiu et al., 1997), aspirin (Barnes and Lee, 1998) and piroxicam
(Jacoby et al., 1996), has been shown to reduce the number and size of tumours in
both the small and large intestine. Another animal model used to study colorectal
cancer is the nude mouse xenograft model, where cultured colorectal cancer cells are
xenografted onto the flanks of nude (athymic) mice (Gupta and DuBois, 2001).
Using this model, the NSAIDs meloxicam (Goldman et al., 1998) and celecoxib
(Williams et al., 2000) have been shown to suppress colorectal cancer cell growth.
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Interestingly, very recent studies from the host laboratory have established that, using
both the Min mouse and nude mouse xenograft models of colorectal cancer, aspirin
induces apoptosis in intestinal tumours. Moreover, aspirin-induced apoptosis was
associated with activation of the NF-kB pathway, suggesting a possible mechanism
for the protective effects of NSAIDs in vivo (Reid et al., 2004). The NF-kB pathway
as a target for the chemopreventative effects of NSAIDs will be discussed in detail
later. It should be noted that although these animal models of colon cancer are useful,
the direct implications for human colorectal cancer are unclear [reviewed in (Corpet
and Pierre, 2005)].
1.4.1.3 Evidence of Protective Effects of NSAIDs from in vitro
Studies
In vitro, NSAIDs have been shown to alter cellular functions that are crucial
for the development of colorectal tumours, which will be discussed in more detail,
including: cell proliferation, cell division, cell cycle phase distribution, induction of
cell cycle quiescence and apoptosis [reviewed in (Ricchi et al., 2003; Hull et al.,
2003; Thun et al., 2002; Haanen, 2001; Shiff and Rigas, 1997)]. In addition to these
effects, NSAIDs modulate several other cellular processes that may be implicated in
their protective effects against colorectal cancer. A few studies have indicated that
NSAIDs can up-regulate the expression of major histocompatibility complex (MHC)
(Rigas et al., 1994) and human leukocyte antigen (HLA) class II molecules (Arvind
et al., 1995). This could ultimately restore the ability of the immune system to
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eliminate transformed cells expressing tumour-related antigens. For a solid tumour to
grow larger than approximately 2 mm in diameter, it must stimulate the formation of
new capiliary blood vessels, a process known as angiogenesis (Thun et al., 2002).
There is a growing body of evidence that NSAlDs can inhibit angiogenesis
[reviewed in (Brown and DuBois, 2005; Thun et al., 2002)]. Both aspirin and the
cyclooxygenase (COX)-2-selective inhibitor, NS-398, have been shown to suppress
the migration and release of angiogenic growth factors by colorectal cancer cells that
are co-cultured with vascular endothelial cells (Tsujii et al., 1998). Moreover, the
authors found that aspirin, but not NS-398, suppressed tube formation of vascular
endothelial cells. Furthermore, it has been demonstrated that indomethacin and NS-
398 inhibit in vitro angiogenesis in rat aortic cells and human dermal microvascular
endothelial cells (Jones et al., 1999). Finally, NSAIDs can modulate the activation of
carcinogens, production of mutagens or formation of harmful peroxyl radicals via
their COX-inhibitory activity (Shiff and Rigas, 1997). The role of COX in the
mechanism of action ofNSAID will be the subject of further discussion later.
1.4.1.3.1 NSAIDs Inhibit Cell Proliferation
Inhibiting colonocyte proliferation has been postulated as a potential
mechanism by which NSAIDs retard the growth of colorectal neoplasias and there is
evidence to support this. In particular, the NSAIDs aspirin (Ricchi et al., 1997; Qiao
et al., 1998a; Smith el al., 2000), sulindac (Shiff et al., 1995; Shiff et al., 1996;
Goldberg et al., 1996), sulindac sulfone (Piazza et al., 1995; Richter et al., 2001),
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indomethacin (Shiff et al., 1996; Smith el al., 2000; Kralj el al., 2001), naproxen
(Shiff et al., 1996), piroxicam (Hanif et al., 1996) and the COX-2-selective
inhibitors, NS-398 (Smith et al., 2000) and SC215 (Richter et al., 2001), have been
shown to inhibit proliferation of colorectal cancer cells. The major mechanisms
whereby NSAIDs inhibit cell proliferation are 1. inhibition of cell division, through
alteration of cell cycle phase distribution or induction of cell cycle quiescence and 2.
promotion of apoptosis. These pathways will now be discussed further.
1.4.1.3.2 NSAID Effects on the Cell Cycle
Progression of a cell through the various phases of the cell cycle is promoted
by a number of cyclin-dependent kinases (CDKs) which, when complexed with
specific regulatory proteins called cyclins, drive the cell forward through the cell
cycle (Schwartz and Shah, 2005). For example, a principal target of CDKs at the
G)/S transition of the cell cycle is the retinoblastoma protein (pRb). pRb is present in
a hypophosphorylated state in quiescent or Go cells (Cobrinik, 2005).
Hypophosphorylated pRb forms an inhibitory complex with the E2F family of
transcription factors by directly binding to the transactivation domain of E2F, thus
blocking the ability of E2F to activate expression of genes that encode products
necessary for S-phase progression (Giacinti and Giordano, 2006). Phosphorylation of
pRb by cyclin/CDK complexes (CDK4/6-Cyclin D and CDK2/Cyclin E) leads to the
release of E2Fs, which in turn activate the transcription of genes required for cell
cycle progression (Schwartz and Shah, 2005). Progression through the cell cycle
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mediated by cyclin/CDK complexes is monitored at several positions, known as cell
cycle checkpoints (Collins and Garrett, 2005). The activity of the CDK/cyclin
complex is further negatively regulated by a number of CDK inhibitors (CDKIs),
including p21 (wafl/cipl) and p27 (kip 1) (Vermeulen et al., 2003a).
There is a body of evidence that NSAIDs alter the expression levels of cell
cycle proteins and induce cell cycle arrest. Sulindac sulfide has been shown to
decrease the expression of cyclins B1 and E, and increase the expression of cyclins
Dl, D2 and D3, particularly in the Gi phase of the cell cycle, in HT-29 colon cancer
cells (Qiao et al., 1998b). It has also been observed that aspirin and indomethacin
reduce the levels of two CDKs, namely p34Ldt2 and p33Ldk2 (Shiff et al., 1996).
Moreover, in parallel with this effect, these agents were found to increase the
proportion of cells in the Gq/Gi phase but reduce the proportion of cells in the S
phase and G2/M phases of the cell cycle. Sulindac and sulindac sulfide have been
reported to induce cell cycle arrest at the G0/G1 phase (Shiff et al., 1995).
Furthermore, this effect was associated with reduced expression and reduced
catalytic activity of CDKs. NSAIDs have also been shown to up-regulate CDKIs,
such as p27kipl and p21waf,/cip 1 (Ricchi et al., 2003). One study (Marra et al., 2000)
demonstrated that sodium salicylate increases the expression of p27kipl and
p21"a"/c,pl in vascular smooth muscle cells. Another study (Yang et al., 2001b)
reported that p211/cipl is induced by sulindac in SW620 colorectal cancer cells.
Furthermore, inactivation ofp21 in APC*1' mice completely eliminated the ability of
sulindac to inhibit APC-initiated tumour formation, thus demonstrating that p21 is
critical for tumour inhibition by this drug (Yang et al., 2001b). Similarly, it has been
shown that the COX-2 selective inhibitor celecoxib induces Gq/Gi cell cycle arrest,
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an effect that was attributed to increased expression of CDKIs p2lwatl/upl and p27kipl
(Grosch et al., 2001). More recently, it has been reported that Go/Gi cell cycle arrest
induced by celecoxib in colorectal cancer cells is correlated with a decrease in the
expression levels of cyclin A and cyclin B1 and an increase in the expression of the
CDKIs p2lwatl/cipl and p27kipl (Maier et al., 2004). It has also been demonstrated that
sulindac sulfide-induced cell cycle arrest in MEFs is mediated by pRb and p2iwjll/upl
(Jung et al., 2005). Furthermore, MEFs deficient in p21 or pRb were more
susceptible to sulindac sulfide-mediated cell death, leading the authors to propose
that this agent may selectively target cells with cell cycle checkpoint deficits. In
another recent study (Xu and Zhang, 2005) it was reported that indomethacin
downregulates the expression of CDK2 and CDK4 and upregulates the expression of
p21wafi/eip1 jn sw48(3 cells transfected with wild-type p53, but not parental SW480
cells, suggesting that indomethacin induces cell cycle arrest at the G2 phase and
inhibits cell proliferation in a p53- p21wall/cipl dependent manner.
1.4.1.3.3 NSAIDs Induce Apoptosis
Apoptosis, or programmed cell death, is needed to maintain homeostasis in
continuously replicating tissues such as the intestine and partial suppression of
apoptosis is known to occur early in colorectal tumorigenesis (Thun et al., 2002).
There is substantial evidence that both traditional NSAIDs, including aspirin (Qiao et
al., 1998a; Stark et al., 2001; Stark and Dunlop, 2005), sulindac (Haanen, 2001; Jung
et al., 2005), sulindac sulfide (Piazza et al., 1995; Shiff et al., 1995; Sinicrope and
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Penington, 2005), sulindac sulfone (Piazza et al., 1995; Babbar et al., 2003),
indomethacin (Kralj et al., 2001; Smith et al., 2000), piroxicam (Hanif et al., 1996;
Shiff et al., 1996) and naproxen (Shiff et al., 1996), and COX-2 selective NSAlDs,
such as celecoxib (Grosch et al., 2001; Maier et al., 2004) and NS-398 (Smith et al.,
2000; Smartt et al., 2003) induce apoptosis of colorectal cancer cells.
After treatment with NSAIDs, for example sulindac (Piazza et al., 1995),
sulindac sulfone (Shiff et al., 1995; Babbar et al., 2003), aspirin (Qiao et al., 1998a;
Smith et al., 2000; Stark et al., 2001) and indomethacin (Smith et al., 2000; Kralj et
al., 2001), colon cancer cells undergo several morphological changes that are
associated with apoptotic activation, including cell shrinkage, development of
membrane blebs characterised by externalisation of phosphatidyl serine, nuclear
condensation, fragmentation of genomic DNA and formation of apoptotic bodies.
Moreover, these effects can be inhibited by agents that block gene expression, such
as cyclohexamide, suggesting that cell death induced by NSAID treatment is genuine
programmed cell death and not necrotic cell death caused by general toxic effects of
the drugs (Chan et al., 1998; Chan, 2002).
Two pathways to apoptosis downstream of the 'death signal' have been
recognised, the transmembrane 'extrinsic' pathway and the mitochondrial 'intrinsic'
pathway (Hersey and Zhang, 2003). Both pathways depend on activation of cysteine
proteases called caspases. These enzymes are synthesised as proenzymes that
become activated by adaptor proteins. Once activated, so-called initiator caspases
can activate effector caspases, which act on a wide range of substrates to cause
apoptosis (Gross et al., 1999). The extrinsic pathway is initiated by ligation of a
trans-membrane death receptor, which contains an intracellular globular protein
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interaction domain called a death domain (DD) and is typified by members of the
tumour necrosis factor receptor (TNFR) family such as Fas (Thorburn, 2004). Upon
ligand binding to death receptors, oligomerisation of activated receptors leads to
recruitment of the adaptor protein, called fas associated death domain (FADD) via
their mutual DDs (Budd, 2001). FADD then recruits caspase-8 via interaction with
their N-terminal death effector domains (Boatright and Salvesen, 2003) and it is
within this death-induced signaling complex (DISC) that the initiator caspase-8 is
activated. Activated caspase-8 can then in turn activate effector caspases, such as
caspase-3, -6 and -7, causing the cell to undergo apoptosis via degradation and
digestion of various cellular components (Thorburn, 2004).
In contrast, the intrinsic pathway is dependent on the release of pro-apoptotic
molecules from mitochondria (Hersey and Zhang, 2003). Following the death trigger,
mitochondria may become slightly permeabilised by disruption of the outer
membrane, leading to the release of cytochrome c, which can complex with Apaf-1
and caspase-9, forming the 'apoptosome' (Budd, 2001). Apaf-1 recruits caspase-9
via its N-terminal caspase-activation recruitment domain (CARD) (Boatright and
Salvesen, 2003). Procaspase-9 becomes activated by undergoing a conformational
change and thereby can activate effector caspases, in particular caspase-3, -6 and -7,
resulting in apoptosis (Flersey and Zhang, 2003). Another factor released from
mitochondria that can mediate apoptosis is Smac, which inactivates the inhibitor of
apoptosis (IAP) and also results in activation of downstream effector caspases (Budd,
2001).
It has been demonstrated that NSAIDs, including sulindac sulfide (Rice et al.,
2001; Richter et al., 2001), sulindac sulfone (Rice et al., 2001; Richter et al., 2001),
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aspirin (Gao et al., 2004), indomethacin (Gao et al., 2004) and celecoxib (Grosch et
al., 2001; Maier et al., 2004) can activate caspases, in particular caspase-3, caspase-7
and caspase-9, enhance cleavage of PARP, a 112 kDa protein that is specifically
cleaved by activated caspase-3 and caspase-6, and stimulate cytochrome c release, all
of which are key markers of the intrinsic pathway to apoptosis. NSAlDs have also
been shown to activate the extrinsic pathway to apoptosis. Indomethacin and
sulindac sulfide induce apoptosis in human leukemic Jurkat cells by a mechanism
that requires the FADD-mediated activation of caspase-8 (Han et al., 2001).
Similarly, apoptosis induced by sulindac sulfide and the COX-2-selective inhibitor,
SC-236, is coupled with upregulation of death receptor (DR) 5, caspase-8 activation
and Bid cleavage in HCT116 colorectal cancer cells (He et al., 2002). Increased
levels of the membrane death receptors, DR4 and DR5, and activation of caspase-8
in response to sulindac sulfide in SW480 colorectal cancer cells have been reported
(Sinicrope and Penington, 2005), indicating stimulation of the extrinsic apoptotic
pathway. Moreover, it was discovered that sulindac sulfide-mediated stimulation of
the extrinsic pathway occurred alongside activation of the intrinsic pathway in
response to sulindac sulfide.
The role of Bcl-2 family members in apoptosis is well established and
extensively reviewed (Gross et al., 1999; Borner, 2003). Bcl-2 family proteins are
central regulators of apoptosis because they integrate diverse survival and death
signals that are generated both outside and inside the cell. The family is subdivided
into two classes: anti-apoptotic members, such as Bcl-2 and Bcl-XL (the Bcl-2-like
survival factors), which protect cells from apoptosis; and pro-apoptotic members,
including Bax and Bak (the Bax-like death factors) and the large group of BH3 (Bcl-
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2 homology region 3)-only death proteins, which trigger or sensitize for apoptosis
(Borner, 2003). The relative levels of the various members of the Bcl-2 family
regulate survival and apoptosis in cells (Ricchi et al., 2003).
A role for the pro-apoptotic gene Bax in NSAID-induced colorectal cancer
cell death has been proposed (Zhang et al., 2000). In contrast to parental cells, Bax'1'
HCT116 colorectal cancer cells were discovered to be resistant to apoptosis induced
by sulindac or indomethacin. Moreover, in several parental colorectal cancer cell
lines, both sulindac and indomethacin inhibited the expression of the anti-apoptotic
protein Bcl-X^, resulting in an altered ratio of Bax to Bcl-X^ and subsequent
mitochondria-mediated cell death. Similarly, aspirin and indomethacin were shown
to induce apoptosis through upregulation of the pro-apoptotic proteins Bax and Bak
and activation of caspase-3 (Zhou et al., 2001). In contrast to these studies, the COX-
2 selective inhibitors, SC-58125 and NS-398 have been reported to sensitize colon
and prostrate cancer cells, respectively, to apoptosis by downregulating the anti-
apoptotic protein Bcl-2 (Liu et al., 1998). Interestingly, in a recent study (Sinicrope
and Penington, 2005), co-administration of sulindac sulfide with HA 14, a small
molecule Bcl-2 inhibitor, or tumour necrosis factor-related apoptosis-inducing ligand
(TRAIL), was discovered to enhance sulindac sulfide-induced apoptosis in colorectal
cancer cells.
Collectively, in vitro studies have demonstrated that NSAIDs can inhibit
various cellular processes which are implicated in tumour development and
progression, including the recognition of transformed cells by the immune system,
angiogenesis and activation of carcinogens. Furthermore, NSAIDs can inhibit cell
proliferation by altering the expression levels of cell cycle proteins or induction of
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cell cycle arrest. Crucially and most importantly, NSAIDs can induce apoptosis -
NSAIDs have been shown to modulate both the extrinsic and intrinsic pathways to
apoptosis, via up-regulation of death receptors and activation of caspases, and can
regulate the expression of Bcl-2 family member proteins, such as Bax. Moreover, the
induction of apoptosis is now recognised as being the predominant anti-tumour
activity of these agents.
The compelling evidence from epidemiological studies, clinical trials, in vivo
studies and in vitro studies strongly implicate NSAIDs as important
chemopreventative agents against colorectal cancer. It is therefore vital to understand
the mechanisms and pathways whereby NSAIDs exert their protective effects for the
development of novel therapeutic agents.
1.4.2 The Genetic Model for Colorectal Tumorigenesis
It is important to consider the tumorigenic process itself when trying to
establish and understand the mechanisms for chemopreventative agents such as
NSAIDs. It is now widely accepted that multiple mutations over time are necessary
for the development of malignancy (Kinzler and Vogelstein, 1996). This multi-step
process is well illustrated by colorectal cancers, which typically develop over
decades and require at least four sequential genetic changes to occur in order to
ensure colorectal cancer evolution (Fodde, 2002). A genetic pathway (Figure 1.6)
























Figure 1.6 - Genetic Changes Associated with Colorectal Tumorigenesis. Tumorigenesis
proceeds through a series of genetic alterations involving oncogenes e.g. K-RAS, that require only one genetic
event for their activation, and tumour suppressor genes e.g. OCC, DPC4 and JV18, that require two genetic events
(one in each allele) for their inactivation. APC mutations initiate the neoplastic process and tumour progression
results from mutations in the other genes indicated. The three stages of adenomas represent tumours of increasing
size, dysplasia, and villous content. DNA mismatch repair (MMR) deficiency speeds up this process. Tumours
continue to progress once carcinomas have formed, and the accumulated loss of suppressor genes on additional
chromosomes correlates with the ability of the carcinomas to metastasise and cause death.
[Figure adapted from (Kinzler and Vogelstein, 1996)]
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carcinoma has been suggested (Fearon and Vogelstein, 1990) and is now widely
accepted. Briefly, the process of tumorigenesis has three stages: initiation, promotion
and progression. Mutation and/or loss ofAPC is the earliest genetic alteration in the
genesis of colorectal tumours and seems to be required to initiate the adenomatous
process, resulting in the clonal growth of a single cell (Fodde et al., 2001b). A small
polyp subsequently develops and eventually, one of these cells overgrows its sister
cells, promoting the growth of a larger tumour. When a cell has acquired enough
mutations and undergone clonal expansions, it acquires the ability to invade and
metastasise and progression to malignancy ensues (Kinzler and Vogelstein, 1998a;
Hawk and Levin, 2005).
NSAIDs have been shown to modulate several key molecules that are
implicated in the progression of colorectal cancer and the specific mechanisms and
pathways regulated by NSAIDs will be the subject of the remainder of this
discussion.
1.5 Mechanism of NSAID Action
The mechanisms which have been proposed for the anti-tumour effects of
NSAIDs are summarised in Figure 1.7. In particular, there is substantial evidence
that inhibition of the COX enzymes is implicated in the preventative effects of
NSAIDs. However, there is also increasing support for the existence of COX-
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Figure 1.7 — Mechanisms Of Action Of NSAIDs. Non-selective NSAIDs. for example aspirin, sulindac
and indomethacin, can inhibit both cyclooxygenase (COX)-1 and COX-2, whereas COX-2 selective NSAIDs, such
as celecoxib and rofecoxib, inhibit only COX-2. These agents induce apoptosis by both COX-dependent and COX-
independent mechanisms. NSAIDs that lack COX-inhibitory activity, for example sulindac sulfone, only induce
apoptosis via COX-independent mechanisms. The inhibition of COX leads to apoptosis primarily by altering
prostaglandin production. In addition, the inhibition of COX leads to an increase in arachadonic acid, which in turn
stimulates the conversion of sphingomyelin to ceramide, a mediator of apoptosis. NSAIDs also exert their effects
and induce apoptosis by COX-independent mechanisms such as modulation of PPAR6, NF-kB, p-catenin or other
non-COX targets. Plus signs indicate stimulation or activation, and minus signs indicate inhibition. Dotted line
denotes modulation.
[Figure adapted from (Janne and Mayer, 2000)]
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proliferator-activated receptors (PPARs), NF-kB and [3-catenin signaling. It is
important to emphasize that the mechanisms for the protective benefits of NSAIDs
against cancer are complex and have yet to be fully elucidated. The work of this
thesis is focussed on COX-independent pathways, but here I will discuss both COX-
dependent and COX-independent effects ofNSAIDs.
1.5.1 COX-dependent Effects
COX is the rate-limiting enzyme that catalyses the production of
prostaglandins (PGs) from arachidonic acid (Figure 1.8). It occurs as two isozymes:
COX-1, a constitutive isoform associated with beneficial housekeeping roles, and
COX-2, an inducible isoform associated with inflammation, mitogenesis and/or
specialised signal transduction mechanisms (Brown and DuBois, 2005). PGs play
critical roles in numerous biological processes, including maintenance of
physiological organ function, regulation of immune function, kidney development,
reproductive biology and gastrointestinal integrity (Gupta and DuBois, 2001;
Backlund et al., 2005). It is noteworthy that since COX-1 is the only COX isoform
expressed in platelets and gastric mucosa in healthy individuals, the toxicity of
NSAIDs in the gastrointestinal mucosa, leading to ulceration and bleeding, is the
result of inhibition of this enzyme (Patrignani, 2000).
It is widely accepted that the anti-inflammatory and analgesic properties of
NSAIDs arise mainly from inhibition of the enzymatic activity of COX [reviewed in
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Figure 1.8 — Arachadonic Acid Cascade. Arachadonic acid is released from membrane phospholipids
by phospholipase A8 and is subsequently converted by either cyclooxygenase (COX)-1 or COX-2 to prostaglandin
(PG) G2 and then to PGH2 by peroxidase catalytic activity. Finally, the production of PGs (PGE2, PGD2, PGI2, PGF^
and thromboxane A2) from PGH2, the precursor of all PGs, is catalysed by a specific isomerase.
[Figure adapted from (Brown and DuBois, 2005)]
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(Backhaul et al., 2005; Gupta and DuBois, 2001; Prescott and Fitzpatrick, 2000;
Patrignani, 2000; Williams et al., 1999b; Shiff and Rigas, 1999)]. As a result, it has
generally been assumed that the anti-neoplastic effects of NSAIDs are also
dependent on inhibition of COX activity.
There are several lines of evidence that inhibition of COX-2 and PG
production contributes to the prevention of colorectal cancer by NSAIDs [reviewed
in (Brown and DuBois, 2005; Backlund et al., 2005; Chan, 2002; Patrignani, 2000)].
I. COX-2 mRNA and COX-2 protein, but not COX-1, are overexpressed in
colorectal polyps and cancers, resulting in increased levels of PGs (Patrignani, 2000).
This is important because ecosanoids, including PGs, can stimulate proliferation and
reduce apoptosis in colonocytes (Shiff and Rigas, 1999). 2. PGE2 levels are elevated
in colorectal tumours and adenomas compared to normal adjacent mucosa (Backlund
et al., 2005). 3. COX-2 contributes to colorectal tumorigenesis in APC knockout
mouse. Both gene disruption and pharmacological inhibition of COX-2 have been
shown to reduce the number and size of polyps in APC47/6(+/-) knockout mice
(Oshima et al., 1996). 4. Overexpression of COX-2 in epithelial cell lines results in
resistance to apoptosis and changes in cell adhesion properties, both of which are
consistent with increased tumorigenic potential (Sakamoto, 1998).
It is also important to consider that the inhibition of COX-2 leads to an
increase in arachidonic acid, which in turn stimulates the conversion of
sphingomyelin to ceramide, a known mediator of apoptosis (Janne and Mayer, 2000;
Chan et al., 1998).
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1.5.2 COX-independent Effects
Despite the compelling evidence for the involvement of COX, in particular
COX-2, in the mechanism of NSAID prevention of colorectal cancer, there is a
growing body of support for the hypothesis that COX-independent pathways may
also be involved in both the anti-inflammatory and anti-tumour activity of NSAIDs
[reviewed in (Arber and Levin, 2005; Chan, 2002; Tegeder et al., 200lb; ShifC and
Rigas, 1999)]. 1. The mechanisms that have been suggested to contribute to the anti-
tumour activity ofNSAIDs, such as inhibition of cell cycle progression, induction of
apoptosis and inhibition of angiogenesis, have been observed only at high
concentration of the respective NSAIDs, which are 100-1000 fold higher than the
amount required to inhibit prostaglandin production (Grosch et al., 2001; Kralj et al.,
2001; Smith et al., 2000; Chiu et al., 1997; Qiao et al., 1998a; Ricchi et al., 1997). 2.
Colorectal cancer cell lines (Hanif et al., 1996) or mouse embryo fibroblasts (Zhang
et al., 1999) that do not express either COX isoform i.e. COX-1'1', COX-2'1' and
COX-1'''ICOX-2'1', show similar sensitivity to high dose NSAID treatment. 3.
Complete lack ofCOX-2 enzyme in mice null for COX-2 did not entirely prevent the
development of intestinal tumours when crossed onto APC217 6(+A) knockout mice
(Oshima et al., 1996) 4. NSAIDs are effective in colon cancer cell lines that do not
produce PGs, even with exogenous stimulation (Hanif et al., 1996). 5. Metabolites of
NSAIDs that have no COX-inhibitory activity e.g. sulindac sulfone or salicylic acid,
have similar growth-inhibitory and chemopreventive activities in vitro and in vivo
(Williams et al., 1999a; Piazza et al., 1997). 6. NSAIDs modulate signal transduction
pathways that are independent of COX [reviewed in (Ricchi et al., 2003; Tegeder et
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al., 2001b)]. Taken together, these data strongly suggest that other pathways in
addition to COX are important for the anti-tumour effects ofNSAIDs.
1.5.3 Non-COX Pathways Modulated by NSAIDs
To date, non-COX pathways that have been reported to be modulated by
NSAIDs include: PPARs, DNA repair, p38 and activator protein-1 (AP-1) signaling.
These pathways will each be discussed in turn before considering in more detail the
two major non-COX pathways known to be regulated by NSAIDs, namely the NF-
kB and p-catenin pathways.
1.5.3.1 PPARs
PPARs function as members of the nuclear hormone superfamily, which
includes the steroid hormone, thyroid hormone and retinoid nuclear hormone
receptors (He et al., 1999). These receptors are ligand-activated transcription factors,
which directly regulate the transcription of target genes (Wang et al., 2006). Three
distinct PPAR isoforms: PPARa, 5 and y, which exhibit distinct tissue distribution,
have been isolated and characterised (Gupta and DuBois, 2001; Wang et al., 2006).
PPARy is highly expressed in adipose tissue and functions as a master regulator of
adipocyte differentiation (Lehmann et al., 1997). PPARa is predominantly expressed
in hepatocytes, cardiomyocytes, proximal tubule cells of the kidney and enterocytes
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(Wang et al., 2006), and is required for the pleiotropic hepatic response to
peroxisome proliferators. PPAR5 is more widely and abundantly expressed than the
other isoforms although little is known about its physiological function. In addition
to adipose tissue, PPARy is highly expressed in the normal large intestine and has
been implicated in breast, colon and prostrate cancer (Tegeder et al., 2001b).
Significantly, activation of PPARs in colon cancer cells reduces their growth and
induces differentiation in vitro (Shiff and Rigas, 1999). PPARs could therefore be a
target ofNSAIDs in the colon.
It has been shown that indomethacin, and several other NSAIDs, can bind to
and induce the transcriptional activity of PPAR isoforms a and y (Lehmann et al.,
1997). Similarly, another report (Jaradat et al., 2001) documented that a panel of
NSAIDs comprising ibuprofen, naproxen and indomethacin can activate PPAR a and
y isoforms in a concentration-dependent manner and with varying efficacy. PPARS
has been identified as a direct target of sulindac (He et al., 1999). In that study,
PPARS was initially discovered to be a major target of APC through analysis of
global gene expression profiles in human colorectal cancer cells. PPARS expression
was repressed by APC and this repression was mediated by P-catenin/TCF-4-
responsive elements in the PPARS promoter. Sulindac could mimic the effects of
APC by downregulating the transcriptional activity of PPARS and overexpression of
PPARS could rescue the ability of high doses of sulindac to induce apoptosis (He et
al., 1999). Another study (Babbar et al., 2003) established that apoptosis induced by
sulindac sulfone is mediated, at least in part, by PPAR-dependent transcriptional
activation of the spermidine/spermine A'-acetyltransferase (SSAT) gene.
Interestingly, sulindac sulfide can act as a PPARy agonist and PPARS antagonist in a
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human prostrate epithelial cell line (Jarvis et al., 2005). Moreover, PPARy was
required for both growth inhibition and p2lwatl/c,pl overexpression in these cells. In
addition, overexpression of PPAR5 partially rescued these cells from growth
inhibition and sulindac sulfide-mediated p21VVdU/upl-upregulation. Genetic ablation of
PPAR5 in colorectal cancer cells does not alter their sensitivity to sulindac-induced
apoptosis, suggesting that there are other targets of sulindac in addition to PPAR8
(Park et al., 2001). Similarly, a recent study (Hawcroft el al., 2003) demonstrated
that indomethacin could bind and activate PPARy but that this was not necessary for
the antiproliferative effect associated with indomethacin in vitro, indicating that there
are other targets of this agent in addition to PPARy.
1.5.3.2 DNA Repair
As mentioned above, defective DNA MMR is implicated in colorectal cancer
and is usually characterised by MSI. There are several reports that MMR genes could
be a target of NSAIDs. One report (Riischoff et al., 1998) suggested that the MSI
phenotype in colorectal cancer cells deficient for a subset of the human MMR genes
(hMLHl, hMSH2 and hMSH6) is markedly reduced during exposure to aspirin or
sulindac. In that study, cell lines deficient in MMR genes, but not with a hPMS2
mutation, were found to die selectively by apoptosis in response to NSAID
treatment, an effect that was reversible, time- and concentration-dependent and
appeared to be independent of COX function. More recently, in a study comparing
MMR-deficient (HCT116) and MMR-proficient (HCT116+ Lhr3 and SW480) cells, it
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was shown that treatment with aspirin results in an increase in MMR protein
expression in the MMR-proficient cell lines, but not the MMR-deficient cell line
(Goel el al., 2003). Moreover, the authors reported that aspirin induced apoptosis in
all the cell lines studied and caused G()/Gi cell cycle arrest in HCT116 cells.
Although the DNA MMR-proficient cells were perhaps more resistant to the
apoptotic effects of aspirin when compared to the MMR-deficient cells, the
observations of that study suggest that aspirin could in fact be used as a
chemopreventive agent irrespective of MSI status. In keeping with these data, recent
studies from the host laboratory have shown that aspirin-induced apoptosis is an
effect that is common to colorectal cancer cell lines, but not non-colorectal cancer
cell lines examined, irrespective of the mutation status of DNA MMR genes (Din et
al., 2004). Specifically, aspirin treatment was found to induce apoptosis in both
HCT-116 and IICT116+ thr3 colorectal cancer cells, indicating that the effect of
aspirin is independent ofMMR status (Din et al., 2005).
1.5.3.3 p38
p38 is a MAPK, which act as serine/threonine protein kinases and are
members of discrete signaling cascades (Ono and Han, 2000). The MAPK family can
be divided into at least three distinct subgroups, namely extracellular signal-regulated
kinases (ERKs), c-Jun N-terminal kinase (JNK)/stress activated protein kinases
(SAPKs), and p38 (Engelberg, 2004). Moreover, ERK5/big MAPK 1 (BMK1) has
recently been described as another subfamily of MAPKs (Kasler et al., 2000).
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MAPKs are activated by dual specificity kinases, called MAPK kinases (MAPKKs
or MAP2Ks) (Saklatvala, 2004). MAPKKs are in turn activated by a family of
serine-threonine kinases called MAPKK kinases (MAPKKKs, MAP3Ks or MEKKs).
These signaling cascades essentially act as focal points for diverse extracellular
stimuli and function to regulate key cellular processes, including: cell proliferation,
oncogenesis, differentiation, inflammation and stress responses (Huang et al., 2004).
It is noteworthy that four mammalian isoforms of p38 have been identified (p38a,
p3 8(3, p388 and p38y) (Lee et al., 2000) and that p38 has both oncogenic and tumour
suppressing activities, depending on the cellular context [reviewed in (Engelberg,
2004; Bulavin and Fornace, Jr., 2004; Rennefahrt et al., 2005)].
There is a growing body of evidence that NSAIDs can modulate p38
signaling. Sodium salicylate has been shown to activate p38 (Schwenger el al.,
1998). Moreover, activation of p38 by sodium salicylate led to inhibition of TNF-
induced IkBcx phosphorylation and degradation. More recent data indicates that
sodium salicylate activates p38 via phosphorylation at Thr 180/Tyr 182 and partially
activates ERK1/2 by phosphorylation at Thr 202/Tyr 204 in HCT116 colorectal
cancer cells (Lee et al., 2003). Furthermore, the authors reported that a specific p38
inhibitor (SB203580), but not other inhibitors, significantly prevented salicylate-
induced apoptosis, strongly implicating p38 in the mechanism of apoptosis caused by
this agent. p38 is also activated by indomethacin in colorectal cancer cells (Kim et
al., 2002) and this activation may play a partial but significant role in indomethacin-
induced apoptosis. Both sulindac sulfide and the selective COX-2 inhibitor, NS398
activate p38 and ERKp44/42 in a dose- and time-dependent manner in HCA-7 and
HCT-15 colorectal cancer cells (Sun and Sinicrope, 2005). In that study, activation of
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p38 and ERKp44/42 was accompanied by an increase in COX-2 expression, an effect
which could be suppressed by selective inhibitors of these MAPKs. Furthermore,
sulindac sulfide-induced apoptosis was significantly enhanced by using MAPK
inhibitors or reducing constitutive COX-2 expression via antisense oligonucleotides,
leading the authors to conclude that MAPK activation mediates COX-2 induction by
sulindac sulfide and that selective inhibitors of MAPKs potentiate apoptosis
induction by this NSA1D. It is of interest to note that recent work from the host
laboratory has shown that aspirin rapidly activates the p38 MAPK pathway in
SW480 colorectal cancer cells (Thorns et al., 2004).
1.5.3.4 AP-1
The AP-1 transcription factor complex is produced by homo- or hetero-
dimeric combinations of basic region-leucine zipper proteins that belong to members
of the Jun (c-Jun, JunB and JunD) and Fos (c-Fos, FosB, Fra-1 and Fra-2) family,
Jun dimerisation partners (JDP1 and JDP2) and the closely related activating
transcription factor (ATF2, LRF1/ATF3 and B-ATF) subfamilies (Kundu and Surh,
2004; Chun and Surh, 2004). AP-1 is activated in response to a variety of stimuli,
including ultraviolet (UV) radiation, growth factors, tumour necrosis factor-alpha
(TNFa) and interleukin-1 (IL-1) (Tegeder et al., 2001b). Activation of AP-1 is
mediated predominantly by MAPK cascades, particularly ERK, JNK and p38
(Kundu and Surh, 2004). After dimerisation, the AP-1 complex binds to TPA (12-0-
tetradecanoylphorbol 13-acetate)-responsive elements (TREs; TGAC/CTCA) in the
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promoter and enhancer regions of target genes (Chun and Surh, 2004; Milde-
Langosch, 2005). It is noteworthy that targets regulated by AP-1 include genes
involved in the immune and inflammatory response, proliferation, invasion,
metastasis, differentiation and survival (Milde-Langosch, 2005).
There is a body of evidence suggesting that AP-1 could be a target of
NSAIDs. Aspirin and Sodium salicylate have been shown to inhibit epidermal
growth factor and UV-induced AP-1 activation in mouse epidermal cells (Dong et
al., 1997). Similarly, another study (Tegeder et al., 2001a) observed that R-
flurbiprofen can inhibit lipopolysaccharide (LPS)-induced AP-1 activation in mouse
macrophages. Aspirin and sodium salicylate have been demonstrated to reduce
Epstein-Barr-mediated upregulation of matrix metalloproteinase (MMP)-9, thus
reducing tumour invasion, via simultaneous inhibition of NF-kB and AP-1 (Murono
et al., 2000). However, in contrast to these studies, a very recent paper (Niederberger
et al., 2006) established that the COX-2-selective inhibitors, etoricoxib and
lumiracoxib had no effect on LPS-induced activation of the AP-1 subunits, c-jun and
c-fos.
1.5.3.5 The NF-kB Signaling Pathway
There is compelling evidence that the NF-kB pathway is a very good
potential target for NSAIDs in the colon and this notion is strongly supported by
previous work from the host laboratory which identified the NF-kB pathway as a
critical target for the apoptotic effects of aspirin (Stark et al., 2001; Stark and
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Dunlop, 2005). The major focus of research in the host laboratory, and consequently
this thesis, has therefore been to investigate the mechanism by which aspirin
mediates the apoptosis of colorectal cancer cells and to investigate whether this
effect is specific to aspirin or is a general effect common to other NSAIDs.
NF-kB is an inducible and ubiquitously expressed transcription factor that
regulates genes involved in cell survival, cell adhesion, inflammation, differentiation
and cell growth (Bharti and Aggarwal, 2002). Active NF-kB complexes are
comprised of homodimers or heterodimers of various combinations of the Rel family
of polypeptides. Mammals express five Rel proteins that belong in two classes
(Greten and Karin, 2004) and these are illustrated in Figure 1.9A. The first class are
synthesised as mature proteins and includes: RelA (p65), RelB and c-Rel. The
second class consists of the precursor proteins, NF-kB 1 (pl05/p50) and NF-kB2
(pl00/p52), which undergo proteolysis to yield their mature products, p50 and p52
respectively (Perkins, 2000). Each member of this family contains a conserved
amino-terminal region of approximately 300 amino acids called the Rel homology
domain (RHD), within which lies DNA-binding and dimerisation domains, a nuclear
localisation signal (NLS) and a site for binding of the NF-kB inhibitors, the IkBs
(inhibitor of kBs). RelA, RelB and c-Rel additionally have a carboxy-terminal
transactivation domain (TAD) (Sun and Andersson, 2002; Chen and Ghosh, 1999;
Hayden and Ghosh, 2004). In resting cells, NF-kB dirners are generally sequestered
in the cytoplasm by interaction with a member of the IkB family, which are
illustrated in Figure 1.9B and includes IkBcx, IkBP, IkBs, IkBy, Bcl-3, plOO and p 105
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Figure 1.9 - The Domain Structure of the Family of Mammalian NFncB/Rel and IkB
Proteins. (a) The mammalian NF-KB/Rel family members are characterised by the presence of a Rel homology
domain (RHD) at their amino terminus. This region is responsible for both DNA binding and dimerisation with IkBs.
Only RelA, c-Rel and RelB contain carboxy-terminal transcriptional activation domains (TADs). The p105 and p100
precursor proteins contain glycine rich regions (GRRs), which are important for the processing of these transcripts
to p50 and p52 respectively, and ankyrin repeats (denoted by pink circles). RelB is the only family member that has
a leucine zipper (LZ) at its amino terminus and this motif is required for transactivation by RelB. The location of key
phosphorylation (serines (S) 276, 311, 529 and 536) and acetylation (lysines (K) 122, 123, 218, 221 and 310) sites
on RelA are also illustrated. (b) The mammalian ikB protein family members are characterised by the presence of
an ankyrin repeat domain, which mediates interaction with Rel proteins. Phosphorylation of two key serine residues
(SS) at the amino-terminal region, serines 32 and 36 in IkBo, triggers polyubiquitination and proteasome-mediated
degradation. It is noteworthy that Bcl-3 has a TAD at its carboxyl terminus and so complexes formed between either
p50 or p52 and Bcl-3 have transcriptional activation properties.
[Figure from (Chen and Greene, 2004)]
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multiple ankyrin repeats, which are protein-protein interaction domains that interact
with NF-kB via the RHD (Ghosh and Karin, 2002). Interaction of IkB with NF-kB
blocks the NLS of NF-kB, thus sequestering the protein in the cytoplasm (Thanos
and Maniatis, 1995; Stancovski and Baltimore, 1997).
1.5.3.5.1 Mechanism of Activation of NF-kB
NF-kB can be activated by a variety of signals including: cytokines, such as
IL-1 and TNFa, tumour promoters, bacterial or viral infection and cellular stress
(Courtois, 2005). The 'classical' pathway to activation of NF-kB is outlined in
Figure 1.10. The key event in this pathway is phosphorylation of two critical serine
(Ser) residues of IkBcx, Ser32 and Ser36 (Viatour et al., 2005). The kinase
responsible for catalysing serine phosphorylation of IkBo is the multi-protein
complex, IkB kinase (IKK). IKK has a molecular mass of approximately 700-900
kDa and consists of three subunits: IKK-a (1KK1) and IKK-P (IKK2) (the catalytic
subunits), IKK-y (the regulatory subunit also known as NF-kB essential modifier
(NEMO)), and other proteins yet to be identified (Hayden and Ghosh, 2004; Karin et
al., 2004). IKK-a and IKK-P are related members of a family of intracellular signal
transduction kinases that comprise an amino-terminal kinase domain and a carboxy-
terminal region with two protein interaction motifs, a leucine zipper and a helix-loop-
helix motif (Karin, 1999a and 1999b). Activation of IKK by proinflammatory and
innate stimuli is dependent on phosphorylation of IKK-a or IKK-P at two conserved
69
Figure 1.10 - Activation Of the NF-kB Pathway. In the classical' pathway to activation of NF-kB,
heterodimers of p50 and RelA polypeptides (the prototypical NF-kB complex), are sequestered in the cytoplasm by
their interaction with the inhibitor protein, IkBcl Following stimulation by an external signal, such as tumour necrosis
factor-a (TNFa), interleukin-1 (IL-1), lipopolysacchardie (LPS) or the human T-cell leukaemia virus (HTLV-1) TAX
protein, IkBo is phosphorylated (P) by the IKK complex, comprising IKK1, IKK2 and NEMO, at the two critical serine
residues, Ser32 and Ser36. Phosphorylated IkBo is then ubiquitinated (Ub) on lysine 21 (K21) and subsequently
degraded by the 26S proteasome. Degradation of IkBo unmasks the nuclear localisation signal on RelA, allowing
NF-kB to translocate from the cytoplasm to the nucleus, where it binds to kB sites within the promoter region of
target genes e.g. Bcl-xL. A parallel non-canonical pathway for stimulus-coupled activation of specific Rel proteins
involves the inducible proteolytic processing of p100 (NF-kB2). Different members of the TNF-receptor superfamily,
including CD40 and B-cell activating factor (BAFF), selectively activate NIK and IKK1, leading to the
phosphorylation of p100 and subsequently, its ubiquitination and partial proteolytic processing by the 26S
proteasome to yield p52. This pathway generally generates p52-RelB heterodimers, in contrast to the p50-RelA
dimmers produced by the canonical pathway. Once produced, p52-RelB dimers can translocate to the nucleus and
activate transcription of various host genes.
[Figure adapted from (Chen and Greene, 2004)]
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serine residues within their activation loop and ubiquitination and phosphorylation of
IKKy (Ghosh and Karin, 2002; Perkins and Gilmore, 2006). It is probable that IKK-a
and IKK-P are phosphorylated and activated by one or more upstream kinases,
although there is some evidence to suggest that py/m-autophosphorylation caused by
induced proximity and/or conformational change could be a mechanism of IKK
activation (Hayden and Ghosh, 2004). Upstream kinases that have been proposed to
act as IKK kinases include members of the MAP3K family, for example NF-kB
inducing kinase (NIK) (Ling et al., 1998), MEKK3 (Yang et al., 2001a) and Tpl2
(Lin et al., 1999). Other candidate IKK kinases include atypical PKC (aPKC)
(Lallena et al., 1999) TGFp-activated kinase (TAK)-l (Wang et al., 2001; Chen,
2005) and Act-1 (Mauro et al., 2003).
It is noteworthy that IKKp is both necessary and sufficient for
phosphorylation of IkBcx on Ser32 and 36 (Hayden and Ghosh, 2004). Upon
phosphorylation at Ser32 and 36, IkBo. becomes a substrate for the Skpl/Cull/F-box
protein-P-TrCP ubiquitin ligase complex and ubiquitinated IkBcx is subsequently
degraded by the proteasome (Perkins and Gilmore, 2006). NF-kB complexes, freed
from their association with IkBcx, translocate from the cytoplasm to the nucleus due
to unmasking of the NLS (Greten and Karin, 2004). Once inside the nucleus, NF-kB
binds to specific sequences in the promoter/enhancer regions of target genes (see
below) and regulates their transcription (Karin et al., 2002; Pahl, 1999).
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1.5.3.5.2 The Noncanonical NF-kB Pathway
In addition to the classical pathway mentioned above, a 'noncanonical' or
alternative pathway of activating NF-kB (illustrated in Figure 1.10), which is
triggered by cytokines (such as lymphotoxin P (FTP), B-cell activating factor
(BAFF) and CD40 ligand) or by viruses (including human T-cell leukaemia virus
(HTLV) and the Epstein-Barr virus (EBV)), and that only affects the NF-kB dimer
between RelB and NF-kB2, has been described (Ravi and Bedi, 2004; Campbell and
Perkins, 2006). Briefly, in response to these stimuli, the IKK-a subunit is selectively
activated by the upstream kinase, NIK (Greten and Karin, 2004). Together, IKKa
and NIK induce the phosphorylation-dependent proteolytic removal of the ikb-like
C-terminal domain of NF-kB2. The proteolytic processing ofNF-kB2 to p52 in turn
results in activation and translocation to the nucleus ofNF-kB complexes containing
this subunit, which generally consist of RelB-p52 heterodimers, (Karin et al., 2002).
Activation of this dimer is known to be important for lymphoid organ development
and adaptive immune responses (Delhalle et al., 2004).
1.5.3.5.3 Activation of NF-kB by Atypical Agents
Most stimuli activate NF-kB via IKK-mediated IkBoi phosphorylation by the
mechanisms outlined thus far. However, further complexity is introduced due to
activation by other, atypical inducers including ultraviolet (UV-C and UV-B) light;
ionizing radiation; hypoxia; phorbol esters; and chemotherapeutic agents, such as
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etoposide (a DNA-damage inducing agent), and anthracyclines (for example
daunorubicin and doxorubicin), where both IKK-dependent and independent
mechanisms of activation have been proposed (Perkins, 2004b; Campbell and
Perkins, 2004 and 2006; Perkins and Gilmore, 2006). Several reports have indicated
that UV-C-, camptothecin-, doxorubicin- and etoposide-induced NF-kB DNA-
binding is IKK-dependent (Huang et al., 2002; Bottero et al., 2001; Campbell and
Perkins, 2004), but exhibits distinct functional differences to other IKK-dependent
activation pathways. For instance, NF-kB induction in response to genotoxic stimuli,
such as UV-C, has been demonstrated to have a requirement for the zinc-finger
domain of IKKy that is not seen with TNFa (Huang et al., 2002; Perkins and
Gilmore, 2006). In contrast to these studies demonstrating IKK-dependent effects of
atypical agents, another paper reported that IkBcx degradation in response to UV-C
treatment occurs via a p38 MAPK-dependent mechanism involving phosphorylation
of IkBcx at a cluster of serine residues contained in its C terminus, which are
specifically targeted by casein kinase II (CKII) (Kato, Jr. et al., 2003). Doxorubicin,
a chemotherapeutic agent, has also been shown to induce proteasome-mediated IicBa
degradation in mouse embryonic fibroblasts (MEFs) devoid of IKK-a and IKK-[3
(Tergaonkar et al., 2003). It is noteworthy that the kinetics of activation ofNF-kB by
atypical agents is much slower than typical activators, such as TNFa or IL-1
(Campbell and Perkins, 2004 and 2006). Additionally, roles are emerging for specific
kinases in the mechanism to activation of the NF-kB pathway by atypical stimuli.
These include DNA-PK (DNA-dependent protein kinase) and ATM (Ataxia
telangiectasia mutated) kinase (Schmitz et al., 2004).
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1.5.3.5.4 Tyrosine Phosphorylation of IkBo
In addition to the well established serine (Ser32 and Ser36) phosphorylation
mechanism, an alternative pathway for activating NF-kB, which involves
phosphorylation of IkB on tyrosine (Tyr42), has been described. Tyrosine
phosphorylation ofNF-kB has been reported in response to various stimuli, including
pervanadate (a protein tyrosine phosphatase inhibitor) (Imbert et al., 1996;
Mukhopadhyay et al., 2000), hypoxia/Reoxygenation (Imbert et al., 1996; Fan et al.,
2003), oxidative stress (Schoonbroodt et al., 2000), crystalline silica (Kang et al.,
2000; Kang et al., 2006), nerve growth factor (NGF) (Bui et al., 2001) and even
TNFa, a classical inducer of NF-kB (Abu-Amer et al., 1998). Furthermore, protein-
tyrosine phosphatase inhibitors have been shown to block TNFa dependent
activation ofNF-kB (Singh and Aggarwal, 1995). The tyrosine kinase responsible for
this alternative pathway is not known but candidates that have been proposed
include: p56lLk (Imbert et al., 1996; Livolsi et al., 2001; Mahabeleshwar and Kundu,
2003); ZAP-70 (Livolsi et al., 2001); c-Abl (Kawai et al., 2002); Syk (Takada et al.,
2003) and c-Src (Abu-Amer et al., 1998; Fan et al., 2003; Kang et al., 2006). It is
important to note that activation of NF-kB mediated by tyrosine phosphorylation of
iKBa can occur in the presence or absence of iKBa degradation. Hydrogen peroxide-
induced phosphorylation of IKBa was shown to be followed by its degradation, a
process that required the C-terminal PEST (proline-glutamic acid-serine-threonine)
domain of IxBa (Schoonbroodt et al., 2000). Similarly, pervanadate was found to
activate NF-kB through tyrosine phosphorylation and degradation of IKBa
(Mukhopadhyay et al., 2000). In contrast to these studies, it has been reported that
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tyrosine phosphorylation of IkBcx in response to pervanadate treatment or hypoxia/re-
oxygenation in Jurkat T cells results in nuclear translocation and activation ofNF-kB
without degradation of IkBcx (Imbert et al., 1996). Similarly, it was demonstrated that
pervanadate treatment induces tyrosine phosphorylation of IkBcx, an event that was
found to protect IkBcx from inducible degradation (Singh et al., 1996). More recently,
it was established that NGF-induced activation of NF-kB can occur without
significant degradation of IkBs (Bui et al., 2001).
1.5.3.5.5 Activation of NF-kB by NSAIDs
Only a few studies, which will be discussed in more detail later, have
demonstrated activation ofNF-kB by NSAIDs. Significantly, previous work from the
host laboratory demonstrated that aspirin activates NF-kB through the classical
pathway, involving serine phosphorylation and degradation of IkBcx (Stark et al.,
2001). In particular, aspirin was found to mediate a reduction in cytoplasmic IkBoi
levels and this effect could be blocked by pre-treatment of cells with the proteasome
inhibitor, MG132 and by mutation of IkBo. at the critical Ser32/36 phosphoacceptor
sites. In keeping with these data, a recent study (Cho et al., 2005) demonstrated
degradation of IkBcx in response to diclofenac. The COX-2-selective inhibitor, NS-
398 has also been reported to cause degradation of IkBoi (Smartt et al., 2003).
However, it is important to note that the precise upstream mechanisms to activation
of NF-kB by NSAIDs are unknown. Studies are ongoing in the host laboratory to
identify these pathways in response to aspirin and other NSAIDs.
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1.5.3.5.6 Regulation of NF-kB Activity by Post-translational
Modifications
Although the primary level of regulation of NF-kB activity lies in the
cytoplasmic release from the IkB inhibitor protein, there is accumulating evidence
that NF-kB is also subject to an ikb-independent level of regulation [reviewed in
(Schmitz et al., 2001 and 2004; Vermeulen et al., 2002; Chen and Greene, 2004;
Viatour et al., 2005)]. Moreover, it is conceivable that such mechanisms could be
very important for modulation ofNF-kB signaling by NSAIDs.
1.5.3.5.7 Enhanced NF-kB Transcriptional Activity by RelA
Phosphorylation
Phosphorylation of NF-kB itself can affect several functions of NF-kB,
including DNA binding and transactivation potential, that is the ability to recruit the
transcriptional apparatus and stimulate target gene expression (Vermeulen et al.,
2002). The RelA subunit of NF-kB is a principal target for phosphorylation by
various kinases (Chen and Greene, 2004) and a summary of the inducible
phosphorylation sites within RelA and the implicated protein kinases is illustrated in
Figure 1.11. These phosphorylation events are found in both the C-terminal
transactivation domains and the RF1D (Vermeulen et al., 2002), are stimuli-specific
and probably cell-type-specific, and occur in the cytoplasm or the nucleus (Viatour et
al., 2005; Perkins and Gilmore, 2006).
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Phosphorylation of RelA at serine 276, which is situated in the RHD, by the
catalytic subunit of protein kinase A (PKAc) in response to treatment with LPS has
been shown to increases the transcriptional activity of RelA by increasing the
interaction between RelA and the transcriptional co-activator, cAMP response
element-binding (CREB)-binding protein (CBP)/p300 in the nucleus (Zhong et al.,
1998). Serine 276 of RelA can also be phosphorylated by the mitogen- and stress-
activated protein kinase-1 (MSK1) in the nucleus in response to TNFa, resulting in
enhanced NF-kB transcriptional activity (Vermeulen et al., 2003b).
TNFa induces phosphorylation of RelA at serine 311, which is also located in
the RHD, through the action of yet another kinase, PKClj (Duran et al., 2003). In that
study, phosphorylation of RelA at serine 311 was found to promote the interaction
between RelA and CBP and the recruitment of CBP and RNA polymerase II to the
interleukin-6 (IL-6) promoter. Furthermore, PKCij-deficient fibroblasts exhibit
normal activation of IKK and nuclear translocation of RelA but have reduced NF-kB
DNA-binding activity in vitro (Schmitz et al., 2004).
RelA is also subject to phosphorylation at two sites within the C-terminal
TAD. After treatment with IL-1 or TNF-a, serine 529 is phosphorylated by CKII
(Bird et al., 1997; Wang and Baldwin, Jr., 1998; Wang et al., 2000). This
phosphorylation event requires IxBa degradation and is prevented by RelA binding
to IkBo in unstimulated cells. Upon stimulation with TNF-a, activation of IKK
results in phosphorylation ofRelA at serine 536 (Sakurai et al., 1999). The ribosomal
subunit kinase-1 (RSK1), a downstream effector of p53 which activates NF-kB in
response to DNA damage, has also recently been shown to mediate phosphorylation
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Figure 1.11 - Summary of Inducible Phosphorylation Sites Within RelA and Implicated
Protein Kinases in Response to Distinct Stimuli. The four major phosphorylation sites in RelA
include serines (S) 276 and 311, which are located in the dimerisation and IkBo binding sub-domain (SD) at either
side of the nuclear localisation signal (NLS) within the Rel homology domain; and serines 529 and 536, which are
located in the transcriptional activation domain (TAD). Phosphorylation of S276 is mediated by the catalytic subunit
of protein kinase A (PKAC) in response to LPS, or by mitogen- and stress-activated protein kinase-1 (MSK1) in
response to tumour necrosis factor-a (TNFa). Activation of protein kinase C-^ (PKCQ by either interieukin-1 (IL1) or
TNFa triggers phosphorylation of S311. TNFa and IL1 also stimulate casein kinase II (CKII), leading to
phosphorylation of serine 529. Targeting of S536 for phosphorylation occurs by either activation of IKKs in response
to LPS, TNFa or the viral protein TAX; or stimulation of ribosomal-subunit kinase-1 (RSK1), which is itself activated
by IL1 or p53.
[Figure from (Chen and Greene, 2004)]
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of serine 536 of RelA in an IKK-independent manner in response to treatment with
drugs such as doxorubicin or etoposide (Bohuslav et al., 2004). It is noteworthy that
phosphorylation of serines 529 and 536 of RelA is functionally relevant as NF-kB-
dependent transcription is greatly impaired by mutating these residues (Ravi and
Bedi, 2004).
RelA is also subject to regulation by GSK-3P and phosphatidylinositol 3-
kinase (PI 3-kinase), which can phosphorylate the RelA C-terminus in vitro, although
the exact phosphorylation sites remain to be determined (Schwabe and Brenner,
2002; Chen and Greene, 2004; Schmitz et al., 2004). Interestingly, phosphorylation
of RelA at threonine 505 has been implicated in pl4ARF-mediated repression of NF-
kB transactivation (Rocha et al., 2003). A more recent study from the same group
identified the checkpoint kinases, ATR (ATM- and Rad3-related) and Chkl
(checkpoint kinase 1), as the kinases responsible for this phosphorylation event
(Rocha et al., 2005).
It is noteworthy that no studies to date have demonstrated phosphorylation of
RelA in response to NSAIDs. However, the discovery that RelA can be
phosphorylated by GSK-3[3, a component of the Wnt signaling pathway, is of
particular interest given that the wingless (Wnt)/[3-catenin pathway is also a strong
target ofNSAIDs and this will be discussed later.
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1.5.3.5.8 Regulation of RelA by Acetylation
In addition to phosphorylation, the transactivation function of RelA has also
been shown to be regulated by reversible acetylation of RelA itself or histones at
target promoters [reviewed in (Quivy and Van Lint, 2004; Schmitz et al., 2004)]. It is
now recognised that various post-translational modifications, including
phosphorylation, acetylation, ubiquitination, methylation and sumoylation, occur on
the amino-terminal tail, in addition to residues located at exposed sites within the
globular domain, of histones. Such modifications represent information contained in
chromatin, not resulting from mutation or changes in the actual DNA sequence,
which defines a heritable pattern of gene expression and is often referred to as
'epigenetic' information (Mellor, 2006).
Post-translational modifications on histones can serve to create or stabilise
binding sites for regulatory proteins, for instance transcription factors, or may even
disrupt or mask chromatin binding sites. Furthermore, the role of a particular
modification may be influenced by the degree and stability of the modification
(Santos-Rosa and Caldas, 2005; Grewal and Rice, 2004). Distinct histone
modifications, on one or more tails, in effect act sequentially or in combination to
form a 'histone code' which is read by proteins containing specific interaction
domains, for example, the bromodomain functions as an acetyl-lysine binding
domain and is found in most histone acetyl transferases (FIATs); the chromodomain
recognises and binds methylated lysines, can bind DNA and is found in histone
methyl transferases (HMTs) (de la Cruz et al., 2005; Santos-Rosa, 2005). It is
noteworthy that bromodomains and chromodomains are also present in some ATP-
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dependent chromatin remodelling enzymes, factors which are involved in causing
conformational changes by ATP-dependent movement of nucleosomes (de la Cruz et
al., 2005). Proteins containing functional domains, such as the bromodomain and
chromodomain, which recognise histone modifications on DNA are therefore the
effectors that mediate downstream responses, such as transcriptional
activation/repression.
It is well established that NF-kB transcriptional activity is dependent upon
interaction with multiple cellular co-activators, such as CBP/p300, p300/CBP-
associated factor (PCAF) or steroid receptor co-activator-1 (SRC-1), which possess
HAT activity (Gerritsen et al., 1997; Perkins et al., 1997; Sheppard et al., 1999;
Zhong et al., 1998; Quivy and Van Lint, 2004). The association of NF-kB with
CBP/p300 has been shown to be dependent upon phosphorylation of RelA at serine
276 by protein kinase A (PKA) and is essential for transcriptional activity of NF-kB
(Zhong et al., 1998). Furthermore, a very recent study (Chen et al., 2005) established
that phosphorylation of RelA at serines 276 and 536 increased the assembly of RelA
with p300, which in turn enhanced acetylation of RelA on lysine 310. It has also
been established that the inactivation of CBP, or PCAF, or SRC-1 by nuclear
antibody microinjection prevents NF-kb-dependent transactivation (Sheppard et al.,
1999). Furthermore, the exogenous expression of CBP, or PCAF or SRC-1, in a
background where RelA is overexpressed, enhances RelA-dependent transcriptional
activation, suggesting a positive regulatory function for each of these three proteins
on NF-kB driven transcription (Gerritsen et al., 1997; Sheppard et al., 1999).
Activation of the IL-6 promoter activity by RelA and CBP/p300 appears to be highly
dependent on the HAT activity of CBP/p300 (Vanden Berghe et al., 1999).
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Moreover, although NF-kB DNA binding is rapid at constitutively active promoters,
hypoacetylated promoters require additional events leading to their hyperacetylation
prior to NF-kB recruitment and activation of transcription (Campbell and Perkins,
2006).
In addition to effects on NF-KB-driven transcriptional activity, stimulus-
induced acetylation of RelA has been shown to control the duration of the NF-kB
transcriptional response (Chen et al., 2001). A summary of the key inducible
acetylation sites within RelA and the resultant effects on its nuclear activity is shown
in Figure 1.12. In one study (Kiernan et al., 2003), lysines 122 and 123 were
identified as key residues for acetylation of RelA by both p300 and PCAF.
Moreover, acetylation of RelA on those residues was discovered to reduce the ability
of RelA to bind target kB sites on DNA and facilitated the removal of RelA from
DNA, thus increasing its export from the nucleus. In another study (Chen et al.,
2002), it was established that the HATs, p300 and CBP, principally target lysines
218, 221 and 310 of RelA for modification. By using hypoacetylated RelA mutants
containing lysine to arginine substitutions at these sites or wild-type RelA co-
expressed in the presence of a donrinantly interfering mutant of p300, the authors
found that acetylation at lysine 221 in RelA enhances DNA binding and disrupts
assembly with IkBol Moreover, it was shown that acetylation of RelA on lysine 218,
in combination with acetylation on lysine 221, is likely important for RelA assembly
with IkBol In contrast, acetylation of lysine 310 was discovered to be required for the
full transcriptional activity of RelA, in the absence of effects on DNA binding or
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Figure 1.12 - Summary of Inducible Acetylation Sites Within RelA and Resultant
Effects on its Nuclear Activity. Acetylation (Ac) of lysines (K) 122 and 123 by p300/CREB-binding protein
(CBP)-associated factor (PCAF) and p300/CBP respectively decreases transcriptional activity of RelA by reducing
the binding of RelA to the kB enhancer. Conversely, acetylation of K221 by p300/CBP slightly increases
transcriptional activity of RelA and increases DNA-binding affinity of RelA for the kB enhancer. Acetylation of K221,
together with acetylation of K218, also prevents the association of RelA with IkBo. In contrast to the other residues
mentioned, acetylation of K310 does not control DNA binding or IkB assembly, but is instead required for the
transactivation function of RelA. SD denotes sub-domain; TAD denotes transactivation domain; green box denotes
nuclear localisation signal.
[Figure from (Chen and Greene, 2004)]
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In addition to co-activators, NF-kB has also been shown to recruit, either
directly or indirectly, co-repressor complexes, which posess histone deacetylase
(HDAC) activity (Quivy and Van Lint, 2004). Deacetylation is thought to play a role
in the termination of transcriptional activity by enhancing binding affinity of NF-kB
to IkBcx (Schmitz et al., 2004). It is now widely accepted that the acetylation status of
RelA is subject to regulation by deacetylases. One study demonstrated that RelA can
interact with the HDAC co-repressor proteins, HDAC1 and HDAC2 (Ashburner et
al., 2001). Acetylated RelA has also been shown to be deacetylated through a
specific interaction with HDAC3 (Chen et al., 2001; Kiernan et al., 2003). Moreover,
deacetylation of lysine 310 by the HDACs, SIRT1 or HDAC3, inhibits the
transcriptional activity of RelA and can augment cellular apoptosis in response to
TNFa (Chen et al., 2002; Yeung et al., 2004). Interestingly, a recent study
established that interaction of RelA with HDACs 1, 2 and 3 in response to UV-C and
daunorubicin resulted in repressed expression of NF-xB-regulated genes (Campbell
et al., 2004). It is important to note that a role for acetylation in the regulation ofNF-
kB activity is further supported by studies showing that deacetylase inhibitors, such
as trichostatin A (TSA) or sodium butyrate, can enhance NF-xB-dependent gene
expression in the presence of TNF-a (Ashburner et al., 2001; Chen et al., 2001; Inan
et al., 2000b).
Similar to phosphorylation of RelA, no studies to date have demonstrated
acetylation of RelA in response to NSAIDs. However, modulation of RelA activity
by acetylation is of particular interest to the host group as recent unpublished data
generated in the host laboratory has indicated that acetylation of RelA is implicated
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in the apoptotic response to aspirin and this will be discussed more fully in Chapter
6.
1.5.3.5.9 Regulation of RelA by Ubiquitination
Two studies to date have suggested a role for ubiquitination in the regulation
of RelA activity. Cytokine-induced phosphorylation of RelA at threonine 254 has
been reported to stabilise the interaction between the peptidyl-prolyl isomerase, Pinl
and RelA (Ryo et al., 2003). Binding of Pinl to RelA was found to inhibit the
interaction of RelA with IkBcx, enhance RelA nuclear localisation and increase RelA
stability via decreased proteasomal degradation of ubiquitinated RelA. Moreover,
ubiquitin-mediated proteolysis of RelA in turn was facilitated by the E3 ubiquitin
ligase, suppressor of cytokine signaling-1 (SOCS-1). In another study (Saccani et al.,
2004), degradation of promoter-bound RelA was shown to be essential for the
termination of the NF-kB pathway in response to TNFa. The potential role for
ubiquitination of RelA in the response to aspirin will be discussed in Chapter 6.
1.5.3.5.10 Regulation of RelA by Other Signaling Pathways
There are several signaling pathways known to modulate the transcriptional
activity of NF-kB which are not involved in nuclear translocation ofNF-kB. Neither
p38 nor JNK directly phosphorylate NF-kB but inhibition of these pathways, using
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specific inhibitors or dominant negative mutants, strongly reduces NF-kb-dependent
transcription (Vanden Berghe et al., 1998; Schmitz et al., 2001). Nuclear
translocation and DNA binding of NF-kB are also unaffected by inhibiting these
pathways, suggesting that p38 and JNK regulate the transactivation function of NF-
kB. However, the precise mechanisms for this are still not clear. It is of interest that
recent unpublished work from the host laboratory has shown that activation of the
p38 MAPK pathway is implicated in the NF-kB response to aspirin (Thorns et al.,
2004). In particular, specific inhibition of p38 signaling by using chemical inhibitors
or siRNA knock-down attenuates the NF-kB response to aspirin and aspirin-induced
apoptosis in SW480 colorectal cancer cells.
The PI 3-kinase signaling pathway has also been implicated in the
transcriptional activation of NF-kB, but the evidence for this is quite controversial.
Several studies support a role for PI 3-kinase and Akt (a downstream kinase of PI 3-
kinase) in regulation of RelA transcriptional activity in response to IL-1 (Schmitz et
al., 2001; Vermeulen et al., 2002; Ghosh and Karin, 2002; Viatour et al., 2005).
However, the PI 3-kinase inhibitors wortmannin and LY 294002 have no effect on
inducible NF-kB nuclear translocation, although the latter can prevent IL-1-induced
RelA phosphorylation (Beraud et al., 1999; Sizemore et al., 1999). Neither Akt nor
PI 3-kinase directly phosphorylate RelA (Schmitz et al., 2004) but it has been
proposed that Akt targets the transactivating function of NF-kB by activating p38
and IKK(3 (Viatour et al., 2005).
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1.5.3.5.11 Target Genes of NF-kB
The active NF-kB transcription factor regulates a large number of target
genes, which can be split into four broad functional categories: immunoregulatory
and inflammatory genes; genes involved in apoptosis; genes that regulate cell
proliferation; and genes that encode negative feedback regulators of NF-kB itself
(Karin et al., 2002; Campbell and Perkins, 2006) (for examples, see Table 1.3).
As mentioned earlier, NF-kB plays a crucial role in the inflammatory
response and has been implicated in a variety of inflammatory diseases such as
rheumatoid arthritis, asthma and Crohn's disease (Pande and Ramos, 2005; Perkins,
2000). It is noteworthy that NF-kB controls the expression of the cytokines, 1T-1 and
TNFa, which are essential mediators of chronic inflammation (Delhalle et al., 2004).
As both IT-1 and TNFa can also activate NF-kB, an interdependence of persistent
NF-kB activation and sustained levels of 1L-1 and TNF-a is implicated (Makarov,
2000; Sun and Andersson, 2002). This essentially allows for the rapid induction of a
response such that NF-kB activation could spread from cell to cell, within a tissue
and beyond. It is important to note that, in addition to mediating the immune
response, the wide variety of NF-kB inducers and target genes have implicated NF-
kB more generally as a 'central regulator of stress responses' (Pahl, 1999).
NF-kB is subject to negative feedback regulation as it controls the
transcription of its inhibitor, IkB, and the pi05 (NF-kB1) and plOO (NF-kB2)
precursors (Karin et al., 2002). Indeed, the critical step for termination and down-
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Table 1.3 - Examples of Target Genes of NF-kB and Their Functions.
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in the nucleus (Rothwarf and Karin, 1999; Sun and Andersson, 2002). These NF-
kB:IkBcx complexes can then be transported from the nucleus to the cytoplasm by
means of the nuclear export signal present on IkBcx (Rothwarf and Karin, 1999; Sun
and Andersson, 2002).
The fact that NF-kB targets include genes that are implicated in critical
cellular processes, in particular regulation of apoptosis and cell proliferation, makes
it a very attractive target pathway for chemopreventative agents such as NSAIDs.
Therefore, the role of NF-kB in regulation of apoptosis and cell proliferation will
now be discussed.
1.5.3.5.12 Regulation of Apoptosis and Cell Proliferation by NF-kB
It is well established that NF-kB has a key role in regulation of apoptosis,
having both pro-apoptotic and anti-apoptotic functions depending on the cell type
and stimulus used (Bours et al., 2000; Kucharczak et al., 2003; Perkins, 2004a; Luo
et al., 2005a; Campbell and Perkins, 2006). A major insight into this functional
aspect of NF-kB came from the observation that the RelA knockout mouse is
embryonic lethal, due to extensive liver apoptosis and that cells from these mice have
an enhanced sensitivity to TNF-induced cell death (Sun and Andersson, 2002).
NF-kB exerts its pro-survival function by inducing the expression of anti-
apoptotic genes, whose products include: c-FLIP (caspase-8/FADD-like-interleukin-
1(3 (IL-ip)-converting enzyme inhibitory protein), BcI-Xl, Al/Bfl-1, cellular
inhibitor of apoptosis (c-IAP), X-chromosome-linked inhibitor of apoptosis (XIAP),
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TRAF (TNFR-associated factor) 1 and TRAF2 (Luo et ah, 2005a; Delhalle et al.,
2004; Ravi and Bedi, 2004). c-FLIP is a proteolytically inactive analogue of caspase-
8 and thus prevents death receptor-induced activation of the initiator pro-caspase-8
and subsequent apoptosis (Kreuz et ah, 2001). Members of the IAP family can
inhibit the activation of various effector caspases by direct interaction, and therefore
prevent death receptor-induced apoptosis (Deveraux and Reed, 1999). The anti-
apoptotic Bcl-2 family members, including Bc1-Xl, prevent apoptosis by inhibiting
cytochrome c release and depolarisation of mitochondria, thus avoiding apoptosome
formation and the apoptotic cascade (Luo et ah, 2005a). In addition to promoting
expression of anti-apoptotic genes, NF-kB activation can also lead to repression of
pro-apoptotic genes, such as bax (Bentires-Alj et ah, 2001). NF-kB has also been
demonstrated to interfere with the transcriptional activity and pro-apoptotic function
of p53 (Webster and Perkins, 1999). The mechanism for the transcriptional
antagonism between NF-kB and p53 involved competition for a limiting pool of their
shared transcriptional co-activators, p300 and CBP. There is also accumulating
evidence that suppression of JNK, a regulator of programmed cell death, contributes
to the anti-apoptotic function of NF-kB (Kucharczak et al., 2003; Ravi and Bedi,
2004; Luo et ah, 2005a).
In contrast to the pro-survival role mentioned above, there is a growing body
of evidence that activation of NF-kB may promote cell death under certain
circumstances (Barkett and Gilmore, 1999; Sun and Andersson, 2002; Campbell and
Perkins, 2004 and 2006). NF-kB can activate expression of some pro-apoptotic
genes, including TNF receptor superfamily members, DR4 and DR5 (Ravi et al.,
2001), DR6 (Kasof et ah, 2001), Fas (Kimura et ah, 2003), and Fas ligand (FasL)
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(Wiener et al., 2004). Under certain conditions, NF-kB may also function to repress
expression anti-apoptotic genes. NF-kB activation has been shown to be required for
doxorubicin-induced apoptosis (Ashikawa et al., 2004). Another report documented
that UY-C and daunorubicin inhibit TNF-a-induced NF-kB transcriptional activity
by a mechanism involving enhanced association of RelA with HDACs and
repression of anti-apoptotic genes (Campbell et al., 2004). Similarly, repression of
NF-kB transcriptional activity has been shown to be causally involved in aspirin-
induced apoptosis of colorectal cancer cells (Stark and Dunlop, 2005). Flowever, the
authors established that sequestration of RelA in the nucleolus was a central
component of the mechanism. The observations of that paper will be discussed more
fully later in this introduction and in Chapter 3.
In addition to its role as a regulator of apoptosis, NF-kB can control cellular
proliferation. NF-kB influences cellular proliferation by directly stimulating the
transcription of genes required for cell cycle progression, for example G1 cyclins
{cyclin D1 and cyclin E), c-myc, and c-myb (Kucharczak et al., 2003). Furthermore,
NF-kB can activate the expression of cytokines, such as IL-2, granulocyte-
macrophage colony-stimulating factor (GM-CSF) and CD40 ligand, which are
growth factors that stimulate the proliferation of lymphoid and myeloid cells (Karin
et al., 2002).
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1.5.3.5.13 Role of NF-kB in Tumorigenesis
Given that NF-kB is involved in the regulation of critical cellular processes,
such as apoptosis and proliferation, it comes as no surprise that there is a strong link
between aberrant regulation of NF-kB and cancer [reviewed in (Karin et al., 2002;
Bharti and Aggarwal, 2002; Gilmore, 2003; Greten and Karin, 2004; Ravi and Bedi,
2004)]. Furthermore, NF-kB has been implicated in the tumorigenic process and this
provides further support for the notion that it is a very good target pathway for
chemopreventative agents such as NSAIDs.
NF-kB is known to be activated by a variety of carcinogens and tumour
promoters, for example UY radiation and phorbol esters (Bharti and Aggarwal,
2002). Certain viral oncoproteins, including EBV latent membrane protein-1 and
HTLV-1 Tax, stimulate cellular pathways which activate NF-kB (Ravi and Bedi,
2004). Moreover, the transforming ability of some viral and cellular oncoproteins,
for example Ras and Bcr-Abl, requires the activation of NF-kB (Greten and Karin,
2004).
An important aspect of tumour growth is angiogenesis, a process that requires
both migratory and invasive capabilities of vascular epithelial cells (Karin et al.,
2002). Invasion and angiogenesis are in turn critical events for tumour metastasis
(Bharti and Aggarwal, 2002). There is substantial evidence demonstrating a role for
NF-kB in angiogenesis. Cells with elevated NF-kB activity deregulate production of
chemokines (chemotactic factors that induce cell migration), such as interleukin-8
(IL-8), thereby leading to increased migratory activity and promotion of angiogenesis
(Karin et al., 2002). Various genes known to be involved in tumour cell invasion and
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angiogenesis are regulated by NF-kB (Bharti and Aggarwal, 2002). NF-kB promotes
the expression of cell adhesion molecules [VCAM-1 (vascular cell adhesion
molecule-1), ICAM-1 (intracellular adhesion molecule-1), E-selectin] and MMP-2
and -9, which are proteolytic enzymes that are involved with degradation of
extracellular matrix proteins, hence promoting tumour invasion of the surrounding
tissue (Ravi and Bedi, 2004). NF-kB also enhances expression of iNOS (inducible
nitric oxide synthase), a protein required for vasodilation, VEGF (vascular
endothelial growth factor) and COX-2, which in turn can induce the expression of
several angiogenic factors (Bharti and Aggarwal, 2002).
Constitutive nuclear NF-kB activity is observed in numerous tumour cell
types, including leukaemia, lymphoma, myeloma, breast and colon (Bharti and
Aggarwal, 2002; Kucharczak et al., 2003). Interestingly, most tumours that have
constitutive NF-kB activity show an increased resistance to chemotherapeutic drugs
(Delhalle et al., 2004). Furthermore, many chemotherapeutic agents induce NF-kB
activity, thereby increasing drug resistance in tumour cells (Greten and Karin, 2004).
The use of chemopreventative agents, such as NSAlDs or resveratrol, to inhibit NF-
kB in combination with chemotherapeutic agents was therefore proposed (Bharti and
Aggarwal, 2002). It has been shown that inhibition of NF-kB activity not only leads
to enhanced apoptosis but also to synergy with radiation or chemotherapy in several
tumour cell lines and xenograft models of cancer (Greten and Karin, 2004). The
design and development of drugs that inhibit activation of the NF-kB pathway, in
particular IKK inhibitors, has therefore been of considerable importance for the
treatment of cancer (Greten and Karin, 2004). Elowever, it is important to re-
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emphasize that in response to certain agents, for example aspirin, activation of NF-
kB as opposed to inhibition may be therapeutically relevant.
There is a body of evidence that inappropriate NF-kB signaling is implicated
in colorectal cancer in particular. The observation that primary colon tumours exhibit
constitutive activation of NF-kB (Gilmore, 2003) is supported by data from in vitro
studies which found that colon cancer cell lines exhibit abnormally high NF-kB
activity and low IkBoi levels (Dejardin et al., 1999). Significantly, several growth
regulatory genes that are known to be involved in colorectal cancer progression e.g.
p53, COX-2, c-myc, are regulated by NF-kB (Karin et al., 2002; Ravi and Bedi,
2004).
Collectively, these data provide compelling evidence that the NF-kB pathway
is a strong potential target for the anti-tumour effects of NSAIDs in the colon. In
spite of this knowledge, however, there have only been a few studies investigating
the effects ofNSAIDs on the NF-kB pathway and these will now be discussed.
1.5.3.5.14 The Effects of NSAIDs on the NF-kB Pathway
The first study to investigate the effects of NSAIDs on NF-kB (Kopp and
Ghosh, 1994) demonstrated that sodium salicylate inhibits activation of the NF-kB
pathway by two different inducers [LPS and PMA-PHA (phorbol 12-myristate 13-
acetate plus phytohemagglutinin)]. Furthermore, in that study, sodium salicylate and
aspirin also inhibited stimulus-induced (PMA-P1TA) activation of NF-KB-dependent
transcription as measured from two different reporter constructs [immunoglobulin
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(Ig)-k enhancer (containing 2 kB sites)-luciferase and the human immunodeficiency
virus (HIV)-l long terminal repeat (LTR) repeat (containing two inducible NF-kB
sites)-luciferase] in transfected cells. In a similar study (Yin et al., 1998), it was
found that sodium salicylate and aspirin, but not indomethacin, inhibit stimulus-
induced (TNFa, NIK, TAX or MEKK1) activation ofNF-KB-dependent transcription
from the HIV-1 LTR-luciferase reporter in transfected cells. Moreover, the
mechanism for the effects of sodium salicylate and aspirin was established to be, at
least in part, the result of binding of these agents to IKK[3 to reduce ATP binding.
Another study by the same group established that sulindac, sulindac sulfone and
sulindac sulfide, but not indomethacin or ibuprofen, reduced TNFa-mediated and
NIK-mediated activation of NF-icB-driven transcription from the HIV-1 LTR-
luciferase reporter in transfected cells (Yamamoto et al., 1999). Furthermore, the
authors established that sulindac, but not ibuprofen or indomethacin, inhibited
stimulus-induced (TNFa or NIK) nuclear translocation ofNF-kB and like aspirin and
sodium salicylate, sulindac specifically inhibited IKK-[3 activity. A very recent study
(Niederberger et al., 2006) established that the COX-2-selective inhibitors,
etoricoxib and lumiracoxib, can inhibit both LPS stimulated DNA-binding activity of
NF-kB and nuclear accumulation ofRelA in response to LPS.
In contrast to previous reports, the host laboratory demonstrated that aspirin
mediates its anti-tumour effect by activating the NF-kB pathway even in the absence
of TNF or other stimulating agents (Stark et al., 2001). It was found that aspirin
induces a reduction in cytoplasmic iKBa that is both time- and concentration-
dependent. Furthermore, the degradation of IkB mediated the nuclear translocation of
p50/RelA NF-kB complexes, thus confirming stimulation of the NF-kB pathway.
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This response to aspirin occurred before detectable cell death by apoptosis,
suggesting a causal relationship. Inhibiting nuclear translocation of NF-kB using
super-repressor IkBoi, a dominant negative form of IxBa that is resistant to
phosphorylation on the two critical serine residues (Ser 32 and 36), effectively
blocked aspirin-induced cell death confirming that aspirin-induced apoptosis is due,
at least in part, to nuclear translocation of NF-kB (Stark et al., 2001). It is also
noteworthy that the observed effects of aspirin on the NF-kB pathway are cell-type
specific to colorectal cancer cell lines (Din et al., 2004) and independent of both p53
status and, as mentioned above, DNA MMR gene proficiency (Din et al., 2005).
Several other papers have reported activation of the NF-kB pathway in response to
NSAIDs. A recent study (Cho et al., 2005) demonstrated that the NSAID diclofenac
mediates degradation of cytoplasmic IkBci and nuclear accumulation of RelA. The
selective COX-2 inhibitor, celecoxib, has been found to increase nuclear
translocation of RelA, NF-kB DNA binding activity and NF-kb-dependent gene
transcription, strongly suggesting that this agent has COX-independent actions
(Niederberger et al., 2001). Another COX-2-selective inhibitor, NS-398, was
reported to cause degradation of IkBcx and a delayed increase in NF-kB DNA-
binding, but not NF-kb-dependent transcriptional activity, in colon cancer cells in
the absence of additional NF-kB activators (Smartt et al., 2003).
Overall, the results from these studies indicate that activation of the NF-kB
pathway is common to NSAIDs and independent of their COX inhibitory nature. It is
also very likely that there is a further level of complexity in the upstream mechanism
of activation of the NF-kB pathway, depending on the cell type and NSAID used.
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1.5.3.5.15 The Nucleolus and Regulation of Transcription, Cell Growth
and Apoptosis
Recent data from the host laboratory has shown that aspirin not only induces
translocation of NF-kB components to the nucleus, but also leads to nucleolar
sequestration of the RelA component of NF-kB (Stark and Dunlop, 2005).
Compartmentalisation of RelA in the nucleolus was found to be stimulus specific.
The classical NF-kB activators, TNF and TRAIL, caused RelA to be concentrated in
the nucleoplasm with no detectable nucleolar staining. However, serum withdrawal
and UV-C radiation (pro-apoptotic stimuli) resulted in sequestration of RelA in the
nucleolus. Using aspirin as a model system, nucleolar accumulation of RelA was
found to require de-novo protein synthesis from the observations that both
cyclohexamide and actinomycin D prevented RelA localisation in the nucleolus.
Furthermore, nucleolar sequestration of RelA was independent of the Crmlp nuclear
export pathway and required translocation from the cytoplasm to the nucleus. Using
a dominant negative RelA construct, nucleolar accumulation of RelA was
demonstrated to be causally involved in aspirin-induced repression of NF-kB
transcriptional activity and apoptosis (Stark and Dunlop, 2005).
The nucleolus from most higher eukaryotes is assembled around clusters of
tandemly repeated ribosomal genes (ribosomal DNA (rDNA) genes) and primarily
functions as a factory for ribosome assembly (Olson et al., 2000). The three major
morphological components of the nucleolus are: the fibrillar centre, the dense
fibrillar component, and the granular component (Dundr and Misteli, 2001). In
addition to being a site dedicated to ribosome biogenesis, non-conventional roles for
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the nucleolus are emerging, which include processing and/or nuclear export of
certain rnRNAs, sequestration of regulatory molecules, modification of small RNAs,
ribonucleoprotein particle assembly, and control of ageing [reviewed in (Pederson,
1998a; Pederson, 1998b; Olson et al., 2002)]. Many nonribosomal proteins, such as
survivin-deltaEx3 (Song and Wu, 2005), c-Myc (Arabi et al., 2003), promyelotic
leukaemia gene product (PML)-containing nuclear body associated proteins
(Mattsson et al., 2001), growth factors (Antoine et al., 1997; Galcheva-Gargova et
al., 1998; Pederson, 1998b), virus proteins (Stauber and Pavlakis, 1998; Wurm et al.,
2001) and regulators of apoptosis, for example p53, DEDD, MDM2 and pl4ARF
(Stegh et al., 1998; Zhang and Xiong, 1999; Lohrum et al., 2000), have been
demonstrated to localise to the nucleolus under certain conditions. It has therefore
been proposed that the nucleolus may have a key role in cell-cycle regulation and
apoptosis (Carmo-Fonseca el al., 2000; Horky et al., 2002). Indeed, one of the most
notable features of the cell cycle is the disassembly of the nucleolus during mitosis
and its subsequent reassembly as the daughter cells proceed into interphase (Dimario,
2004).
The nucleolus has been identified as a key site for regulation of c-Myc, an
oncoprotein that regulates the transcription of genes that are associated with cell
growth, proliferation and apoptosis (Oster et al., 2002). c-Myc and proteasomes have
been observed to accumulate at the nucleoli of cells containing elevated c-Myc
protein levels (achieved by overexpression or proteasome inhibition) (Arabi et al.,
2003), leading the authors to propose that c-Myc is subject to ubiquitin-mediated
proteolysis in the nucleolus. A more recent study (Datta et al., 2004) demonstrated
that c-«7yc-induced progression through the cell cycle is inhibited by the
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sequestration of the protein in the nucleolus. Furthermore, interaction between c-Myc
and the Fbw7 ubiquitin ligase within the nucleolus is important for regulation of c-
Myc's growth promoting function (Welcker et al., 2004). c-Myc has also been shown
to associate with ribosomal DNA and activate RNA polymerase I transcription,
indicating that regulation of ribosome biogenesis by c-Myc could be important for its
effects on cell growth (Arabi et al., 2005).
The nucleolus has also been implicated in the regulation of the tumour
suppressor protein, p53 [reviewed in (Olson, 2004; Dundr and Misteli, 2001; Zimber
et al., 2004)]. p53 activity is primarily controlled by its interaction with the MDM2
oncoprotein, which regulates p53 degradation in the cytoplasm through its targeting
to the ubiquitination pathway. MDM2 has been shown to undergo nucleocytoplasmic
shuttling and its activity is regulated by ARF, which blocks the export of MDM2 to
the cytoplasm and sequesters MDM2 in the nucleolus. Furthermore, ARF inhibits the
E3 ubiquitin-ligase activity associated with MDM2. As a consequence, p53 is not
degraded and its level in the nucleus rises. Increased levels of ARF essentially induce
cell-cycle arrest by inhibiting the MDM2-dependent degradation of p53. Specifically,
ARF has been shown to differentially regulate the E2F-1/DP-1 complex (Datta et al.,
2002), a complex known to be involved in G|/S cell cycle progression.
Interestingly, ARF has recently been shown to regulate the transactivation
function of RelA and was found to inhibit both NF-KB-driven transcription and anti-
apoptotic activity, independent of MDM2 and p53 (Rocha et al., 2003). Moreover,
ARF induces ATR- and Chkl-mediated phosphorylation of RelA on threonine 505, a
site required for ARF-dependent repression ofRelA transcriptional activity (Rocha et
al., 2005; Rocha and Perkins, 2005). The nucleolar protein, NF-kB binding protein
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(NFBP), has been identified in a yeast two-hybrid screen for novel NF-kB interacting
proteins (Sweet et al., 2003). Similarly, it was discovered that the nucleolar protein,
nucleophosmin/B23, is an NF-KB-interacting partner (Dhar et al., 2004). It is also
noteworthy that nucleolar shuttling of the NF-kB regulator, NIK, has recently been
shown to affect the function of that kinase (Birbach et al., 2004). Another recent
paper reported that nucleolar localisation of NRF (NF-kB repressing factor)
correlates inversely with its mobility.
Collectively, these data indicate that nucleolar sequestration of key
transcription factor components, for example RelA, might be very important in the
apoptotic response to NSAIDs, in particular aspirin. It follows, therefore, that the
nucleolus could be a good candidate target site for chemopreventative agents in
general.
1.5.3.6 p-catenin Signaling
In addition to COX, NF-kB and the other pathways mentioned so far, the
cellular factor P-catenin has been identified as a major target ofNSAIDs. P-catenin is
a 92 kDa protein that has two major roles in cells. As a component of adherens
junctions, P-catenin was first implicated in cell-cell adhesion (Bienz, 2005). P-
catenin, together with a-catenin and y-catenin, binds to the intracellular domain of E-
cadherin, a transmembrane protein involved in homotypic cell-cell contacts, thus
linking cadherin adhesion receptors to a-catenin, which in turn links to the actin
cytoskeleton (Morin, 1999; Harris and Peifer, 2005). This function of P-catenin is
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based on the stable, membrane-associated subcellular pool of p-catenin (Bienz,
2005). In addition to its role in cell adhesion, P-catenin was found to have signaling
functions when it was discovered to be the mammalian homologue of armadillo, a
segment polarity gene involved in the Wnt signaling pathway in Drosophila (Morin,
1999). In this role, P-catenin functions as a transcriptional co-activator by forming a
complex with the lymphoid enhancer factor (LEF) and T cell factor (TCF) classes of
transcription factors to activate transcription of Wnt target genes (Lustig and
Behrens, 2003; Harris and Peifer, 2005). This signaling function of P-catenin is
conferred by a soluble cytoplasmic pool that is highly unstable in the absence of a
Wnt signal (Bienz, 2005).
1.5.3.6.1 The Wnt Signaling Pathway
An overview of the canonical Wnt pathway is shown in Figure 1.13
[reviewed in (Behrens and Lustig, 2004; Lustig and Behrens, 2003; Giles et al.,
2003; Polakis, 2000; Dale, 1998)]. Briefly, Wnts are a large family of secreted
glycoproteins, with at least 19 known human members, that have key roles in
development (Giles et al., 2003). Wnt signaling is initiated following Wnt ligand
binding to seven transmembrane receptors called frizzleds, with low-density
lipoprotein receptor-related protein (LRP) family receptors 5 and 6 acting as essential
co-receptors of Wnt ligands (Lustig and Behrens, 2003). Secreted factors, for
example WIF, FrzB and Dickkopf (Dkk) can modulate the interaction of Wnts with
frizzled receptors by acting as direct or indirect antagonists (Giles et al., 2003).
101
LRP
Figure 1.13 - Overview of The Wnt Signaling Pathway. Binding of Wnt ligand to frizzled receptors
activates dishevelled, which in turn blocks the function of the multi-protein complex comprising: APC, the scaffold
proteins axin or conductin, GSK-3P, diversin and CKI. In the absence of Wnts, the multi-protein complex
phosphorylates (P) p-catenin via CKI and GSK-3p. Phosphorylated p-catenin then becomes multi-ubiquitinated (Ub)
by p-TrCP and is subsequently targeted for degradation by the proteasome. In the presence of Wnt or after
mutations of APC, the phosphorylation and degradation of p-catenin is blocked, which allows the association of p-
catenin with TCF transcription factors. TCF/p-catenin complexes bind to specific promoters on DNA and hence
activate transcription of Wnt target genes, together with the appropriate transcriptional repressors or activators. The
canonical Wnt signaling pathway also branches to the planar cell polarity and Ca2* signaling pathways (indicated by
dashed lines).
[Figure adapted from (Lustig and Behrens, 2003)]
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In the absence ofWnt stimulation, cytoplasmic |3-catenin levels are normally
regulated by a multi-protein destruction complex which targets p-catenin for
degradation in proteasomes (Behrens and Lustig, 2004). This multi-protein
destruction complex comprises axin (or its homologue conductin), GSK-3P, APC,
casein kinase I (CKI) and diversin (Lustig and Behrens, 2003). Axin/conductin,
together with APC, form a structural scaffold in this complex that facilitates the
efficient phosphorylation of P-catenin (Giles et al., 2003). Phosphorylation of P-
catenin occurs via a two-step mechanism at four amino terminal residues (Behrens
and Lustig, 2004). First, Ser45 is phosphorylated by CKI, creating a primary binding
site on p-catenin for GSK-3P, which subsequently phosphorylates Ser33, Ser37 and
Thr41. Phosphorylation of P-catenin targets it for binding to P-TrCP, an F box
protein and E3 ubiquitin ligase, thus triggering ubiquitination of P-catenin and its
subsequent degradation in proteasomes (Giles et al., 2003).
In the presence of Wnt stimulation, binding of Wnt to the frizzled receptor
leads to phosphorylation and activation of dishevelled (Dsh), which is subsequently
recruited to the cell membrane (Bienz and Clevers, 2000). Activated Dsh can recruit
axin and the destruction complex to the plasma membrane, leading to degradation of
axin (Moon et al., 2004). Furthermore, activated Dsh can also inhibit GSK-3P
activity (Ben-Ze'ev and Geiger, 1998). Collectively, these events stabilise P-catenin
levels by reducing phosphorylation and degradation of P-catenin by the destruction
complex. Stabilised (hypophosphorylated) P-catenin is then free to translocate to the
nucleus, where it associates with TCF/LEF transcription factors, leading to activation
of transcription ofWnt target genes (Giles et al., 2003). Accumulation of P-catenin is
therefore critical for activation of the Wnt transcriptional response (Taipale and
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Beachy, 2001). The interaction between stabilised |3-catenin and TCFs can be
modulated by several direct and indirect mechanisms. In the absence of Wnt
signaling, TCF's can associate with transcriptional repressors, such as groucho, to
block the expression of Wnt target genes (Lustig and Behrens, 2003). Furthermore,
the transcriptional activity of TCF/p-catenin complexes can be enhanced by
transcriptional activators, including p300/CBP (Hecht et al., 2000). Several nuclear
effector proteins, namely ICAT and Chibby, can bind to |3-catenin and in doing so,
disrupt the interaction of [3-catenin with TCF (Behrens and Lustig, 2004).
Having outlined the Wnt/[3-catenin pathway, it is clear that there are strong
parallels with the NF-kB pathway. These similarities and the potential for cross-talk
between the NF-kB and Wnt/p-catenin pathways will be discussed more fully later
but in keeping with this notion, it is noteworthy that the NF-kB and Wnt signaling
pathway regulate a similar panel of target genes. Therefore, in order to highlight
similarities with the NF-kB pathway and to emphasize the relevance for the anti-
tumour effects of NSAIDs, Wnt target genes that are implicated in cancer
development will be the major focus of the following discussion of target genes of p-
catenin.
1.5.3.6.2 Target Genes of p-catenin
Several Wnt targets (for examples see Table 1.4) [reviewed in (Doucas et al.,
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Table 1.4 - Examples of Target Genes of p-catenin and Their Functions.
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identified include genes which have roles in cell cycle progression and apoptosis.
The promoters of both c-myc, a proto-oncogene, and cyclin D1, an activator of cyclin
dependent kinases, contain TCF binding sites and are controlled by TCF/p-catenin
complexes (He et al., 1998; Tetsu and McCormick, 1999). c-Myc regulates the
transcription machinery and its expression has been shown to be inversely related to
apoptosis in colorectal cancer cells (Greco et al., 2001). Furthermore, upregulation of
c-Myc leads to repression of the CDKI, p21wafl/cipl, and thus stimulates GfS
progression through the cell cycle (van de Wetering et al., 2002). Cyclin D1
regulates the GfS phase of the cell cycle by direct activation of Gi CDKs (Behrens
and Lustig, 2004) and so TCF/p-catenin complexes can also promote cell cycle
progression through upregulation of cyclin D1 (Lustig and Behrens, 2003).
Interestingly, adenomas from FAP patients have elevated cyclin D1 levels (D'Orazio
et al., 2002) and sporadic colorectal tumours showing nuclear accumulation of P-
catenin exhibit cyclin D1 overexpression (Oda et al., 1999). Expression of survivin,
an anti-apoptotic gene known to be upregulated in colon tumours, has been shown to
be downregulated by APC and analysis of the promoter revealed TCF-4-binding
sites, thus implicating it as a Wnt target (Zhang et al., 2001a).
Wnt targets also include several growth factors and their receptors, which
could affect cell proliferation and hence influence tumour progression. The levels of
VEGF, a pro-angiogenic protein, have been shown to be elevated in colorectal cancer
and moreover, expression of VEGF is upregulated by Wnt signaling through TCF-
binding sites in its promoter, which could lead to stimulation of angiogenesis (Zhang
et al., 2001b). The tyrosine kinase c-Met is the receptor for the epithelial growth,
motility and survival factor, hepatocyte growth factor (HGF)/scatter factor. c-Met
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has been shown to be upregulated in the polyps of FAP patients, an effect that can be
abrogated by dominant-negative TCF in colorectal tumour cells (Boon et al., 2002).
Amplification of c-Met occurs in approximately 10% primary colon tumours and this
may promote cell motility and invasion (Lustig and Behrens, 2003).
Wnt targets that are specifically implicated in tumour progression include
members of the MMP family. B-catenin/TCF complexes can activate the expression
of MMP-7 (Crawford et al., 1999), a protein that is frequently upregulated in
colorectal cancer (Oving and Clevers, 2002). Deficiency of the MMP matrilysin in
Min mice results in a decrease in tumour number and size (Crawford et al., 1999).
The cell adhesion molecules, CD44 (a protein implicated in metastasis formation
through interaction with proteoglycans) and Nr-CAM (a member of the Ig
superfamily of adhesion receptors) have been implicated as Wnt targets, and could
therefore affect the motility of tumour cells and their capacity to metastasise
(Behrens and Lustig, 2004). CD44 is strongly expressed in aberrant crypt foci
(Wielenga et al., 1999) and Nr-CAM has been demonstrated to be overexpressed by
(3- or y-catenin in colorectal cancer cell lines (Conacci-Sorrell et al., 2002).
Other Wnt targets include transcription factors, including ITF-2
(immunoglobulin transcription factor-2), Id2 (dominant negative helix-loop
regulator) and AF17 (transcriptional regulator and fusion partner of MLL (mixed
lineage leukaemia) in certain acute lymphoblastic leukaemia and myeloid leukaemia)
(Lustig and Behrens, 2003), thus allowing for potential cross-talk between different
pathways.
Like NF-kB and other signal transduction cascades, the Wnt pathway
incorporates mechanisms for negative feedback control. The scaffold component of
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the destruction complex, conductin/axin2, is a direct target ofWnt signaling (Jho et
al., 2002) and conductin/axin2 is overexpressed in early colorectal adenomas (Lustig
et al., 2002). Negative control of the pathway can also be achieved via naked cuticle
(Nkd), which interferes with dishevelled; dominant negative forms of TCF-1; or
expression of the ubiquitin ligase (3-TrCP, which is activated by Wnt signaling at the
post-transcriptional level (Spiegelman et al., 2000).
It is of particular interest that COX-2 and PPARS, which were described
above as being well defined targets of NSAIDs, are targets ofWnt signaling (Giles et
al., 2003). PPARS is upregulated early in tumorigenesis by binding of TCF/p-catenin
complexes to TCF-responsive elements (He et al., 1999). Another study (Howe et
al., 1999) demonstrated that COX-2 is upregulated in mouse mammary cell lines by
induction of stabilised P-catenin through Wnt-1. COX-2 catalyses the production of
eicosanoids, including PGs, from arachidonic acid and eicosanoids in turn can
promote cell viability through binding and activation of PPARSs (Lustig and
Behrens, 2003). Hence a plausible hypothesis is that NSAIDs block PPARS function
at two levels: indirectly by blocking eicosanoid synthesis through COX-2 and
directly by stimulating interaction of PPARS with specific promoters.
1.5.3.6.3 Alterations of Wnt Signaling in Colorectal Cancer
In support of the notion that P-catenin is a potential target for NSAIDs in the
colon, there is a body of evidence that defects in the Wnt signaling pathway have a
central role in the development and progression of colorectal cancer. In addition to
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being a component of the Wnt pathway, APC is a key tumour suppressor gene in
colorectal cancer. It is mutated in the germ line in FAP, a hereditary syndrome with a
penetrance of 100% (Jo and Chung, 2005). Moreover, APC is somatically mutated in
approximately 80% of sporadic colorectal cancers and its inactivation is generally
one of the earliest events in colon tumorigenesis (Gregorieff and Clevers, 2005;
Polakis, 1999). The majority of sporadic mutations in APC are nonsense or
frameshift mutations that lead to a truncated APC protein (Fearnhead et al., 2002).
Furthermore, approximately 60-80% of these mutations occur in the 700 bp
'mutation cluster region', which corresponds to the (3-catenin/axin binding domain
(Sieber et al., 2000; Lustig and Behrens, 2003). Mutational inactivation ofAPC leads
indirectly to reduced phosphorylation and subsequent degradation of P-catenin. This
causes an accumulation of stabilised P-catenin and activation of target genes (Moon
et al., 2004). Loss of APC function is therefore equivalent to a constitutive, positive
Wnt signal (Taipale and Beachy, 2001). In support of this, P-catenin is overexpressed
in colon cancer cells with mutant APC (Munemitsu et al., 1995). Moreover, by
reintroducing wild-type APC into those cells, p-catenin levels could be reduced,
strongly suggesting that the major tumour suppressive function of APC lies in its
ability to regulate free p-catenin levels. Similarly, constitutive transcriptional
activation of a P-catenin-Tcf complex, as measured by transcription of a Tcf reporter
gene, has been observed in APC'1' colorectal cancer cells (Korinek et al., 1997).
Furthermore, reintroduction of wild-type APC into those cells abrogated the
transcriptional transactivation.
While mutations in APC have the effect of mimicking constitutive Wnt
signaling through an indirect effect on P-catenin, activating mutations in the gene
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encoding P-catenin (CTNNB1) have an equivalent functional effect. Activating
CTNNB1 mutations have been identified in approximately 50% colorectal cancers
that express wild-type APC, although, since the majority of colon cancers have APC
defects, this represents less than 10% of all cases of colorectal cancer (Morin, 1999;
Lustig and Behrens, 2003). APC and CTNNB1 mutations are mutually exclusive in
colorectal cancer, consistent with the view that mutation of either gene has the same
effect on P-catenin stability and TCF activation (Giles et al., 2003). Mutations in
CTNNB1 which are functionally relevant to cancer are activating and occur in the
amino-terminal regulatory region, in or around exon 3, affecting one or more of the
four putative phosphorylation sites for GSK-3P (Polakis, 2000; Behrens and Lustig,
2004). These mutations render P-catenin refactory to destruction by the axin complex
and hence increase the stability of P-catenin (Bienz and Clevers, 2000). It is
noteworthy that mutations of CTNNB1 have mainly been detected in colorectal
tumours exhibiting the MSI mutator phenotype, characterised by defective DNA
MMR due to somatic mutation or epigenetic inactivation of genes encoding DNA
MMR proteins or, in the case of HNPCC, germ line DNA MMR gene mutations
(Kitaeva et al., 1997; Sparks et al., 1998). Moreover, both hereditary and sporadic
forms ofMSI colorectal cancers have been shown to have a relatively high frequency
of CTNNB1 mutations and a low incidence of APC mutations (Mirabelli-Primdahl et
al., 1999). Similar to mutation of APC in the Min mouse, transgenic mouse models
with a conditional knock-in mutation of one of the P-catenin alleles to an oncogenic
form (lacking GSK-3P target sites) produces adenomatous polyps in the intestine and
microadenomas in the colon (Harada et al., 1999). Hence, there is substantial
evidence that any mutation leading to stabilised nuclear P-catenin is sufficient for
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neoplastic transformation in colonic mucosa and is one of the earliest events in
tumorigenesis in the mammalian intestinal tract [reviewed in (Gregorieff and
Clevers, 2005; Bienz and Clevers, 2000)].
1.5.3.6.4 The Effects of NSAIDs on the P-catenin Pathway
Several studies have investigated the effects of NSAIDs on (3-catenin. One
study (Hawcroft et al., 2002) found that indomethacin induces a dose-dependent
decrease in [3-catenin protein levels and that this down-regulation of P-catenin was
associated with indomethacin-induced Gi cell cycle arrest. Another study (Dihlmann
et al., 2001) reported that aspirin and indomethacin inhibit transcription of a P-
catenin/TCF-responsive reporter gene in a dose-dependent manner. However, this
effect did not involve changes in levels of endogenous P-catenin. Similarly, repressed
expression of P-catenin-dependent genes in response to diclofenac has been observed
in the absence of any effect on cytoplasmic P-catenin levels (Cho et al., 2005). It
appears that the observed reduction of P-catenin/T-TCF signaling by aspirin and
indomethacin is due to increased stabilisation of phosphorylated p-catenin (Dihlmann
et al., 2003). In contrast, one paper documented that sulindac sulfone caused a
reduction in the high levels of accumulated P-catenin in SW480 colorectal cancer
cells (mutated in APC) and suggested that induction of apoptosis by sulindac sulfone
was the result of activation of protein kinase G (PKG) in response to sustained
increases in cyclic guanosine 3',5'-monophosphate (cGMP) levels (Thompson et al.,
2000). More recently, the same group have demonstrated that exisulind-induced p-
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catenin degradation precedes induction of apoptosis and that the down-regulation of
inappropriate (3-catenin-activated genes such as cyclin Dl accounts in part for the
pro-apoptotic effects of exisulind in colorectal cancer cells (Li et al., 2002). A dose-
dependent down-regulation of P-catenin has been observed in response to
indomethacin (Veeramachaneni et al., 2003). Similarly, sulindac metabolites can
induce degradation of (3-catenin (Rice et al., 2003). A recent study of a panel of
NSAIDs (Gardner et al., 2004) established that some, but not all of the NSAIDs,
mediated a reduction in catenin-related transcription. Another study has proposed
that the anti-proliferative effects of indomethacin may contribute to enhanced cell
adhesion via translocation of (3-catenin from the nucleus to the cell membrane
(Kapitanovic et al., 2006). Interestingly, a recent study demonstrated that repression
of (3-catenin signaling by a panel of 19 different NSAIDs requires both PPARy and
its co-receptor, retinoid-X-receptor-a (RXR-a) and is independent of COX-inhibitory
activity (Lu et al., 2005). Furthermore, (3-catenin was found to interact with RXR-a
and PPARy by immunoprecipitation.
The findings of in vitro studies are supported by several in vivo studies
examining the effects of NSAIDs on P-catenin. One study (McEntee et al., 1999)
reported that sulindac caused a >50% decrease in p-catenin levels and diminished
Bcl-2 levels in small intestinal tumours from Min mice harvested between 2 and 4
days of treatment when compared to untreated controls. Moreover, colonic tumours
had elevated Bcl-2 expression compared to their small intestinal counterparts and the
levels of Bcl-2 and P-catenin were unaffected by sulindac treatment for 2 or 4 days.
This strongly suggested that reduction of Bcl-2 was associated with regression of
small intestinal tumours and provides a possible explanation for the observed
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differences in sensitivity of colonic and small intestinal tumours to sulindac-induced
regression. A recent study (Roy et al., 2005) demonstrated that the NSAID,
nabumetone, can reduce (3-catenin levels in non-neoplastic intestinal mucosa of the
Min mouse but had no effect on (3-catenin levels in the uninvolved colonic mucosa of
AOM-treated rats. However, in both the Min mice and AOM-treated rats, treatment
with nabumetone led to an increase in GSK-3(3 levels. Nabumetone supplementation
reduced the level of nuclear P-catenin in AOM-induced tumours and nuclear cyclin
D1 in both the non-neoplastic mucosa and adenomatous tissue in AOM-treated rats.
E-cadherin was also found to be significantly increased in the uninvolved mucosa of
both the Min mouse and AOM-treated rat in animals supplemented with nabumetone.
Taken together, the results from that study implicate P-catenin signaling in the
mechanism of chemoprevention by nabumetone. Finally, it has been established that
sulindac can target nuclear accumulation of p-catenin and P-catenin/TCF-mediated
transcription in adenomas of patients with FAP, in addition to colorectal cancer cell
lines (Boon et al., 2004).
Collectively, the data from these in vitro and in vivo studies provide
compelling evidence to implicate the involvement of P-catenin in the mechanism by
which NSAIDs mediate their anti-tumour effects.
1.5.3.7 Interaction of NF-kB and P-catenin
As mentioned above, parallels exist between the Wnt/p-catenin and NF-kB
pathways and several lines of evidence now suggest that cross-talk occurs between
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the two pathways. Firstly, the kinases, GSK-3(3 and IKK, are common to both
signaling pathways. In addition to phosphorylation of p-catenin through Wnt
signaling, GSK-3P has been shown to be required for cell survival and NF-kB
activation (Hoeflich et al., 2000). In that study, it was established that GSK-3P-
deficient embryos could be rescued by inhibition of TNF, a known potent activator
of NF-kB and treatment of wild-type fibroblasts with lithium, an inhibitor of GSK-
3p, was demonstrated to sensitize cells to TNFa treatment and inhibit transactivation
of NF-kB. These findings led the authors to propose that NF-kB is regulated by
GSK-3P at the level of the transcription complex. P-catenin is also subject to
regulation by IKK, a component of the NF-kB signaling cascade (Lamberti et al.,
2001) since both IKKa and IKKp interact with and phosphorylate P-catenin in vitro
and in vivo. Secondly, both P-catenin and the NF-kB inhibitor protein. IkBcx, interact
with the same E3 ubiquitin ligase component, P-TrCP and are thus targeted for
destruction via the ubiquitin pathway (Arnit and Ben Neriah, 2003). Moreover,
expression of P-TrCP is itself activated by Wnt signaling, providing the potential for
cross-talk between the Wnt and NF-kB pathways (Maniatis, 1999). Finally, as
highlighted above, the NF-kB and Wnt/p-catenin pathways regulate the transcription
of similar categories of genes involved in cell proliferation, cell cycle/apoptosis and
tumour progression. Moreover, many of these genes, for example cyclinDl and c-
myc, contain both NF-kB and TCF/LEF binding sites.
The similarities between the NF-kB and Wnt/p-catenin pathways described
above provide strong circumstantial evidence that that they could be mechanistically
linked. In support of this suggestion, RelA was found to specifically suppress P-
catenin/TCF-dependent transcription, an effect that was independent of the DNA
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binding ability of the P-catenin/TCF complex (Masui et al., 2002). P-catenin can also
physically interact with both RelA and p50 by coimmunoprecipitation (Deng et al.,
2002), resulting in reduced NF-kB DNA binding, reduced transactivation activity
and reduced target gene expression. Furthermore, a more recent study by the same
group established that APC/GSK-3P, through P-catenin, can cross-regulate the NF-
kB pathway (Deng el al., 2004). Interestingly, diclofenac has been shown to
attenuate Wnt/p-catenin signaling via activation ofNF-kB in colon cancer cells (Cho
et al., 2005).
Collectively, these studies demonstrate that cross-regulation of the NF-kB
and Wnt/p-catenin pathways does occur and that such interactions may be implicated
in the mechanisms underlying the protective effects ofNSAIDs.
1.6 The Need for Safer Alternatives to NSAIDs
Despite the compelling evidence for benefit from case/control, cohort,
controlled trials and clinical observational studies, the prolonged use of NSAIDs is
limited by significant toxicity. Harmful side effects include: gastrointestinal bleeding
and perforation; intracranial haemorrhage; renal side effects; hypersensitivity
reaction to salicylate and accelerated cartilage destruction in osteoarthritis (Kaza et
al., 2002; Rainsford, 1999). The combination of the side effect profile and the fact
that NSAIDs provide only partial protection against colorectal cancer, provides the
rationale for development of safer and even more effective alternatives.
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1.6.1 Rational Design of COX-2 Selective NSAIDs
The major use of NSAIDs is for pain relief and reduction of inflammatory
action in musculoskeletal disorders, especially arthritic processes. The rational drug
design and development of new specific, preferential COX-2-selective drugs, such as
celecoxib, rofecoxib and nimesulide, was on the premise that side effects of
traditional NSAIDs such as aspirin, which inhibit both COX-1 and COX-2, could be
avoided or at least minimised. Clinical trials of COX-2-selective drugs in preventing
or reducing colorectal neoplasia have recently been carried out, although there has
been some controversy surrounding them. One study (Steinbach et al., 2000)
reported that twice-daily treatment with 400 mg cclecoxib for 6 months in patients
with FAP resulted in a significant (28%) reduction in the mean number of colorectal
polyps and a similar (30.7%) reduction in polyp burden. Another study demonstrated
a significant reduction (14.5% overall and 31% in patients with clinically significant
disease) in duodenal polyposis in FAP patients after treatment with celecoxib 400 mg
twice daily (Phillips et al., 2002). Similarly, once-daily treatment with 25 mg
rofecoxib was found to significantly reduce the number and size of rectal polyps in
FAP patients (Higuchi et al., 2003). Maximal effects were seen after 9 months
treatment, with a 6.8% reduction in polyp number and a 16.2% reduction in polyp
size. A separate study (Hallak et al., 2003) established that there was a highly
significant reduction in the rate of polyp formation (70-100%) in 10 FAP patients
receiving 25 mg rofecoxib once-daily for up to 30 months.
Despite encouraging evidence to suggest selective agents might be effective
and perhaps be associated with less side effects, the results of two major trials have
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called into question the safety of COX-2-selective drugs. The first trial results to
emerge were from the Rofecoxib (Vioxx) study. The authors reported an increased
risk of thrombotic events in patients receiving the drug for more than 18 months
(Bresalier et al., 2005). These safety concerns over increased cardiovascular risk
resulted in a 'black box' warning being issued by the Food and Drug Administration.
Subsequently, rofecoxib was removed from the market by Merck on September 30th
2004 (Topol, 2004; Samoha and Arber, 2005). Similar to the findings of the
rofecoxib trial, the results from an independent evaluation of a trial of celecoxib also
demonstrated cardiovascular side effects after several months of treatment, especially
in the high-dose group (Solomon et al., 2005).
1.6.2 The Need for Rational Design of Novel Therapeutic Agents
In light of the above safety concerns over COX-2-selective NSAIDs and
given the toxicity of traditional NSAIDs, it is therefore of vital importance to fully
understand the mechanism of action ofNSAIDs so that safer drugs can be developed.
The identification of pathways targeted by NSAIDs, in particular the NF-kB and P-
catenin pathways, and the specific mechanisms involved in their regulation is
therefore critical for the rational design of novel therapeutic agents.
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1.7 Preliminary Results From MSc Mini Project
Modulation of the NF-kB pathway by a panel of non-aspirin NSAIDs,
comprising sulindac and indomethacin (non-selective COX inhibitors) and sulindac
sulfone (lacks COX-inhibitory effect), was investigated to determine whether the
effects were similar to those of aspirin (Loveridge, 2001). Preliminary results from
this mini-project were as follows: 1. Annexin V-FITC analysis of SW480 colon
cancer cells showed that sulindac, sulindac sulfone and indomethacin induced
apoptosis of SW480 colon cancer cells in a dose-dependent manner, similar to the
effect observed for aspirin. 2. Using immunocytochemistry, it was found that the
non-aspirin NSAIDs caused nuclear translocation of the RelA component of NF-kB
in a similar fashion to aspirin. 3. All NSAIDs mediated repression of NF-kB
transcriptional activity in colorectal cancer cells as measured by the 3enhancer-CON-
A (3x kB ConA-Luc) NF-kB dependent luciferase reporter plasmid. 4. In contrast to
aspirin, Western blot analysis demonstrated that non-aspirin NSAID treatment had
no apparent effect on IkBcx levels. These preliminary results indicated that apoptosis
associated with activation of the NF-kB pathway is common to NSAIDs and
independent of their COX-inhibitory nature. However, the differences observed
between aspirin and the other NSAIDs also suggested a further level of complexity in
modulation of the NF-kB signaling pathway by NSAIDs. Tyrosine phosphorylation
of IkBcx has previously been shown to cause nuclear translocation ofNF-kB without
degradation of IkBcx (Imbert et al., 1996) (see section 1.5.3.5.5 and Chapter 4), and
so this mechanism could possibly explain the differences observed between aspirin
and the other NSAIDs.
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1.8 Hypothesis of PhD Project
In view of the evidence from the literature, previous work carried out in the
host laboratory, and work from my MSc project, the following hypothesis was set up:
NSAIDs as a class impart their anti-tumour effect by modulation of the NF-kB
pathway and effects on [3-catenin signaling regulate this response.
1.9 Research Aims
The central theme of the work presented in this thesis was to understand the
mechanisms underlying the antineoplastic properties of NSAIDs so that safer
alternatives can be developed. The specific aims were:
1. To establish whether modulation of NF-kB is absolutely required for the effects
of non-aspirin NSAIDs on apoptosis.
2. To define the mechanism by which non-aspirin NSAIDs activate the NF-kB
pathway.
3. To determine the importance of NSAID effects on Wnt/p-catenin signaling in
modulation of the NF-kB response to NSAIDs, in particular nuclear regulation of
NF-kB activity.
4. To establish the role of post-translational modifications, specifically




The research presented in this thesis utilises the SW480 colorectal cancer cell
line, which was derived from a primary Dukes' stage B colon carcinoma that arose in
a 50-year-old male patient (Leibovitz et al., 1976). There are potential limitations in
examining a single cell line because effects may be cell line specific and may not be
representative of the in vivo situation. However, the host laboratory has a wealth of
data indicating that SW480 cells do represent the generality of responses to aspirin.
Furthermore, the practicality of studying different agents at various time points
means that using panels of cell lines is unfeasible. In addition, it has been shown that
appropriate phenotypic features are retained in SW480 cells, even with long-term in
vitro culture (Hewitt et al., 2000). Hence, the investigation of SW480 as a single cell
line is backed up by substantial work in other cell lines and systems and is
considered supportable and practically deliverable.
Initially, previous results from my MSc project demonstrating that non-
aspirin NSAIDs activate the NF-kB pathway were confirmed and the importance of
NF-kB activation for non-aspirin NSAID effects on apoptosis was determined by
using a dominant negative RelA construct generated by the host laboratory (Chapters
3 and 4). The upstream mechanism ofNF-kB activation upon NSAID treatment was
investigated by use of chemical and molecular inhibitors. Immunoprecipitation for
tyrosine phosphorylated IkBci and kinase assays for candidate kinases were also
carried out.
The second research strand focussed specifically on investigating the role of
Wnt/p-catenin signaling in modulation of the NF-kB response to NSAIDs and
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regulation of nuclear NF-kB activity (Chapter 5). The effect of NSAIDs on
cytoplasmic p-catenin levels were assessed by Western blotting.
Immunocytochemistry was used to study the subcellular localisation of P-catenin in
response to NSAIDs. NSAID effects on P-catenin driven transcription were
subsequently investigated by using the TOP/FOP reporter plasmids that contain
TCF/LEF binding sites upstream of the firefly luciferase gene. Interaction of the NF-
kB and Wnt/p-catenin pathways was then examined by means of
immunoprecipitation, to determine whether RelA co-immunoprecipitated with P-
catenin after NSAID treatment, and co-localisation studies were subsequently
undertaken using immunocytochemistry. Finally, the dominant negative RelA
construct was used to determine whether blocking NSAID-induced nucleolar
localisation of RelA had any effect on p-catenin.
In the third strand, the role of ubiquitination and acetylation in nucleolar
localisation of RelA in response to NSAIDs were investigated by means of
immunoprecipitation and subsequent Western blot analysis, to establish the change in
these modifications of RelA after NSAID treatment (Chapter 6). The proteasome
inhibitor, MG132, was then used to determine whether this agent induced similar
effects to those observed for NSAIDs on the NF-kB and Wnt/p-catenin pathways.
The effects of NSAIDs and MG132 on localisation and levels of proteasomes were
also studied by Western blot analysis and immunocytochemistry respectively.
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Chapter 2 - Materials and Methods
This chapter outlines the experimental protocols and materials used
throughout the course of this thesis. For all procedures outlined, standard safety and
COSHH regulations were adhered to. All chemicals referred to in this chapter were
supplied by Sigma, unless otherwise stated. Certain stock solutions [marked with an
asterisk (*)] were prepared, sterilised by autoclaving and stored at the appropriate
temperature by the Technical Services Department at the MRC FIGU. Where the pH
of solutions had to be adjusted, this was accomplished by adding concentrated
sodium hydroxide (NaOH), potassium hydroxide (KOFI) or hydrochloric acid (HC1)
as appropriate while monitoring the pH using a microprocessor pH meter (Hanna
Instruments).
2.1 Cell Culture and Reagents
2.1.1 Cell Lines, Maintenance and Media
SW480 cells, an adherent cell line derived from a Dukes' stage B colon
carcinoma (see section 1.10), were obtained from the American Type Culture
Collection/European Collection of Cell Cultures (ATCC/ECACC; number CCL-
228). SW480 cells constitutively expressing a kinase dead mutant of c-Src (SW480-
SrcKD) and equivalent control cells (SW480-pBpuro) were a kind gift from Prof. M.
Frame (Cancer Research UK Beatson Laboratories, Glasgow).
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SW480 cells were maintained in L-15 medium (Gibco BRL) supplemented
with 10% foetal calf serum (FCS)* and 1% penicillin and streptomycin* at 37°C in a
humidified atmosphere containing 5% CCL. SW480-pBpuro and SW480-SrcKD cells
were maintained in RPMI medium (Gibco BRL) supplemented with 10% FCS and
1% penicillin and streptomycin at 37°C in a humidified atmosphere containing 5%
2 2
CO2. All cell lines were grown in 25 cm or 75 cm" flasks (Greiner Bio-one) until a
confluent monolayer was formed.
Cells were passaged or seeded for experimentation at a 1:3 —> 1:5 dilution by
washing in phosphate buffered saline (PBS)* [137 mM sodium chloride (NaCl), 2.7
mM potassium chloride (KC1), 10 mM sodium phosphate dibasic (anhydrous)
(NaaFlPCL), 2 mM potassium phosphate monobasic (KFI2PO4), pFl 7.4], followed by
a 5 minute (min) incubation with Trypsin/Versene (T/V)* (1:1).
To freeze cell lines, 1 ml of appropriate cell culture media was added to
detached cells prior to centrifugation at 200 x g for 5 minutes at room temperature.
The media was then discarded and the cell pellet resuspended in 1 ml freezing media
[10% dimethylsulfoxide (DMSO) in FCS] before being transferred to a cryotube.
Cells were subsequently incubated on ice for 1 hour (hr) then stored in liquid
nitrogen. To retrieve frozen cells, aliquots were rapidly thawed at 37°C, cells
collected by centrifugation at 200 x g for 5 min, washed in culture medium then
seeded into 25 cm2 tissue culture flasks.
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2.1.2 Reagents (NSAIDs, Other Stimuli and Inhibitors)
Stock solutions of Aspirin (Sigma) (0.5 M, pH 7.0), Sulindac (Sigma) (0.1 M,
pH 7.0) and Sulindac Sulfone (MP Biomedicals) (0.1 M, alkaline pH) were prepared
by solubilising the reagents in distilled water (dhBO), using 5 M NaOH to adjust the
pH as required. Stock solution of indomethacin (Sigma) (0.25 M) was prepared by
solubilising the reagent in ethanol (EtOH). All drugs were filter sterilized using a 0.2
micron filter (Schleicher and Schuell Microscience) prior to use in cell culture.
Stock solution of TNFa (R&D Systems, Minneapolis, USA) (100 mg/ml) was
prepared in PBS containing 1% bovine serum albumin (BSA) (Sigma). Stock
solution of LPS (from E. coli 026:B6) (Sigma) (1 mg/ml) was prepared in PBS.
Pervanadate was made by adding 40 pi of a 500 mM sodium orthovanadate
(NaaVCfi) stock solution [prepared in dffiO (pH 10) by boiling yellow solution until it
appeared colourless and allowing to cool to room temperature, then readjusting the
pH to 10 and repeating the boiling and cooling steps until the solution remained
colourless and the pH stabilised at 10] and 5 pi of 30% hydrogen peroxide (H2O2)
(Sigma) to 455 pi of PBS. This mixture was incubated for 5 min at room temperature
prior to the addition of catalase (200 pg/ml) (Sigma) to remove the excess H2O2. The
pervanadate solution (final concentration 100 pM) was further incubated for 5 min at
room temperature before being diluted and immediately applied to cells.
Stock Solutions of PP2 (calbiochem) (2.5 mM), MG132 (calbiochem) (50
mM) and genistein (Sigma) (100 mM) were prepared in DMSO.
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2.1.3 Treatment Protocol
Cells were seeded at a density of 1 x 103 in 25 cm2 ml flasks or 0.5 x 10s on
sterile coverslips (22 mm x 22 mm) (VWR International) in 6 well plates (Greiner
Bio-one), grown until 60-80% confluent then treated continuously with the relevant
NSAID or stimulus in low serum (0.5% FCS) medium for a further 16 hrs or as
specified. Following treatment, cells were washed with PBS and harvested by the
method appropriate to the assay (see below).
To study the effects of inhibitors on the response to NSAIDs, cells were
seeded and grown as above. Once 60-80% confluent, cells were pre-treated with the
required inhibitor in low serum medium for 1 hr prior to continuous treatment with
NSAIDs as specified.
2.2 Generation and Amplification of Plasmids
The plasmids used in these studies and details of their construction or
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6 pg/5 x 106 cells
The 3enhancer-CON-A
vector contains three
synthetic copies of the
NF-xB-consensus
sequence, driven by an
Ig-k chain promoter






6 pg/5 x 106 cells As for 3x kB ConA-Lucbut minus the NF-xB
consensus sequences
Gift from Prof Ron Hay,
University of Dundee;
used in (Hay el at., 2003)
pCMV-Luciferase
(pCMV-Luc)
6 pg/5 x 106 cells
pCMV-Luc vector
contains a single copy of
the firefly luciferase gene





6 pg/5 x 106 cells
RelA cDNA fused in
frame to the carboxyl
terminus of EGFP
downstream of the CMV
promoter
Gift from E. Qwarnstrom,
University of Sheffield;
described in (Carlotti el
al„ 1999)
GFP-RelA(A27-30)
6 pg/5 x 10° cells GFP-RelA with a deletion
of amino acids 27 to 30
Described in (Stark and
Dunlop, 2005)
pEGFP-C1
6 pg/5 x 10s cells
pEGFP-C1 contains a
single copy of the
GFPmutl variant driven




6 pg/5 x 106 cells
TCF reporter plasmid
containing two sets (with
the second set in the
reverse orientation) of
three copies of the TCF
binding site (wild type)








6 pg/5 x 10s cells
TCF reporter plasmid
containing two full and
one incomplete copy of
the Tcf binding site
(mutated) followed by
three copies in the
reverse orientation,








6 pg/5 x 106 cells
WT IxBa (PK-tagged)
subcloned under the
















Table 2.1 - Plasmids Used for Transfections.
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2.2.1 Transformation of Competent Cells
In order to generate a sufficient quantity of plasmid, vectors were amplified
in E. coli cells. Each of the plasmids used carried the gene for ampicillin or
kanamycin resistance, allowing selection of bacteria that were successfully
transformed. A single transformed bacterial clone could then be grown in bulk and
the required plasmid subsequently extracted. Initially, the vectors were transformed
into E. coli that had been made chemically competent for transformation. The
bacteria used were Subcloning Efficiency™ DH5a™ Competent Cells (Invitrogen
Life Technologies Life Technologies) and the method as per manufacturers
instructions. Briefly, Competent E. coli cells were thawed on ice prior to
transformation by the gentle addition of 10-15 ng of ligated plasmid DNA to
approximately 5 x 106 bacteria and incubating cells on ice for 30 min. Following heat
shock at 42°C for 45 seconds (sec), cells were incubated on ice ice for 2 min and 900
pi SOC medium (Invitrogen Life Technologies) [2% tryptone, 0.5% yeast extract, 10
mM NaCl, 2.5 mM KCl, 10 mM magnesium chloride (MgCf), 10 mM magnesium
sulphate (MgSCL), 20 mM glucose] added prior to incubation at 37°C for 60 min
with vigorous shaking (225 rpm). An aliquot (100 pi) of the transformed bacteria
was plated onto L-agar (Luria Bertani Broth (L-broth)* [0.1% tryptone, 0.05% yeast
extract, 171 mM NaCl] containing 0.15% agar) plates containing the appropriate
antibiotics [L-agar-Amp* (L-agar containing ampicillin (100 pg/ml)) or L-agar-Kan*
(L-agar containing kanamycin (50 pg/ml))] and the plates were then incubated at
37°C overnight to allow colony formation.
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2.2.2 Growth of Transformed E. coli
Following transformations, a single transformed E. coli colony was picked
from the plate and grown in 2 ml L-broth containing the appropriate antibiotics
[ampicillin (100 pg/ml) or kanamycin (50 pg/ml)] overnight at 37°C with vigorous
shaking (225 rpm). An aliquot (500 pi) of this culture was used to innoculate 500 mis
of L-broth, containing antibiotics as above, which in turn was grown overnight to
allow large scale amplification of the plasmid in E. coli. Transformed E. coli
colonies were stored on L-agar plates at 4°C for up to one month or at -70° in L-
broth containing 50% glycerol for longer term storage. Strains were re-isolated from
glycerol stocks by spreading some of the frozen cells using a sterile loop onto an L-
agar plate containing the appropriate antibiotic and then incubating the plate
overnight at 37°C.
2.2.3 Plasmid Preparation
Plasmids were harvested from bacterial cells using a purification kit (Qiagen)
and reagents provided by the manufacturer according to their instructions. Briefly,
cells were collected by centrifugation at 6,000 x g for 15 min at 4°C. Cell pellet was
then resuspended in 10 ml chilled buffer PI [10 mM ethylenediaminetetraacetate
(EDTA), 50 mM Tris(hydroxymethyl)methylamine (Tris)-HCl (pFI 8.0), lOOpg/ml
ribonucleaese A (RNase A)] and subsequently lysed with 10 ml buffer P2 [200mM
NaOH, 1% sodium dodecyl sulphate (SDS)] to allow disruption of the bacterial cell
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wall. This alkaline lysate was neutralised with 10 ml chilled buffer P3 [3.0 M
potassium acetate (C2H3KO2) (pH 5.5)] and then incubated on ice for 20 min. Cell
debris was removed by centrifugation at 20,000 x g for 30 min. The soluble fraction
(including the plasmid DNA) was applied to a pre-equilibrated QIAGEN-tip 500,
which contains a specific Anion-Exchange resin. The plasmid DNA adhered to the
resin whilst the remaining debris, such as RNA, protein and metabolites, was
removed by washing the tip with 60 ml buffer QC [1.0 M NaCl, 50 mM 4-
morpholinepropanesulfonic acid (MOPS) (pH 7.0), 15% isopropanol]. The plasmid
DNA was detached from the resin by the addition of buffer QF [1.25M NaCl, 50mM
Tris-HCl (pH 8.5), 15% isopropanol], precipitated with isopropanol and immediately
pelleted by centrifugation at 15,000 x g for 30 min at 4°C. The DNA was then
washed with 70% EtOH, re-pelleted by centrifugation at 15,000 x g for 10 min at
4°C and allowed to air-dry before being dissolved in 300 pi TE buffer* [lOmM Tris-
HCl (pH 8.0), ImM EDTA] and stored at -20°C.
Plasmid DNA was quantified by optical densomitery on a UV
spectrophotometer (GeneQuant Pro, Biochrom Ltd.). 1 pi DNA was diluted with 99
pi dH20 and placed in quartz cuvettes. DNA quantities were calculated automatically
from the measured absorbcncy at 260 nm (A260) and 280 nm (A280), taking into
account the dilution factor of 100. An A260/ A280 ratio of 1.8 was taken as optimum
purity of DNA.
It is noteworthy that endotoxin-free plasmid purification kits are now
available from Qiagen and these should be used in the future to minimise the
possibility of contamination of DNA samples, and hence experiments, with such
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toxins. Endotoxins, for example LPS, are known to activate NF-kB and so
contamination with these agents could potentially affect the results of experiments.
2.3 Transient Transfection of Adherent Cells
Cells were grown in 25 cm flasks or on sterile coverslips in the wells of 6
well plates until 50-60% confluent prior to transfection. Transient transfection of
cells with plarnid DNA was carried out using Lipofectin (Invitrogen Life
Technologies) as per manufacturers instructions. Briefly, for each transfection, 20 pi
lipofectin was added to 200 pi optimem (Gibco BRL) and left for 45 min at room
temperature. 200 pi optimem was added to the plasmid DNA (3-6 pg) to be used for
transfection prior to the addition of 200 pi of the lipofectin/optimem mix. Samples
were then left for 15 min at room temperature before a further 1.6 ml optimem was
added to each sample. Cells were washed twice with 2 ml optimem before 2 ml DNA
mix was added. Cells were then incubated for 5-6 hrs at 37°C. After this incubation,
the DNA mix was discarded and cells were grown for 24hrs in the appropriate low
serum medium before being harvested or treated as described in section 2.1.3.
For overexpression of wild type (WT) IkBu, SW480 cells were transiently
transfected with WT IicBa or pCDNA3.1 (mock) using lipofectin as described above.
After transfection, cells were incubated for 36 hrs in high serum medium (10 %
FCS), to allow expression ofWT ItcBa or pCDNA3.1, prior to treatment as specified.
130
2.4 Reporter Assays
Cells were transiently transfected with 6 pg of a luciferase reporter vector
(either ConA-Luciferase (ConA-Luc), 3x kB ConA-Luc, pCMV-Luciferase (pCMV-
Luc), pTOPFlash or pFOPFlash) and 3 pg of the pCMV-|3-galactosidase (pCMV(3)
reporter vector as described above, prior to treatment as specified. Luciferase and (3-
galactosidase activity were then measured in cell extracts using a luciferase reporter
assay kit (Promega) and a (3-galactosidase assay kit (Promega), as per manufacturers
instructions. Briefly, transfected cells were washed twice with 2 ml PBS then
adherent cells lysed with 500 pi 1 X Reporter Lysis Buffer (made by diluting 5 X
Reporter Lysis buffer (Promega) in dEfO) for 15 min at room temperature. Lysate
was then scraped, placed into a 1.5 ml eppendorf and vortexed prior to centrifugation
at 15,800 x g for 1 min. The supernatant was then collected and assayed.
To determine relative light units of [3-galactosidase activity, 50 pi reporter
cell extract was added to 50 pi 2 X assay buffer (Promega) in a well of a 96 well
plate (Sero-Wel, Bibby Sterilin Ltd.). The plate was incubated at 37°C for 30 min (or
until a yellow colour appeared) then the reaction stopped by adding 150 pi sodium
carbonate (Promega). The P-galactosidase activity was determined by measuring the
the absorbance of the samples at 420 nm using an ELISA plate reader (Labsystems,
Original Multiskan MS).
Luciferase activity was measured by adding 50 pi luciferase reagent
(Promega) to 10 pi reporter cell extract using a Lumat LB 9507 (EG + G Berthold)
luminometer. Relative luciferase activity was calculated as unit of luciferase activity
per unit of (3-galactosidase activity. Where used, FOPFlash activity was expressed
relative to TOPFlash activity.
2.5 Preparation of Protein Extracts
2.5.1 Cytoplasmic and Nuclear Extracts
Treated cells were washed with 2ml PBS prior to harvesting by scraping cells
into 5 ml PBS. Cells were subsequently pelleted by centrifugation at 200 x g for 5
min and then lysed for five min at 4°C in approximately 3 X cell volume of lysis
buffer [50 mM NaCl, 10 mM N-(2 hydroxyethyl)piperazine-N'-2-ethanesulfonic acid
(HEPES) (pFl 8.0), 500 mM sucrose, ImM EDTA, 0.5 mM spermidine, 0.15 mM
spermine, 0.2% triton X-100] containing Complete™ protease inhibitor cocktail
(Roche Applied Science) at 1:1250 dilution, 1 mM pepstatin A (Sigma) and 100 mM
Pefabloc SC (Roche Applied Science). Phosphatase inhibitors [100 pM sodium
fluoride (NaF), 10 mM [^-glycerophosphate, 10 mM NasVCA}] were also added where
appropriate, that is for the analysis of phosphorylated proteins. Nuclei were pelleted
by centrifugation at 3,300 x g for 20 min at 4°C and the supernatant (cytoplasmic
extract) collected and stored at -20°C prior to analysis.
Nuclear extracts were obtained by resuspending and lysing nuclei in
approximately 1.5 X nuclear volume of hypotonic buffer [350 mM NaCl, 10 mM
HEPES, 25% glycerol, 0.1mM EDTA, 0.5 mM spermidine, 0.15 mM spermine]
containing protease inhibitors, pepstatin A and Pefabloc SC as per above for
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cytoplasmic extracts, and then incubating on ice for 30 min. Debris was cleared by
centrifugation at 15,800 x g for 5 min at 4°C and the supernatant (nuclear extract)
collected and stored at -20°C prior to analysis.
2.5.2 Whole Cell Extracts
Treated cells were washed twice with 2 ml PBS then adherent cells lysed in
approximately 4 X cell volume whole cell lysis buffer [50 rnM HEPES (phi 7.4), 150
mM NaCl, 20 rnM EDTA, 0.5% NP-40 (Calbiochem)], containing Complete™
protease inhibitor cocktail at 1:1250 dilution, 1 mM pepstatin A, 100 mM Pefabloc
SC, 1 mM PMSF and phosphatase inhibitors [100 pM NaF, 10 mM (3-
glycerophosphate, 10 mM Na3"V04] (where appropriate), for 30 min at 4°C. Cell
lysate was then scraped off, placed into 1.5 ml eppendorfs and centrifuged at 10,000
x g for 15 min at 4°C. The supernatant (whole cell extract) was subsequently
collected and stored at -20°C prior to analysis.
2.6 Calculation of Protein Content by Bradford Assay
Bradford Reagent (Bio-RAD) was diluted 1 : 5 with dFDO and filtered using
Whatman filter paper (27.0 cm) prior to use. 1 pi protein sample was added to 200 pi
Bradford Reagent in the wells of a 96 well plate. A concentration curve was included
in each experiment using BSA standards (0.2 pg/pl, 0.5 pg/pl, 0.8 pg/pl, 1.0 pg/pl,
1 J J
1.5 M-g/j-il and 2.0 p.g/p.1). The standards were loaded in duplicate and samples loaded
in triplicate. Following a 10 min incubation at room temperature, the absorbance was
measured at 595 nm (A595) using an ELISA (enzyme-linked immunosorbent assay)
plate reader. The protein concentration was calculated from the A595 automatically by
the plate reader, taking into account the standards. The average of the 3 readings for
each sample was determined and subsequently used.
2.7 SDS Polyacrylamide Gel Electrophoresis (PAGE)
A tenth of the volume of Sample Buffer [20% glycerol, 2% SDS, 0.25%
bromophenol blue, 1 X Stacking Buffer [500 mM Tris, 0.4% SDS, pH 6.8], 5% [3-
mercaptoethanol] was added to protein samples (10-30 pg) prior to boiling at 95°C
for 5 min and then placing on ice. The Protean II mini-gel apparatus (Bio-RAD) and
a two tier gel system, comprising a lower resolving gel and upper stacking gel, were
used to resolve protein extracts by denaturing SDS PAGE. Resolving gels were 8%
polyacrylamide, 8.5% polyacrylamide, or 10 % polyacrylamide. Stacking gels were
4% polyacrylamide. lOpl of Kaleidoscope pre-stained molecular weight standards
(Bio-RAD) were loaded in a single well of each gel and run in parallel with protein
samples to aid the identification of proteins of interest. Gels were electrophoresed in
1 X Running Buffer [25 mM Tris, 0.2 M glycine, 0.1% SDS] at 160 volts for
approximately 1 hr.
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2.7.1. Resolving Gel Monomer Solutions
8% 8.5% 10%
dH20 4.02 ml 3.93 ml 3.65 ml
40% Acrylamide/
Ratio: 19:1 - bis acrylamide (Severn Biotech Ltd.) 1.48 ml 1.57 ml 1.85 ml
4 X Resolving Buffer [1.5 M Tris, 0.4% SDS, pH 8.8] 1.9 ml 1.9 ml 1.9 ml
N.B. Immediately before pouring, 112 pi 10% ammonium persulfate (APS) and 5 pi
N,N,N',N'-tetramethylethylenediamine (TEMED) were added to the solution.




Ratio: 19:1 - bis acrylamide 0.218 ml
4 X Stacking Buffer 0.444 ml
N.B. Immediately before pouring, 28 pi 10 % APS and 5 pi TEMED were added to
the solution.
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2.8 Western Blot Analysis
Antibodies used for Western blot analysis and details of the host species they
were raised in, dilutions, incubation time and manufacturer are summarised in Table
2.2. Western blot analysis was carried out using standard procedures. Briefly, protein
extracts were resolved on SDS PAGE gels as described in section 2.7. Proteins were
then transferred to PVDF membrane (Bio-RAD) using a semi-dry blotter (Bio-RAD)
with 1 X semi-dry transfer buffer [47 mM Tris, 40 mM glycine, 0.037% SDS, 100
mM methanol] at 10 volts for 30 min as per manufacturers instructions. The
membrane was then blocked in PBS containing 0.1% TWEEN® 20 (Sigma) (PBST)
plus 5 % dried milk (PBSTM) for one hr at room temperature or overnight at 4°C
prior to the addition of primary antibody for 1 hr at room temperature or overnight at
4°C. The membrane was subsequently washed with PBST (3X10 min) before being
incubated with the appropriate secondary antibody conjugated to horseradish
peroxidase for 30 min at room temperature. The membrane was then washed with
PBST (3 X 10 min) before detection of specifically bound antibody by
chemiluminescence. ECL reagents (Santa Cruz Biotechnology) were mixed 1:1,
applied to the membrane for 1 minute, excess removed then the membrane covered
with cling film and exposed to Hyperfilm (Amersham Biosciences) for 10 sec to 10
min. Films were subsequently developed using an SRX-101A X-ray processor









Anti-kBa Sheep (Polyclonal) 1 : 4000 in PBSTM
(PBS + 0.1%
TWEEN®20
(Sigma) + 5% dried
milk)
1 hr at room
temperature (RT)
Gift from Ron Hay
Anti-kBa Rabbit
(Polyclonal)
1: 1000 in PBSTM 1 hr at RT Santa Cruz
Anti-Cu/Zn SOD Sheep
(Polyclonal)
1 : 4000 in PBSTM 1 hr at RT The Binding Site
Anti-3-catenin Mouse (IgG)
(Monoclonal)








1 : 15,000 in
PBSTM





1 : 500 in PBSTM 1 hr at RT Upstate Cell
Signaling Solutions
Anti-PK Tag Mouse (IgG)
(Monoclonal
1 : 1000 in PBSTM 1 hr at RT TCS Cell Works
Anti-RelA Rabbit
(Polyclonal)








1 : 4000 in PBSTM 1 hr at RT R&D Systems
Anti-c-Src Mouse (IgG)
(Monoclonal)





















1 : 1000 in PBSTB
(PBST + 5 % BSA)
































1 : 1000 in PBSTM 30 min at RT Santa Cruz
Biotechnology
Table 2.2 - Antibodies Used for Western Blot Analysis.
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2.8.1 Stripping Membranes
Membranes were stripped in a fume hood with 50 ml strip buffer [62.4 mM
Tris, 2 % SDS, pH 6.7], which was pre-warmed in a glass dish to 60°C using a heat
block. One or two membranes were placed into the buffer and 400 pi (3-
mercaptoethanol added and gently mixed prior to heating at 60°C for a further 30-45
rnin. The strip solution was then discarded and membranes washed with PBST (3 X
10 min) before being re-blocked in PBSTM for 1 hr or overnight at 4°C. Membranes
were then re-probed with primary antibody as above.
2.9 Annexin V-Fluorescin Isothiocyanate (FITC) and
AnnexinV-Biotin Apoptosis Assays
SW480, SW480-pBpuro and SW480-SrcKD cells were treated as specified.
Staining for cell surface phosphatidyleserine was used as a marker for apoptosis and
was carried out using an AnnexinV-FITC (non-transfected cells) or Annexin V-
Biotin (transfected cells) apoptosis detection kit (Calbiochem), as per manufacturers
instructions. Briefly, for both protocols, the media from a flask of treated adherent
cells was transferred to a 15 ml conical tube and placed on ice. Adherent cells were
then washed with PBS prior to incubation with T/V at 37°C until cells appeared to be
detached. Cells were then released from flasks with firm tapping and subsequently
resuspended in the media that was initially removed. The number of cells/ml was
determined by haemocytometric counts then cells were resuspended at a
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concentration of approximately 1 x 106 cells/ml. 0.5 ml cell suspension was then
transferred to a 1.5 ml eppendorf along with 10 pi media binding reagent
(Calbiochem) and 1.25 pi Annexin V-FITC or Annexin V-Biotin (Calbiochem).
Cells were incubated for 15 min at room temperature in the dark, pelleted by
centrifugation at 1,000 x g for 5 min at room temperature and then resuspended in
0.5 ml cold 1 X binding buffer (made by diluting 5 X binding buffer (Calbiochem)
with dH20). The percentage of cells undergoing apoptosis in the population was
determined using fluorescent microscopy. For non-transfected cells, the total number
of cells per field of view was determined using brightfield microscopy then the
number of apoptotic cells quantified using the FITC channel. Where the Annexin V-
Biotin kit was used, 15 pi of streptavidin-texas red (TxRd) conjugate (Calbiochem)
(diluted to 15 pg/ml in 1 X binding buffer) was added prior to microscope analysis.
In this case, GFP expressing cells were identified in the FITC channel then the
number of these cells undergoing apoptosis quantified using the TxRd channel. For
all cases, at least 200 cells from a minimum of 10 independent fields of view were
analysed.
2.10 Immunocytochemistry
Antibodies used for immunocytochemistry and details of the host species in
which they were raised, dilutions, incubation time and manufacturer are summarised
in Table 2.3. SW480, SW480-pBpuro and SW480-SrcKD cells were grown on
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Table 2,3 - Antibodies Used for Immunocytochemistry.
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sterilised coverslips in 6 well plates until 60-80% confluent then treated as specified.
After treatment, cells were washed briefly with PBS then fixed in 1 : 1 methanol :
acetone at -20°C for 20min. Cells were subsequently washed with PBS (2X10 rnin)
prior to incubation with 10% donkey serum (Sigma) for 30 min to block non-specific
binding. After blocking, cells were incubated with primary antibody diluted in 10%
donkey serum for 1 hr and washed with PBST (2X10 min) prior to incubation with
secondary antibody diluted in 1.5% donkey serum for 30 min. Cells were washed
with PBS (2X10 min) then coverslips mounted in Vectastain (Vector Laboratories)
containing DAPI (4',6'-diamido-2-phenylindole) (1 pg/ml) (Sigma) to stain DNA.
Stained cells were analysed using fluorescent microscopy, which was
performed with a Zeiss Axioplan microscope, 63X Plan Neofluor objective and
Chroma 83000 filter set. Each channel was recorded independently and pseudocolor
images superimposed. Images were captured using in house scripts written for IPLab
Spectrum 3.6.
2.11 Live Cell Imaging
SW480 cells were grown until 50-60% confluent and then transiently
transfected with GFP-tagged expression constructs using lipofectin as described in
section 2.3 prior to treatment as specified. Cells were washed briefly with PBS then
analysed under 1 ml PBS using an Axiovert 100 inverted microscope (Zeiss). Phase
contrast and fluorescent images were captured from random fields of view and these
images represent the typical localisation of RelA within the cell population.
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2.12 Immunoprecipitation
Antibodies used for immunoprecipitation and details of the host species they
were raised in, dilutions, incubation time and manufacturer are summarised in Table
2.4. SW480 cells were grown in 75 cm" flasks until 60-80% confluent and then
treated as specified. After treatment, cells were washed twice with 5 ml PBS then
whole cell extracts prepared as described in section 2.5.2. The protein content of the
extracts was then immediately determined by Bradford Assay as described in section
2.6.
500 pg of whole cell extract described above was added to ~ 30 pi ProteinA-
sepharose (Amersham) (used for polyclonal antibodies) or Protein A/G-Sepharose
(Santa Cruz Biotechnology) (used for monoclonal antibodies) beads, which had been
pre-washed with 500 pi immunoprecipitation (IP) buffer [50 mM HEPES (pH 7.4),
150 mM NaCl, 20 mM EDTA, 0.5% NP-40 (Calbiochem)], containing Complete™
protease inhibitor cocktail at 1:1250 dilution, 1 mM pepstatin A, 100 mM Pefabloc
SC, 1 mM PMSF and phosphatase inhibitors [100 pM NaF, 10 mM [3-
glycerophosphate, 10 mM NasVOzi] (where appropriate). Samples were rotated at
4°C for 1 hr with beads alone to reduce non-specific binding. Extracts that had been
pre-cleared (as above) were added to another 30 pi ProteinA-sepharose or
ProteinA/G-spepharose beads (pre-washed with 500 pi IP buffer) then the
appropriate antibody [or no antibody (control)] was added to the required dilution
factor. Samples were incubated with rotation at 4°C overnight then beads washed 3
X 5 min with 500 pi IP buffer followed by 2 X 5 min washes with 500 pi IP wash
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1 : 25 Upstate Cell Signaling Solutions
Table 2.4 - Antibodies Used for Immunoprecipitation
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buffer (IP buffer without NP-40). 30 pi PBS and 3 jj.1 10 X Sample Buffer (see
section 2.7) was added to each sample before boiling at 95°C for 5 min to release
proteins from beads. Samples were then centrifuged at 10,000 x g for 1 min to
remove beads and the supernatants resolved by SDS polyacrylamide gel
electrophoresis as described in section 2.7. N.B. a small sample (30 pg) of cell
extracts which had not been immunoprecipitated (inputs) were also loaded onto each
gel. Western blot analysis was subsequently carried out as outlined in section 2.8 to
detect proteins of interest.
2.13 Detection of Tyrosine Phosphorylated IkBq by Mass
Spectrometry
Whole cell extracts were prepared from treated cells, then
immunoprecipitation using anti-IxBa antibody carried out as described in sections
2.5.2 and 2.12 respectively. Samples were then resolved by SDS PAGE as described
in section 2.7. Recombinant IkBgi (gift from Ron Hay, University of Dundee) (2.5
pg) was loaded onto each gel alongside samples to aid identification of the band
containing immunoprecipitated IkBol After electrophoresis, the gel was placed in a
clean tray and washed with d^O (3X5 min) with gentle shaking. To stain proteins,
the gel was incubated with 20 ml GelCode® Blue Stain Reagent (Pierce), again with
gentle shaking. After staining, the gel was de-stained by washing with dH20 for a 1-2
hr period, changing the water several times. Once de-stained, the relevant bands were
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cut out from the gel in a fume hood using a clean scalpel and placed in 1.5 ml
eppendorfs prior to freezing at -70°C.
Samples to be examined by mass spetrometry were sent to Dr Alexander
Henzing at the University of Edinburgh Chemistry Department, where he carried out
the analysis. Briefly, matrix-assisted laser desorption/ionization time-of-flight
(MALDI-ToF) mass spectrometry was employed and polypeptides identified by
peptide mass fingerprinting and sequence database searching as previously described
(Jensen et al., 1997). In-gel digestion of excised polypeptide bands was performed
with trypsin as previously documented (Shevchenko et al., 1996), followed by
sample preparation using miniaturized sample concentration/desalting techniques as
previously reported (Goborn et al., 1999). For the mass spectrometric analysis, a
PerSeptive Biosystems Voyager DE™STR MALDI-ToF mass spectrometer (Applied
Biosystenrs) was used. Peptide ion signals were assigned with a mass error less than
50 parts per million. Lists of tryptic peptide masses were used to search protein
sequence databases using the ProFound tool
(http://www.unb.br/cbsp/paginiciais/profound.htm)
2.14 In Vitro Kinase Assays
c-Src kinase was immunoprecipitated from 500 pg whole cell extracts using
anti-c-Src rabbit polyclonal antibody (Santa Cruz Biotechnology) as described in
section 2.12. After beads were washed with 500 pi IP buffer (3X5 min), the beads
were washed again with 500 pi kinase assay buffer [20 mM HEPES (pH 7.0), 6 mM
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MgCl2, 20 mM Na3V04] (2X5 min). In vitro Kinase assays were carried out by
standard methods. Briefly, where untagged recombinant IkBol (gift from Prof Ron
Hay, University of Dundee) was used as a substrate, 5 pg of this substrate was added
to the washed beads in the presence of 19 pi kinase reaction mix [18.5 pi kinase
assay buffer, 0.5 pi 100 mM adenosine triphosphate (ATP)] to give a final volume of
25 pi. Reactions were then incubated for 30 min at room temperature and
subsequently stopped by the addition of 2.5 pi 10 X Sample Buffer (as per section
2.7) and boiling at 95°C for 5 min. Samples were then centrifuged at 1000 x g for 1
min to remove the beads and supernatants resolved by SDS PAGE as described in
section 2.7 on 10% polyacrylamide gels. Western blot analysis using anti-phospho-
tyrosine antibody was carried out as described in section 2.8 to determine the extent
of c-Src mediated tyrosine phosphorylation of IkBcx.
Where GST-tagged recombinant IkBol (Santa Cruz Biotechnology) and
synthetic c-Src substrate (Santa Cruz Biotechnology) were used in kinase assay
reactions as substrates, the samples were prepared as outlined above but in screw cap
eppendorfs. 5 pg of the appropriate substrate was added to washed beads in the
presence of 20 pi kinase reaction mix (19.5 pi kinase assay buffer, 0.25 pi 100 mM
t9 ...
ATP) containing 0.25 pi [ PJyATP (~2.5 pCi) (Amersham Biosciences) to give a
final volume of 25 pi. Reactions were incubated for 30 min at room temperature then
samples centrifuged at 1000 x g for 1 min to remove beads and the supernatant
removed and placed into a new screw cap eppendorf. Proteins were then precipitated
by adding 45 pi cold 10% Trichloroacetic Acid (Riedel de-Haen), vortexing,
standing for 5 min and then placing back on ice. 5 pi of the total kinase reaction was
spotted independently onto P81 phosphocellulose cation-exchange paper (Whatman)
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to allow calculation of the specific activity of ATP in the kinase reaction (in
cpm/pmol). 35 pi of each reaction was then spotted independently onto P81
phosphocellulose cation-exchange paper prior to washing three times with 500 pi
cold 0.5% phosphoric acid and then once with 500 pi acetone to eliminate low
specificity/non-specific binding. Filters were then left to dry prior to placing into
Wheaton liquid scintillation vials (Wheaton Scientific) and adding 2 ml Fluoran Safe
XE scintillation fluid (BDH Laboratory Supplies). P incorporation was then
measured by scintillation counting using an LS 6500 Multi-Purpose Scintillation
Counter (Beckman Coulter™). Counts per minute obtained in the kinase reaction
[minus blank (no substrate control)] were divided by the specific activity to
determine the moles of phosphate transferred in each reaction.
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Chapter 3 - Effects of NSAIDs on NF-kB Pathway
3.1 Introduction
The NF-kB pathway was identified in the host laboratory as being a central
component of the mechanism responsible for aspirin-induced apoptosis in colorectal
cancer cells (Stark et al., 2001; Stark and Dunlop, 2005). As discussed in Chapter 1,
aspirin inhibits both COX-1 and COX-2 and there is substantial evidence that
inhibition of COX-2 in particular is implicated in the anti-neoplastic effects of this
agent and other related NSAIDs [reviewed in (Brown and DuBois, 2005; Backlund et
al., 2005; Kawai et al., 2002; Patrignani, 2000)]. It is therefore important to
determine whether the NF-kB effect observed in response to aspirin is related to
COX inhibition. This was addressed here by studying NF-kB signaling in response to
NSAIDs that have COX-2 non-selective activity and also an NSAID that lacks COX-
inhibitory effects. The panel of NSAIDs used in this research comprised: aspirin,
sulindac and indomethacin (non-selective COX-inhibitors); and sulindac sulfone, an
oxidative metabolite of sulindac (lacks COX-inhibitory activity). The chemical
structures of these agents are shown in Figure 3.1. It is noteworthy that aspirin
(acetylsalicylic acid) is a member of the salicylate family whereas indomethacin,
sulindac and sulindac sulfone are members of the arylalkanoic acid family and have a

























Figure 3.1 - Chemical Structures of NSAIDs Used in Study.
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In addition to their COX-inhibitory profiles, it is important to emphasize that
the panel of NSAIDs chosen for this study have all been previously shown to have a
protective effect against colorectal cancer (see Chapter 1). Significantly, the results
of three recent randomised trials have reported that low-dose aspirin can prevent the
recurrence of adenomas in patients with previous colorectal cancer (Baron et al.,
2003; Sandler et al., 2003; Benamouzig et al., 2003). Three randomised control trials
have demonstrated that sulindac reduces the number and size of colorectal adenomas
in patients with FAP (Labayle et al., 1991; Nugent et al., 1993; Giardiello et al.,
1993). A recent randomised control trial reported that sulindac sulfone caused
considerable regression of sporadic adenomatous polyps (Arber et al., 2006). To
date, no randomised trials specifically looking at the treatment of colorectal cancer
with indomethacin have been carried out. However, a randomised, placebo-
controlled trial found that indomethacin prolonged mean survival in patients with
disseminated solid malignancy, 22% of which were colorectal cancer cases
(Lundholm et al., 1994). Support for the protective effects of aspirin sulindac,
sulindac sulfone and indomethacin has also come from animal and in vitro studies
(see Chapter 1). These NSAIDs have all been shown to reduce the size and number
of polyps in chemical-induced models of colorectal cancer (Barnes and Lee, 1998;
Chiu et al., 1997; Mahmoud et al., 1998; Reddy et al., 1993; Haanen, 2001; Pollard
and Luckert, 1981), and induce cell cycle arrest (Shiff et al., 1995; Shiff et al., 1996;
Xu and Zhang, 2005) and apoptosis (Stark et al., 2001; Haanen, 2001; Piazza et al.,
1995; Smith et al., 2000) of colorectal cancer cells in vitro.
The objective of this research strand was to investigate the effects of non-
aspirin NSAIDs on NF-kB signaling in SW480 colon cancer cells. The specific aim
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was to establish whether sulindac, sulindac sulfone and indomethacin could induce
apoptosis of colorectal cancer cells via modulation of the NF-kB signaling pathway
in a similar fashion to aspirin. In addition to answering the question of COX-
dependency, it is important to understand the effects of non-aspirin NSAIDs in terms
of identifying potential pathways affected by these agents. Such understanding could
lead to the design of new therapeutic agents. Furthermore, this work could further
extend understanding about the generality of modulation of the NF-kB signaling
pathway by NSAIDs as a class in the context of their effects on prevention and/or
treatment of colorectal cancer.
3.2 Results
3.2.1 NSAIDs Induce Apoptosis of SW480 Colorectal Cancer Cells
The first objective was to confirm that the non-aspirin NSAIDs induce
apoptosis in SW480 colorectal cancer cells. Annexin V-FITC apoptosis assays were
employed to detect cells showing externalisation of phosphatidylserine, a marker for
apoptosis, in response to treatment with sulindac (0-500 pM), sulindac sulfone (0-
500 pM), indomethacin (0-250 pM) and aspirin (0-5 mM) (for comparison). It is
noteworthy that the concentrations of NSAIDs used in this study are comparable to
those published in other studies (Piazza et al., 1995; Chan et al., 1998; Qiao et al.,
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Figure 3.2 - NSAIDs Induce Apoptosis of SW480 Colorectal Cancer Cells. (A) SW480
colon cancer cells were treated with Aspirin (0, 3 mM, 5 mM), Sulindac (0, 300 pM, 500 pM), Sulindac Sulfone (0,
300 pM, 500 pM) or Indomethacin (0, 125 pM, 250 pM). The percentage of apoptotic cells was determined using
fluorescent microscopy, in a minimum of 200 cells from multiple fields of view, to detect Annexin V-FITC binding to
externalised phosphatidyl serine. The values for non-treated cells were pooled together and the results presented
are the mean of three independent experiments (+/- standard deviation). (B) SW480 cells were treated overnight
(16 hrs), in three independent experiments, with Aspirin (0, 3 mM, 5 mM), Sulindac (0, 300 pM, 500 pM), Sulindac
Sulfone (0, 300 pM, 500 pM) or Indomethacin (0, 125 pM, 250 pM) then cytoplasmic extracts (15 pg) resolved by
SDS PAGE on 10% polyacrylamide gels and anti-Caspase-3 Western blot carried out. Actin was used as a loading
control. Representative blots are shown.
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apoptosis in a concentration-dependent manner compared to non-treated controls. To
further verify NSAID-induced apoptosis in SW480 colorectal cancer cells, Western
blot analysis was used to examine cytoplasmic caspase-3 levels, an established
marker of apoptosis (Borner, 2003; Thorburn, 2004). Figure 3.2B demonstrates that
there is a dose-dependent cleavage of caspase-3 in response to all the NSAIDs,
verifying that these drugs do indeed induce apoptosis in SW480 colorectal cancer
cells.
3.2.2 NSAIDs Induce Nucleolar Accumulation of RelA
Having confirmed that the panel of NSAIDs induce apoptosis, the next goal
was to determine whether this was associated with activation of the NF-kB pathway.
Since previous data indicates that aspirin mediates nucleolar translocation of RelA
(Stark and Dunlop, 2005), immunocytochemistry was used to examine the
subcellular localisation of RelA in SW480 colon cancer cells treated with the panel
of NSAIDs. RelA was found to be predominantly cytoplasmic in untreated control
cells (Figure 3.3). However, in response to each of the NSAIDs, RelA accumulated
in the nucleoplasm and localised to distinct sub-nuclear bodies. These nuclear bodies
were observed within areas devoid of DAPI staining and co-localised with nucleolin
(C23), a critical structural nucleolar protein. This provides strong evidence that RelA
does indeed accumulate in the nucleolus in response to NSAIDs (see Red arrows in
Figure 3.3 for good examples of nucleolar RelA). Moreover, these data indicate that
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Figure 3.3 - NSAIDs Induce Nucleolar Translocation of RelA. in three independent
experiments, SW480 cells were treated for 16 hrs with Sulindac (300 pM, 500 pM), Sulindac Sulfone (300 pM, 500
pM), Indomethacin (125 pM, 250 pM), Aspirin (3 mM, 5 mM) or untreated (control). Representative micrographs (63
x) illustrating localisation of RelA and the nucleolar protein, nucleolin (C23), are shown. DAPI depicts DNA. White
arrow indicates nuclear RelA that is excluded from the nucleolus. Red arrows highlight examples of nucleolar RelA.
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activation of the NF-kB pathway and nucleolar translocation of RelA is not a
restricted response to aspirin, but is induced by multiple NSAIDs. It is noteworthy
that the response seems to vary slightly with the different NSAIDs. The lower dose
of sulindac (300 pM) induced mainly nuclear RelA (see white arrow in Figure 3.3)
whereas a higher concentration (500 pM) was required for nucleolar sequestration of
RelA. This is in keeping with previous data showing that in response to aspirin, RelA
is nuclear then nucleolar with increasing concentration (Stark and Dunlop, 2005). In
contrast, the lower doses of aspirin (3 rnM), sulindac sulfone (300 pM), and
indomethacin (125 pM) were all sufficient to cause nucleolar sequestration of RelA.
It is also of interest that there was more distinct cleavage of caspase-3 with the lower
doses of aspirin (3 mM), indomethacin (125 pM) and particularly sulindac sulfone
(300 pM), than was observed for sulindac (300 pM).
3.2.3 NSAID-mediated Nucleolar Accumulation of RelA is
Associated with Repression of NF-kB Transcriptional
Activity
In light of the observation that RelA accumulates in the nucleolus in response
to treatment with non-aspirin NSAIDs, the next focus of investigation was to
determine whether, as with aspirin, this compartmentalization regulates nuclear NF-
kB transcriptional activity. Thus, SW480 colon cancer cells were transiently
transfected with the 3x kB ConA-Luc NF-xB-dependent luciferase reporter plasmid,
along with the pCMVp control plasmid, then treated with aspirin, sulindac, sulindac
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sulfone and indomethacin as per the previous experiments. All the NSAIDs were
found to induce a significant decrease in levels of relative NF-KB-driven luciferase
activity, compared to untreated controls (Figure 3.4A). This decrease was dependent
upon NSAID concentration and ranged from 2.5 fold [Aspirin (3 mM)] to 25 fold
[Indomethacin (250 pM)]. It is noteworthy that a greater repression was seen with
sulindac sulfone and indomethacin compared to sulindac or aspirin. Significantly,
sulindac, sulindac sulfone and indomethacin had a minimal effect on relative
luciferase activity when cells were transfected with a pCMV-Luc plasmid, indicating
a considerable degree of specificity in the observed decrease in transcription from the
3x kB ConA-Luc reporter construct in response to these agents (Figure 3.4B). It
should be pointed out that the pCMV-Luc experiment shown in Figure 3.4B was
performed by Dr L. Stark. The specificity of the aspirin effect on repression of NF-
KB-driven transcriptional activity has previously been established (Stark and Dunlop,
2005).
3.2.4 Nucleolar Accumulation of RelA is Causally Involved in
NSAID-induced Apoptosis
The next goal was to confirm that apoptosis induced by non-aspirin NSAIDs
was primarily caused by nucleolar translocation of RelA. Previous studies from the
host laboratory identified a motif at the N-terminus of RelA that was responsible for
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Figure 3.4 - Nucleolar Translocation of RelA is Associated with Repression of NF-kB
Driven Transcription in Response to NSAIDs. (A) SW480 cells were transiently transfected with 3x
kB ConA-Luc and pCMVp prior to treatment with Aspirin (0, 3 mM, 5 mM), Sulindac (0, 300 pM, 500 pM) Sulindac
Sulfone (0, 300 pM, 500 pM) or Indomethacin (0, 125 pM, 250 pM). (B) SW480 cells were transiently transfected
with pCMV-Luc and pCMVp then were treated with Sulindac (500 pM) Sulindac Sulfone (Sul. Sulf.) (500 pM)
Indomethacin (Indo.) (250 pM) or non-treated (NT) (control). Luciferase assays were earned out to measure NF-kB
transcriptional activity and p-galactosidase assays were used to normalise these results for transfection efficiency.
% transcriptional activity was calculated relative to non-treated controls. Results presented are the mean of three
(A) or two (B) independent experiments (+/- standard deviation).
N.B. Experiments outlined in (B) above were performed by Dr L. Stark
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(Stark and Dunlop, 2005). RelA deleted for this motif [RelA(A27-30)] acted in a
dominant negative manner in that it blocked nucleolar translocation of endogenous
protein. Furthermore, expression of RelA(A27-30) blocked aspirin-mediated
repression ofNF-kB transcription and apoptosis. This dominant negative mutant was
therefore used to investigate whether inhibiting nucleolar translocation of RelA also
blocked apoptosis induced by sulindac, sulindac sulfone and indomethacin. It should
be noted that all experiments described in this section were performed by Dr L.
Stark.
The first question to be addressed was whether deleting the NoLS abrogated
nucleolar translocation of RelA induced by these agents. Using live cell imaging of
SW480 cells transfected with GFP-tagged WT RelA [GFP-RelA(WT)] or A27-30
RelA [GFP-RelA(A27-30)], RelA was shown to be mainly cytoplasmic after
transfection of either construct but prior to NSAID exposure (Figure 3.5). However,
in response to sulindac, sulindac sulfone and indomethacin, GFP-RelA(WT) showed
distinct nuclear and nucleolar localisation of RelA. In contrast, GFP-RelA(A27-30)
(lacks N-terminal NoLS), did not translocate to the nucleolus and consequently,
accumulated in the nucleoplasm. This was not a non-specific effect because NSAID
exposure had no effect on the localisation of GFP expressed from a construct lacking
RelA sequences (data not shown). These data confirm the critical importance of the
N-terminal NoLS of RelA for nucleolar translocation of the protein in response to
NSAIDs. Furthermore, the effect was generic across each of the NSAIDs studied.
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Figure 3.5 - RelA(A27-30) Blocks NSAID-induced Nucleolar Localisation of RelA. in
three independent experiments, SW480 cells were transiently transfected with GFP-RelA(WT) or GFP-RelA(A27-
30) and subsequently treated for 16 hrs with Sulindac (300 pM), Sulindac Sulfone (Sul. Sulf.) (300 pM),
Indomethacin (Indo.) (125 pM) or non-treated (NT) (control). Cellular distribution of GFP-tagged protein was
determined in live/adherent cells using an Axiovert 100 inverted fluorescent microscope (magnification, 40 x).
Representative GFP and GFP/Phase images are shown.
N.B. Experiments outlined above were performed by Dr L. Stark
159
The next question to be addressed was whether the observed effects of
NSAIDs on cell viability were also dependent on nucleolar localisation of RelA. To
investigate this, the GFP-RelA(A27-30) expression construct was utilized to
determine if it could block the effects of NSAIDs on cell viability by inhibition of
nucleolar sequestration of RelA. Haemocytometric counts showed that sulindac,
sulindac sulfone and indomethacin caused a marked reduction in the number of
viable SW480 cells in cultures expressing GFP alone or GFP-RelA(WT) (data not
shown). Moreover, this effect was blocked in cultures transfected with RelA(A27-30)
and these cells showed inhibition of nucleolar translocation as described above.
Phase-contrast microscopy confirmed that sulindac, sulindac sulfone and
indomethacin cause a marked reduction in viable cells in cultures expressing GFP-
RelA(WT) (Figure 3.6). Again, this effect on cell number and morphology was
blocked in cells expressing RelA(A27-30). It is important to note that transfection
efficiency was comparable for both vectors - Western blot analysis confirmed that
WT and mutant protein were expressed at a similar level and were unchanged by
NSAID treatment (data not shown).
Finally, the dependency of RelA on NSAID-induced apoptosis as an
explanation for the observed reduction in cell viability was investigated. AnnexinV-
Biotin assay, along with a streptavidin-TxRd conjugate, was used to determine cells
that were apoptotic in relation to cells which were transfected with WT and mutated
RelA. The percentage of cells undergoing apoptosis was then determined in
transfected and non-transfected cell populations. As in the cell viability studies
described above, apoptosis induced by sulindac, sulindac sulfone and indomethacin
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Figure 3.6 - RelA(A27-30) Blocks NSAID-induced Reduction in Cell Viability, in three
independent experiments, SW480 cells were transiently transfected with GFP-RelA(WT) or GFP-RelA(A27-30) and
subsequently treated for 16 hrs with Sulindac (300 pM), Sulindac Sulfone (Sul. Sulf.) (300 pM), Indomethacin (Indo.)
(125 pM) or non-treated (NT) (control). Effect of deletion of amino acids 27-30 of RelA on cell viability in response to
NSAIDs was analysed by phase-contrast microscopy. Representative phase-contrast images (magnification, 20 x),
taken from randomly selected fields of view, are shown.
N.B. Experiments outlined above were performed by Dr L. Stark
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was inhibited in cells expressing RelA(A27-30) (Figure 3.7). In keeping with
previously published findings (Stark and Dunlop, 2005), apoptosis was actually
enhanced in cells expressing GFP-RelA(WT) compared with cells expressing GFP
alone (data not shown). NSAID-induced apoptosis was observed to a similar extent
in all non-transfected cells (data not shown). Collectively, these data provide
compelling evidence that each of the NSAIDs studied cause signal-specific nucleolar
localisation of RelA and that this effect is of pivotal importance for the apoptotic
effects ofNSAIDs.
3.2.5 Non-aspirin NSAIDs Induce Nuclear Translocation of RelA
Without IkBo Degradation
It has previously been shown in the host laboratory that degradation of IkBcx
in response to aspirin is required for nuclear translocation of NF-kB and nucleolar
accumulation of RelA (Stark et al., 2001; Stark and Dunlop, 2005). Flaving
established that nucleolar sequestration of RelA is critical for NSAID-induced
apoptosis, the upstream mechanism of activation of the NF-kB pathway in response
to non-aspirin NSAIDs was further investigated. Using Western blot analysis,
cytoplasmic levels of IkBoc were examined in SW480 colon cancer cells after NSAID
treatment. Figure 3.8 demonstrates that IkBcx is degraded in a dose-dependent
manner after aspirin treatment, as previously reported (Stark et al., 2001). However,
in marked contrast, there was no change in levels of cytoplasmic IkBcx in response to
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Figure 3.7 - Inhibiting Nucleolar Translocation of RelA Blocks NSAID-induced
ApoptOSiS. SW480 cells were transiently transfected with GFP-RelA(WT) or GFP-RelA(A27-30) and
subsequently treated for 16 hrs with Sulindac (300 pM), Sulindac Sulfone (Sul. Sulf.) (300 pM), Indomethacin (Indo.)
(125 pM) or non-treated (NT) (control). Annexin V-Biotin staining, with a streptavidin-TxRd conjugate, was used to
identify apoptotic cells. The percentages of cells expressing GFP-tagged RelA undergoing apoptosis were
determined by fluorescence microscopy in a minimum of 250 transfected cells for each sample. The number of
apoptotic cells in the non-transfected population was also determined (data not shown). Results presented are the
mean of three independent experiments (+/- standard deviation).
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Figure 3.8 - Non-aspirin NSAIDs do not Induce Cytoplasmic licBa Degradation. SW480
cells were treated overnight (16 hrs), in three independent experiments, with Aspirin (0, 3 mM, 5 mM), Sulindac (0,
300 pM, 500 pM) Sulindac Sulfone (0, 300 pM, 500 pM) or Indomethacin (0, 125 pM, 250 pM) then cytoplasmic
extracts (15 pg) resolved by SDS PAGE on 10% polyacrylamide gels and anti-kBa Western blot carried out.
Copper/zinc super oxide dismutase (Cu/Zn SOD) was used as a loading control. Representative blots are shown.
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sulindac, sulindac sulfone or indomethacin, even at the highest doses. This is in
keeping with previous work in the host laboratory which found no change in
cytoplasmic IkBo levels at time points up to 16 hrs of exposure to sulindac. It is
important to consider that the predominant isoform of IkB in colonic epithelial cells
is IkBP (Wu et al., 1999; Inan et al., 2000a). However, preliminary data from the
host laboratory has shown that IkB(3 does not change after sulindac treatment and so
it is unlikely that this isoform is targeted in response to NSAIDs.
3.3 Discussion
In previous reports from the host laboratory, the NF-kB pathway was
identified as a key target pathway for the anti-tumour effects of aspirin in large
bowel epithelial cells. To address the question of whether the NF-kB effect is COX-
dependent and given that previous studies from the host laboratory have mainly
focused on aspirin, a panel of non-aspirin NSAIDs with varying COX-inhibitory
profiles was used in the series of experiments presented in this chapter. The aim was
to determine whether these agents also induce apoptosis of colorectal cancer cells via
modulation of NF-kB signaling in a similar manner to that has been described for
aspirin (Stark et al., 2001).
Sulindac, sulindac sulfone and indomethacin all induced apoptosis (Figure
3.2), nucleolar translocation of RelA (Figure 3.3) and repression of basal NF-kB
activity in a similar manner to aspirin (Figure 3.4). Furthermore, using the
RelA(A27-30) mutant, nucleolar sequestration of RelA was demonstrated to be
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causally involved in sulindac, sulindac sulfone and indomethacin-induced apoptosis
(Figure 3.7). When reviewing these data, it would have been a good idea to
quantitate the immunocytochemistry results showing localisation of RelA to the
nucleolus in response to NSAIDs as this would have allowed the use of statistics to
verify an effect. The use of statistics to quantitate and authenticate an effect for
apoptosis data in response to NSAIDs would also have been informative. It should be
noted that the internal control plasmid (pCMVp) which was used to normalise results
for transfection efficiency when looking at the effects of NSAIDs on NF-kB
transcriptional activity (Figure 3.4) does itself contain several kB sites. It would
therefore be a good idea in the future to look at expression of a few downstream
genes to substantiate reporter assay data showing repression of NF-kB activity.
Nevertheless, taken together, the findings presented in this chapter strongly support
the notion that NSAIDs as a class activate the NF-kB pathway. Moreover, NSAID-
induced activation of NF-kB ultimately leads to apoptosis through sequestration of
RelA in the nucleolus in association with repression of NF-kB driven transcription.
Interestingly, these effects are likely to be COX-independent as sulindac sulfone
lacks COX-inhibitory activity.
The observation that RelA accumulates within the nucleolus after NSAID
exposure (Figure 3.3) raises questions on the functional consequences of such
localisation and on the mechanisms by which it gets there. As discussed in Chapter 1,
it is increasingly apparent that sequestration of transcription factors in the nucleolus
has a role in cell-cycle regulation and apoptosis. However, the cellular mechanisms
for routing of proteins to the nucleolus are not known. There is no structural or
functional evidence for the existence of a frontier separating the nucleolus from the
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surrounding nucleoplasm and so soluble molecules could, in principle, diffuse
between subnuclear compartments (Carmo-Fonseca et al., 2000). However, nucleolar
accumulation is generally mediated by the presence of a specific nucleolar targeting
sequence (Scheer and Hock, 1999) or through molecular interaction with a nucleolar
interaction partner. One example is ARF, which has been shown to sequester MDM2
in the nucleolus (Olson, 2004).
Previous studies from the host laboratory demonstrated that amino acids 27-
30 of RelA are responsible for nucleolar localisation of the protein (Stark and
Dunlop, 2005). It was also postulated from that study that an additional co-factor is
required for nucleolar translocation of RelA. Kinetic studies demonstrated that
induced RelA distributes throughout the nucleoplasm in complexes prior to
localisation in the nucleolus. However, it accumulates in the nucleoplasm, but not the
nucleolus, in response to aspirin exposure or serum withdrawal when protein
synthesis is blocked. Potential candidate co-factors include the nucleolar proteins
NFBP and nucleophosmin (B23), which have both recently been shown to interact
with RelA (Sweet et al., 2003; Dhar et al., 2004). Moreover, nucleophosmin/B23
transcription has been identified as an early gene response to specific external stimuli
(Wu and Yung, 2002). The NF-kB regulator, NIK and NRF are also good candidates
as nucleolar shuttling has been shown to affect the function and mobility of these
proteins respectively (Birbach et al., 2004; Niedick et al., 2004). The nucleolar
protein, ARF, is a particularly strong candidate as it has recently been found to
regulate the transactivation function of RelA and can inhibit both NF-KB-driven
transcription and anti-apoptotic activity (Rocha et al., 2003).
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Although there is substantial evidence for a pro-survival function of NF-kB,
there is a growing body of evidence supporting a pro-apoptotic or tumour suppressor
role for NF-kB. 'Atypical' activators of NF-kB, such as UV-C and daunorubicin,
result in DNA binding of NF-kB complexes with much slower kinetics than TNF-a
(Perkins, 2004b; Campbell and Perkins, 2006). Furthermore, these atypical stimuli
have been shown to repress rather than activate transcription of the RelA-responsive
anti-apoptotic target genes, Bcl-Xi, X-IAP and A20 (Campbell et al., 2004). In that
study, the observed repression of anti-apoptotic genes by UV-C and daunorubicin
was demonstrated to be the result of induction of RelA by interaction with HDACs,
indicating that repression is an active process. Interestingly, a subsequent study from
the same group (Campbell et al., 2006) demonstrated that induction ofNF-kB DNA-
binding and transcriptional repression in response to topoisomerase inhibitors,
including daunorubicin, relates to the capacity of these agents to intercalate with
DNA. Furthermore, oxygen free radicals were not required for the NF-kB to repress
transcription.
In the work presented here, activation of the NF-kB pathway by the panel of
NSAIDs induced nuclear translocation of NF-kB complexes. The functional end
result of NSAIDs is equivalent to that published for UV-C and daunorubicin, since
both cause transcriptional repression of NF-kB. However, there are important
differences in the mechanism by which this is brought about. Whereas UV-C and
daunorubicin actively repress RelA by increasing the association of NF-kB with
HDACs (Campbell et al., 2004), the NSAIDs used in this study cause sequestration
of the RelA component in the nucleolus. Once in the nucleolus, RelA is physically
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separated from its target promoters, resulting in a decrease in transcription of anti-
apoptotic genes and consequently, apoptosis.
An interesting observation from the data outlined in Figure 3.3 is that nucleoli
are very large and pronounced upon treatment with NSAIDs when compared to the
untreated control. In particular, the lack of DAPI staining in regions corresponding to
nucleoli is very striking in cells treated with sulindac (500 pM) and aspirin (5 mM).
It is well established that the appearance of the nucleolus changes during the various
phases of the cell cycle. Fully active nucleoli are large, with extensive intermingling
of fibrilar centres, dense fibrilar component and granular component. As the cell
approaches mitosis, the nucleolus first decreases in size and then disappears as
chromosomes condense and RNA synthesis stops, so that there is generally no
nucleolus in a metaphase cell. At the end of mitosis when ribosomal RNA synthesis
restarts, tiny, compact nucleoli reappear at the chromosomal locations of ribosomal
RNA genes (Carmo-Fonseca et al., 2000; Alberts et al., 1983). It is noteworthy that a
few papers have demonstrated that certain proteins localise to the nucleolus at
particular stages of the cell cycle. In a study of the subcellular distribution of Rad52,
a protein involved in DNA repair, a fusion protein comprising GFP and Rad52 was
found throughout cells in M phase, localised to the nucleoplasm, but was excluded
from nucleoli, in Gi phase and accumulated in nucleoli in both S phase and quiescent
(Go) cells (Liu et al., 1999). Protein phosphatase 1 (PP1) y, a ubiquitous
serine/threonine phosphatase that regulates many cellular processes, has also been
found to have distinct localisation patterns throughout the cell cycle (Trinkle-
Mulcahy et al., 2003). Specifically, PPly, when expressed as a fluorescent protein
fusion, showed a nucleolar accumulation during interphase, localised to kinetochores
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on entry to mitosis, dramatically re-localised to chromosome-containing regions at
the transition from early to late anaphase and also accumulated at the cleavage
furrow and midbody by telophase. In light of the above, it may therefore be very
informative in the future to examine cell cycle dynamics and subcellular localisation
of RelA.
Another interesting finding from the data presented was that substantial
transcriptional repression was observed with the lower concentration of sulindac
(300 pM) but there was minimal nucleolar localisation of RelA at this concentration
(see Figures 3.3 and 3.4). This suggests the possibility that repression of NF-kB
driven transcription by NSAIDs could also involve other mechanisms and so
apoptosis may not be due exclusively to transcriptional repression through nucleolar
localisation of RelA. Flence, it is interesting to speculate that other, as yet undefined,
active mechanisms associated with nucleolar translocation could be implicated in
repression ofNF-kB driven transcription by NSAIDs.
The observation that all the NSAIDs used in this study activate the NF-kB
pathway calls into question several previous studies demonstrating that NSAIDs
inhibit cytokine-mediated activation of NF-kB. One report (Kopp and Ghosh, 1994)
documented inhibition of cytokine-induced NF-kb-dependent transcription by
sodium salicylate and aspirin. It was subsequently demonstrated that the NSAIDs
aspirin (Yin et al., 1998) and sulindac (Yamamoto et al., 1999) inhibit cytokine-
mediated activation of NF-kB by stereochemical inhibition of IKK and reduction of
ATP binding, consequently blocking IKK activity. Another group have also very
recently reported inhibition of LPS-induced NF-kB DNA-binding and nucleolar
accumulation of RelA by the COX-2-selective inhibitors, etoricoxib and lumiracoxib
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(Niederberger et al., 2006). However, it is important to note that in those studies,
cells were pre-treated with the appropriate NSAID for only a short period of time
before a burst of treatment with powerful NF-kB stimuli. These experimental
conditions are not necessarily representative of the in vivo situation. Moreover,
NSAIDs have been shown to inhibit the growth of colorectal cancer cells without
additional cytokine stimulation (Qiao et al., 1998a). Furthermore, several papers
support the findings of this study that NSAIDs activate NF-kB in the absence of
additional NF-kB stimuli. The NSAID, diclofenac (Cho et al., 2005) and the COX-2-
selective inhibitors, celecoxib (Niederberger et al., 2001) and NS-398 (Smartt et al.,
2003), have been reported to activate the NF-kB pathway without additional cytokine
stimulation. Even so, it would be of interest in the future to establish whether aspirin
and the other NSAIDs used in this study inhibit cytokine-mediated activation of the
NF-kB pathway in SW480 colon cancer cells.
Flaving established that activation of the NF-kB pathway was common to the
panel ofNSAIDs used in this study, it was presumed that the upstream mechanism of
activation by the other NSAIDs would be the same as aspirin, involving
phosphorylation and degradation of IkBoc. Idowever, the discovery that IkBcx is not
degraded in response to sulindac, sulindac sulfone or indomethacin treatment (Figure
3.8) suggested that there is an alternative upstream mechanism and a further layer of
complexity in the pathway. One possible alternative pathway utilised by the non-
aspirin NSAIDs will be the focus of investigation and discussion in the next chapter.
Nevertheless, it should be noted that it would be important in the future to confirm
preliminary data from the host laboratory from time course experiments which
indicated that IkBoi is not degraded in response to sulindac (500 pM) treatment at any
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In summary, the data presented in this chapter indicates that NSAIDs as a
class activate the NF-kB pathway and that this is a critical mechanism whereby these
agents induce apoptosis. In keeping with the mechanism previously described by the
host laboratory for aspirin (Stark and Dunlop, 2005), nucleolar sequestration of
RelA, with associated repression ofNF-KB-driven transcription, was demonstrated to
be vital for induction of apoptosis by sulindac, sulindac sulfone and indomethacin.
However, in contrast to aspirin, there was no degradation of IkBcx in response to
treatment with sulindac, sulindac sulfone or indomethacin. This observation indicates
that although NSAIDs have the same end point, that is activation of NI -kB, they
have a different upstream mechanism to achieve activation of the pathway. Hence,
the focus of the next part of research in this thesis was to look at other mechanisms
by which IkBoi is induced to dissociate from RelA.
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